Immunochemical Investigations on Peroxynitrite - Modified Immunoglobulin G by Khan, Humera
IMMUNOCHEMICAL INVESTIGATIONS ON 
PEROXYNITRITE - MODIFIED 
IMMUNOGLOBULIN G 
THESIS 
SUBIVIITTED FOR THE AWARD OF THE DEGREE OF 
octor of pljilogophp 
IN 
BIOCHEMISTRY 
BY 
HUMERA KHAN 
Approved 
Dr. Khursheed Alam {Supervisor) 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF MEDICINE 
JAWAHARLAL NEHRU MEDICAL COLLEGE 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH (INDIA) 
2010 
T7174 
Khursheed Alam, Ph.D. 
Associate Professor 
DEPARTMENT OF BIOCHEMISTRY 
JAWAHARLAL NEHRU MEDICAL COLLEGE 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH-202 002, INDIA 
CERTIFICATE 
I certify that the work presented in the thesis entitled "Immunochemical 
Investigations on Peroxynitrite Modified-Immunoglobulin G" has been 
carried out by Humera Khan under my direct guidance and supervision, and is 
suitable for the award of Ph.D. degree in Biochemistry of the Aligarh Muslim 
University, Aligarh. 
(Dr. RhHrsneed Alam) 
Associate Professor 
Email: kalam786(tt)rediffmail.com 

Acknowledgements 
In the name of Allah, Most Gracious, Most Merciful. 
First of all I would like to thank Allah, the Almighty, the most benevolent and 
merciful for providing me courage to complete this work. 
It is a privilege to begin this acknowledgment by expressing my profound 
sense of gratitude to my supervisor Dr. Khursheed Alam for his judicious guidance 
and intellectual motivation throughout the present study. His suggestions and 
research acumen have been a source of inspiration to me. I am grateful to him for 
his careful and critical review without which this thesis would have been far less 
illuminating and readable. 
I thank Professor Asif All, Chairman, Department of Biochemistry, J. N. 
Medical College, for the essential facilities. 
I express my gratitude to Dr. Moinuddin and other faculty members of the 
Department for their moral support during my research work. I am also thankful to 
Prof. Y. D. Sharma, Dr. D. K. Dikshit and Dr. Rizwan Khan for their help. 
I wish to express my gratitude to Dr. Kiran Dixit, Dr. Vikrant, Dr. 
Prashant, Dr. Nadeem, Dr. Kahkasha, Dr. Asad, Rafia, Saheem, Ashraf, Ejaz, Dr. 
Imteyaz, Dr. Shahid and Dr. Imran who were always there to encourage and help 
me. 
Words will hardly register the message of my indebtedness to my family 
members who encouraged me all through the trials and tribulations of this study. I 
express my gratitude to my husband Mohd. Shoaib Siddiqui and my father Prof. M. 
Ishrat Husain Khan who encouraged and helped me at various stages during the 
course of the present study. My kids Shayaan and Rushil need a special mention for 
their sacrifices, cooperation during long hours of my absence and unconditional 
love which encouraged me to go on further. Last but not the least I am also thankful 
to my mother, brothers and sister for their constant encouragement and best wishes. 
Further, I would like to thank the staff of the Central Photography Section of 
this Medical College as well as members of the non-teaching and technical staff of 
the Biochemistry Department. 
(Humera Khan) 
Contents Page Number 
Abbreviations 
Abstract iii 
List of Figures vii 
List of Tables xi 
Introduction 1 
Materials & Methods 60 
Results 71 
Discussion 149 
References 158 
Abbreviations 
IgG 
A278 
DTT 
AP 
ELISA 
APS 
BSA 
CD 
HSA 
DTPA 
EDTA 
FT-IR 
HPLC 
NOS 
iNOS 
nNOS 
eNOS 
N02^ 
NO 
NO3" 
i^M 
3-NT 
nm 
PON 
ONOO" 
PAGE 
PBS 
ROS 
O 2 -
Immunoglobulin G 
Absorbance at 278 nm 
Dithiothreitol 
Alkaline phosphatase 
Enzyme linked immunosorbent assay 
Ammonium persulphtae 
Bovine serum albumin 
Circular dichroism 
Human serum albumin 
Diethylenetriamine pentaacetic acid 
Ethylene diamine tetraacetic acid 
Fourier transformed-infra red 
High performance liquid chromatography 
Nitric oxide synthase 
inducible NOS 
neuronal NOS 
endothelial NOS 
Nitryl (nitronium) cation 
Nitric oxide 
Nitrate 
Micromolar 
3-Nitro tyrosine 
Nanometer 
Peroxynitrite 
Peroxynitrite anion 
Polyacrylamide gel electrophoresis 
Phosphate buffered saline 
Reactive oxygen species 
Superoxide anion radical 
VL 
CL 
RNS 
rpm 
SDS 
SOD 
Tm 
TEMED 
Tris 
UV 
variable domain 
constant domain 
Reactive nitrogen species 
Revolution per minute 
Sodium dodecyl sulphate 
Superoxide dismutase 
Melting temperature 
N,N,N',N'-tertramethylethylenediamine 
Tris (hydroxymethyl) amino methane 
Ultraviolet 
ABSTRACT 
Ill 
Peroxynitrite is a bifacet reactive entitity which is formed rapidly through 
reaction of the superoxide anion with nitric oxide and has in vivo existence. It is a 
short lived, highly reactive oxidant and nitrating agent and can modify proteins, 
nucleic acids, lipids, etc. Numerous studies have implicated peroxynitrite in 
autoimmune and inflammatory processes. In proteins, tyrosine residues are the 
major targets of peroxynitrite attack. The hallmark of the peroxynitrite attack on 
proteins is the formation of 3-nitrotyrosine and 3,3 dityrosine respectively. Tyrosine 
nitration may change the rate of proteolytic degradation of nitrated proteins and 
favour either its faster clearance or accumulation in cell. Increased nitrotyrosine 
formation has been reported in acute lung injury, sepsis, rheumatoid arthritis, 
Alzheimer's disease, liver transplantation, systemic lupus erythematosus, etc. 
In the present study, human IgG has been modified in vitro by peroxynitrite 
and structural changes studied by physicochemical methods. Results of UV-visible 
spectroscopy revealed hyperchromicity in the profiles of peroxynitrite-modified IgG 
samples compared to native IgG. This may be attributed to peroxynitrite-induced 
modification of mainly tyrosine residues as well as unfolding of IgG molecule. 
Furthermore, the nitration was evident from appearance of yellow colour in 
peroxynitrite-modified IgG samples. The yellow colour intensity of the samples was 
directly proportional to peroxynitrite concentration. Moreover, in peroxynitrite 
modified-IgG samples a new peak of nitrotyrosine at 420 nm was clearly visible. 
HPLC results confirmed the generation of nitrotyrosine in peroxynitrite-modified 
samples. The emission profiles of peroxynitrite-modified IgG samples exhibited 
fluorescence quenching compared to native IgG. It may be the consequence of 
peroxynitrite mediated addition of nitro group in the phenolic ring. Dityrosine 
formation in peroxynitrite-modified IgG samples was also observed. 
The surface hydrophobicity of a protein affects its physical stability, 
solubility, aggregation tendency as well as adsorption behaviour and to study 
proteins' surface hydrophobicity ANS (l-anilinonaphthalene-8-sulfonic acid) is 
extensively utilized as a fluorescent probe. The fluorescence emission spectra of 
ANS mixed native- or peroxynitrite-modified IgG samples showed increase in the 
emission intensity as well as blue shift in the maximum emission wavelength. The 
surface hydrophobicity of peroxynitrite-modified IgG samples was found to 
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increase, as modification increased, resulting in more binding of ANS. On 
modification by peroxynitrite the hydrophobic clusters/patches in IgG were exposed 
for ANS binding and it lead to increase in ANS fluorescence intensity and blue shift. 
This observation could be a reflection of change in IgG structure due to 
peroxynitrite-mediated nitration. Quantitation of reactive carbonyl in peroxynitrite-
modified IgG samples showed generation of carbonyls consistent with increasing 
amount of peroxynitrite. The increase in carbonyl content in peroxynitrite-modified 
IgG samples may be due to oxidative action of peroxynitrite. 
Peroxynitrite-induced secondary changes in IgG samples were 
analyzed by circular dichroism technique. In native IgG a large negative dichroism 
at 217 nm was observed which characterizes P-sheet structure. Upon treatment with 
peroxynitrite, IgG showed gradual decrease in P-sheet content and increase in a-
helix. FT-IR studies substantiated the CD findings pertaining to decrease in P-sheet 
content. Furthermore, melting temperature (Tm) of peroxynitrite-modified IgG 
samples was observed to be lower than native IgG. During temperature-induced 
denaturation, the protein absorbance changes with temperature until the process of 
unfolding is complete. The observed thermal instability in modified samples may be 
the result of peroxynitrite-induced nitration of tyrosine residues coupled with 
denaturation. Results of polyacrylamide gel electrophoresis showed formation of 
high molecular weight species in peroxynitrite-treated IgG. It may be linked to 
cross-linking and aggregate formation by the oxidative and nitrosative action of 
peroxynitrite. 
In immunological part of our study, native IgG as well as its peroxynitrite-
modified forms were injected into rabbits to induce antibody response. IgG modified 
by lowest concentration of peroxynitrite (0.4 mM) induced maximum antibody 
response. Use of higher concentrations of peroxynitrite proved detrimental for 
induction process probably due to damage/masking of immunogenic epitopes. 
Although induced antibodies were immunogen specific but showed cross-reactivity 
with native- and peroxynityrite-modified proteins/amino acids, a characteristic 
feature of polyspecific antibodies commonly associated with autoimmune diseases. 
Furthermore, peroxynitrite-modified proteins/amino acids showed better binding 
with anti-peroxynitrite (0.4 mM)-modified-IgG antibodies than their native 
counterparts. 
Rheumatoid arthritis is an autoimmune disorder characterized by chronic, 
long standing inflammatory process within diartlirodial joints. Direct binding 
ELISA carried out on rheumatoid factor positive RA sera showed higher binding 
with peroxynitrite (0.4 mM)-modified IgG compared to native IgG. Inhibition 
ELISA results with IgG purified from RA sera supported the findings of direct 
binding immunoassay. Carbonyl level in RA sera was found to be higher as 
compared to normal human sera. HPLC analysis of RA sera showed nitrotyrosine. 
This points out the role of nitrotyrosine in disease initiation/progression and also the 
likely link between autoantibodies in RA sera and peroxynitrite-modified protein 
antigens. 
Diabetes mellitus is a global healthcare challenge with regard to its 
secondary complications. Direct binding ELISA carried out with sera of confirmed 
cases of type 2 diabetes showed overall higher binding with peroxynitrite (0.4 mM)-
modified IgG compared to native IgG. Inhibition ELISA results with IgG purified 
from diabetes sera substantiated the findings of direct binding studies. Quantitation 
of nitrotyrosine in randomly selected diabetes sera by HPLC showed presence of 
nitrotyrosine. The findings in diabetes may be important because the altered IgG 
might not work as an effective molecule to confer the required level of immunity 
and hence the patient is more prone to infection. Furthermore, the excessively 
formed free radicals (oxygen/nitrogen based) in early or late stages of type 2 
diabetes can also alter IgG structure. The altered IgG can trigger immune reactions 
leading to induction of autoantibodies. 
Conclusions 
Physicochemical studies carried out on peroxynitrite-modified-IgG suggest 
generation of nitrotyrosine, formation of carbonyls and changes in secondary 
structures. IgG modified by 0.4 mM, 0.8 mM and 1.2 mM peroxynitrite was injected 
into rabbits for anfibody induction. Direct binding and inhibifion ELISA results 
suggest that IgG modified by 0.4 mM peroxynitrite was most active immunogen and 
induced highest antibody response. IgG modified by more than 0.4 mM of 
peroxynitrite was found to be less immunogenic. It seems that peroxynitrite is toxic 
to proteins even at low doses and at higher concentrations this can damage protein 
beyond repair. Experimentally produced antibodies against peroxynitrite (0.4 mM)-
VI 
modified IgG were polyspecific with respect to antigen binding. The binding of 
peroxynitrite (0.4 mM)-modified-IgG by autoantibodies in rheumatoid arthritis and 
type 2 diabetes sera points out the role of oxidatively modified and nitrated protein 
antigens in the initiation/progression/secondary complications of the diseases. 
ROS/RNS levels are increased in autoimmune diseases and their over-production 
may exceed the scavenging capacity of antioxidant enzymes or inhibitors, and can 
modify proteins, DNA, lipoprotein structure leading to generation or exposure of 
neo-antigenic determinants and antigen driven autoimmune responses. The 
accumulation in inflamed tissue of nitrotyrosine-containing autologous proteins, that 
appear as foreign to the immune system, might induce an autoimmune response and 
sustain a chronic inflammatory response. 
VII 
List of Figures Page Numbei 
Fig. 1 Vertebrate immune system 
Fig. 2 Basic structure of the human immunoglobulin 
Fig. 3 Hinge regions in IgG subclass 
Fig. 4 Ribbon diagram of one Fc chain co-crystallized with 
Staphylococcus aureus protein A 
Fig. 5 Flexibility of IgG molecule 10 
Fig. 6 Backbone representation of the IgG molecule 13 
Fig. 7 Domain interactions of immunoglobulin molecule 14 
Fig. 8 Carbohydrate sequence of IgG and site of its attachment on 
heavy chain 
16 
Fig. 9 Reaction targets and fate of peroxynitrite 28 
Fig. 10 Peroxynitrite formation/reactions in mitochondria 30 
Fig. 11 Free radical pathways of tyrosine nitration 34 
Fig* 12 Autoimmune diseases (organ-specific or non-organspecific) 43 
p,. 1^ Generation and immunogenicity of NT-carrying self- .„ 
proteins 
Fig-14 Role of peroxynitrite and protective effects of SOD on 
cartilage 
56 
Fig. 15 Assembly for laboratory synthesis of peroxynitrite 65 
VIII 
Fig* 16 Elution profile of human serum IgG on Protein-A agarose 72 
column 
Fig' 17 Absorpfion spectrum of normal human IgG 73 
Fig. 18 Standard curve for glucose quantitation 73 
Fig. 19 Absorption profile of freshly synthesized peroxynitrite 74 
Fig. 20 Spectra of nafive- and peroxynitrite-modified IgG 75 
Fig. 21 Absorption spectrum of 3-nitrotyrosine 78 
Fig. 22 Effect of quenchers on peroxynitrite-induced nitration of 79 
IgG 
Fig. 23 Emission profile of nafive- and peroxynitrite-modified IgG 
excited at 275 nm 
Fig. 25 Emission profile of peroxynitrite-modified IgG excited at 
325 nm 
Fig. 26 Far-UV CD spectra of native- and peroxynitrite-modified 
IgG 
80 
Fig. 24 Emission profile of ANS, native IgG and peroxynitrite- 82 
modified IgG 
83 
86 
Fig. 27 FT-IRspectraof nafive-and peroxynitrite-modified IgG 87 
Fig. 28 Melting profile of native-and peroxynitrite-modified IgG 89 
Fig. 29 SDS-PAGE of nafive- and peroxynitrite-modified IgG 90 
Fig. 30 Quantitation of carbonyls in native- and peroxynitrite- 92 
modified IgG 
IX 
Fig. 31 HPLC chromatogram of 3-nitrotyrosine 93-95 
Fig. 32 Standard curve of 3-nitrotyrosine 96 
Fig. 33 HPLC detection of nitrotyrosine in native- and peroxynitrite- 97,98 
modified IgG 
Fig. 34 Direct binding ELISA of experimentally produced 100 
antibodies 
Fig. 35 Inhibition ELISA of anti-peroxynitrite-modified IgG 101 
antibodies 
Fig. 36-38 Cross-reactivity of anti-peroxynitrite-modified IgG , Q-, , Q^ -
antibodies 
Fig. 39-41 Inhibition ELISA of anti-native IgG antibody binding 107-109 
Fig. 42-45 Binding of 1:100 diluted rheumatoid arthritis sera to native 112-115 
IgG and peroxynitrite-modified IgG 
Fig. 46 Direct binding ELISA of a purified rheumatoid arthrifis IgG 116 
and normal human IgG 
Fig. 47-50 Inhibition of RA IgG binding by native IgG and 117-120 
peroxynitrite-modified IgG 
Fig. 51 Quantitationofcarbonyls in normal human and RA sera 123 
Fig. 52 HPLC chromatogram of normal human serum 124 
Fig. 53-57 HPLC chromatogram of RA serum 125-129 
Fig. 58-61 Binding of diabetes sera with native- and peroxynitrite- 131-134 
modified IgG 
Fig. 62 Direct binding ELISA of a purified diabetes IgG and normal 136 
human IgG 
Fig. 63-66 Inhibition of diabetes IgG binding by native- and 137-140 
peroxynitrite-modified IgG 
Fig. 67 Quantitation of carbonyls in normal human sera and diabetes 142 
sera 
Fig. 68-72 HPLCchromatogram of diabetes sera 143-147 
XI 
List of Tables Page Number 
Table 1 Major characteristics of human immunoglobulins 5 
Table 2 IgG subclass 6 
Table 3 Physical and chemical properties of IgG subclasses 6 
Table 4 Reactive oxygen species as free radicals 21 
Tables Non-radical reactive oxygen species 21 
Table 6 Reactive nitrogen species 21 
Table 7 Products and intermediates of peroxynitrite-amino acids 32 
interaction 
Table 8 Peroxynitrite and human diseases 37 
Table 9 Diagnostic specificity of autoantibodies 41 
Table 10 American Rheumatism Association criteria for RA 50 
classification 
Table 11 Novel autoantibodies of diagnostic relevance in rheumatoid 51 
arthritis 
Table 12 Absorption characteristics of native- and peroxynitrite- 77 
modified IgG 
Table 13 Nitrotyrosine content of IgG modified with peroxynitrite 78 
Table 14 Antinitration quenchers of IgG 79 
Table 15 Fluorescence characteristics of native- and peroxynitrite- 80 
modified IgG excited at 275 nm 
Table 16 ANS-binding characteristics of native- and peroxynitrite- 82 
modified IgG 
Table 17 Quantitation of dityrosine in peroxynitrite-modified IgG 83 
Table 18 Fluorescence characteristics of native- and peroxynitrite- 84 
modified IgG excited at 325 nm 
Table 19 CD characteristics of native- and peroxynitrite-modified 86 
IgG 
XII 
Table 20 Melting temperatures of native- and peroxynitrite-modified 89 
IgG 
Table 21 Quantitation of 3-nitrotyrosine in peroxynitrite-modified IgG 99 
samples 
Table 22 Cross-reactions of anti-peroxynitrite-modified IgG 106 
antibodies 
Table 23 Cross reactions of anti-native IgG antibodies 110 
Table 24 Inhibition data of RA IgG binding by native- and 121 
peroxynitrite-modified IgG 
Table 25 Quantitation of nitrotyrosine in RA sera 130 
Table 26 Inhibition data of diabetes IgG binding by native- and 141 
peroxynitrite-modified IgG 
Table 27 Quantitation ofnitrotyrosine in diabetes sera 148 
INTRODUCTION 
Immunoglobulins are a group of closely related glycoproteins composed of 
88-97% protein and 3-12% carbohydrate (Kimball, 1983; Leibiger et al, 1999). 
They are produced by plasma cells in response to an immunogen and function as 
antibodies. 
The immune system 
The vertebrate immune system consists of well diversified molecules that 
recognize and respond to parasitic invasion in a very complex manner (Hughes and 
Yeager, 1997). The immune system is classified as innate - consisting of barriers to 
prevent penetration and spread of infectious agents, and adaptive system -
consisting of lymphocytes and immunoglobulins (Fig. 1). Lymphocytes consist of 
T-cells and B-cells that regulate immune response and impart cellular and humoral 
immunity to the organism. The B-cells develop into plasma cells that secrete 
antibodies. The T-cells develop into effector cells that kill infected cells as well as 
activate macrophages and B-cells. Immunoglobulins confer humoral immunity in 
humans (Spiegelberg, 1974). 
Basic structure and classification of immunoglobulins 
Antibodies (immunoglobulins) are roughly Y-shaped molecules or 
combination of such molecules. The basic structural unit of most mammalian 
antibodies is a glycoprotein (MW -150,000 daltons) composed of four polypeptide 
chains — two light chains, and two heavy chains, which are connected by disulfide 
bonds (Fig. 2). Each light chain has a molecular weight of -25,000 daltons and is 
composed of two domains, one variable domain (VL) and one constant domain (CL) 
(Wang etal, 2006; Schur, 1972; Burton, etal, 1986; Milstein, 1969). 
Immunoglobulin classes 
The immunoglobulins can be divided into 5 different classes based on 
differences in the amino acid sequences in the constant region of the heavy chains 
(Hamilton, 1987). The major characteristics of the five immunoglobulin classes are 
summarized in Table 1. 
1. IgG - Gamma heavy chains 
2. IgM - Mu heavy chains 
3. IgA - Alpha heavy chains 
4. IgD - Delta heavy chains 
5. IgE - Epsilon heavy chains 
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Fig. 1 Organization of the vertebrate immune system 
Source: (Hamilton, 2001). 
Fig. 2 Schematic drawing of the basic structure of the human immunoglobulin. 
The amino-terminal end is characterized by sequence variability (V) in 
both the heavy and light chains, referred to as the VH and VL regions 
respectively. The rest of the molecule has a relatively constant (C) 
structure. The constant portion of the heavy chain is further divided into 
three structurally discrete regions: CHI, CH2 and CHS. The hinge region 
is a segment of the heavy chain, located between the CHI and CH2 
domains. Carbohydrate groups are attached to the CH2 domains of the 
heavy chains (not shown). 
IgG, IgA, and IgM together constitute over 95% of the whole 
immunoglobulin pool in a normal human and are designated as major 
immunoglobulin classes. Because they are common to all humans, the 
immunoglobulin classes can also be designated as isotypes. 
Light-chain isotypes 
The light chains also proved to be antigenically heterogeneous and two main 
isotypes were defined. Light chain types are based on differences in the amino acid 
sequence in the constant region of the light chain. These differences are detected by 
serological means. 
1. Kappa light chains 
2. Lambda light chains 
Immunoglobulin subtypes 
The light chains can also be divided into subtypes based on differences in the 
amino acid sequence in the constant region of the light chain. Lambda subtypes are-
a) Lambda 1 
b) Lambda 2 
c) Lambda 3 
d) Lambda 4 
Each immunoglobulin molecule is composed of a pair of identical heavy 
chain and a pair of identical light chain; hence, a given immunoglobulin molecule 
can have either kappa or lambda chains (Table 1). A normal individual will have a 
mixture of immunoglobulin molecules in serum, some with kappa chains (IgGK), 
and others with lambda chains (IgGX). Normal serum IgG has a 2:1 ratio of kappa 
chain over lambda chain-bearing IgG molecules (Goodman, 1987). 
Immunoglobulin subclasses 
Antigenic differences between the heavy chains of IgG and IgA exist. Some 
important structural and biological characteristics of IgG subclasses are listed in 
Table 2. 
IgG subclasses 
In the 1960's, four heavy-chain subgroups of antigenically distinct human 
IgG were first identified by use of polyclonal antiserum prepared against human IgG 
myeloma proteins (Ballieux et al, 1964; Grey and Kunkel, 1964; Terry and 
Fahey, 1964). Some interesting biological and structural differences have been 
Table 1: Major characteristics of Human Immunoglobulins 
Heavy-chain class 
H-chain subclasses 
L-chain type 
Sedimentation 
coefficient 
Polymeric forms 
Molecular weight 
Serum 
concentration 
(mg/dl) 
Intravascular 
distribution 
IgG 
y 
Y 1,2,3,4 
Kand A, 
7S 
no 
150,000 
600-1300 
45% 
IgA 
a 
a 1,2 
Kand A, 
7S,9S,11S 
dimers, 
trimers 
(160,000) 
n 
60-300 
42% 
IgM 
M 
— 
Kand A, 
19S 
pentamers 
900,000 
30-150 
80% 
IgD 
6 
-
Kand A, 
7-8S 
no 
180,000 
3 
75% 
IgE 
8 
-
KandX, 
8S 
no 
190,000 
0.03 
51% 
Source: (Virella, 1998). 
demonstrated for IgG proteins of different subclasses. The classes of 
immunoglobulin G can be divided into subclasses based on small differences in the 
amino acid sequences in the constant region of the heavy chains (World Health 
Organization, 1966). The structural differences among these subtypes are the 
number and location of interchain disulfide bonds and the length of the hinge region. 
a) IgGl - Gamma 1 heavy chains 
b) IgG2 - Gamma 2 heavy chains 
c) IgG3 - Gamma 3 heavy chains 
d) IgG4 - Gamma 4 heavy chains 
Despite the use of different reagents and assay methods, there is general 
agreement on the actual percentage of each IgG subclass in the serum of normal 
adults: IgGl: 60.3-71.5%, lgG2: 19.4-31.0%, lgG3: 5.0-8.4%, IgG4: 0.7-4.2% 
(French, 1986; Morell and Skvaril, 1971; Shakib et al, 1975; French and Harrison, 
1981). The greatest structural difference between the IgG subclasses reside in the 
hinge region (Table 3, Fig. 3). The "hinge region" is located between CHI and CH2, 
Table 2: IgG subclasses 
% of total IgG in 
normal serum 
Half-life (days) 
Complement fixation 
Segmental flexibility 
Affinity for monocyte 
and PMN receptors 
Binding to protein A 
c 
Binding to protein G 
IgGl 
60% 
21 
++ 
+++ 
+++ 
++ 
+++ 
IgG2 
30% 
21 
+ 
+ 
+ 
++ 
+++ 
IgG3 
7% 
7 
+++ 
++++ 
++++ 
-
+++ 
IgG4 
3% 
21 
-
++ 
+ 
++ 
+++ 
Source: (Virella, 1998). 
a b 
By the classical pathway; A protein isolated from select strains of 
Staphylococcus aureus which has the ability to bind IgG of different species 
including human (Fig. 4) 
c 
A protein similar to protein A, but isolated from Group G Streptococci, which also 
binds IgG proteins of different species. 
Table 3: Physical and chemical properties of the four human IgG subclasses 
Properties 
Heavy chain type 
Molecular weight (x 1000) 
Hinge amino acid number 
Interchain disulfide bond 
number 
Light chains: K: X ratio 
IgGl 
yi 
146 
15 
2 
2.4 
IgG2 
72 
146 
12 
4 
1.1 
IgG3 
73 
170 
62 
11 
1.4 
IgG4 
Y4 
146 
12 
2 
8.0 
Source: (Hamilton, 2001). 
Ig(. 
DiMillidc 
hoiicl 
Fig. 3 Length of hinge regions in IgG subclass. 
General structure of the four subclasses of human IgG, which differ in 
the number and arrangement of the interchain disulfide bonds (thick 
black lines) linking the heavy chains. A notable feature of human IgG3 is 
its more interchain disulfide bonds. 
Source: (Goldsby et al., 2006). 
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Fig. 4 A ribbon diagram of one Fc chain co-crystallized with a fragment of an 
IgG-binding bacterial protein {Staphylococcus aureus protein A). This 
fragment contains two constant immunoglobulin domains. 
Source: (http://www.tulane.edu/~biochem/med/1 fc2_igg.gif). 
and its name is derived from the fact that studies by a variety of techniques, 
including fluorescence polarization, spin-labeling, electron microscopy, and x-ray 
crystallography, have shown that the Fab fragments can rotate and waggle (Fig. 5), 
forming a "Y" to a "T" and vice versa. 
Genetics of immunoglobulins 
I. Immunoglobulin genes 
Human immunoglobulin (Ig) molecules are coded by three unlinked gene 
families: two for light (L) chains located on chromosomes 2 (K chains) and 22 (k 
chains), and one for heavy (H) chains located on chromosome 14. 
A. Variable region diversity. Each individual is able to produce several million 
antibody molecules with different antigenic specificities, and this diversity 
corresponds to the extreme heterogeneity of the variable (V) regions in those 
antibody molecules, implying that each individual must possess a large number of 
structural genes for Ig chains. 
B. Constant region homogeneity. The allotypic determinants on the constant (C) 
region segregate as a single Mendelian trait, suggesting that there may be only one 
gene for each of the several Ig chain C regions. 
C. Multiple genes code for immunoglobulin polypeptide chains. V and C regions 
are encoded by separate genes that are brought together by a translocation event 
during lymphocyte development. 
II. Genetic basis of antibody diversity 
It has been estimated that an individual is capable of producing up to 10^  
different antibody molecules. How this vast diversity is generated from a limited 
number of germline elements has long been one of the most intriguing problems in 
immunology. There are two possible mechanisms for this variability, either the 
information is transmitted from generation to generation in the germ line, or it is 
generated somatically during B-lymphocyte differentiation. 
III. Antigenic determinants of immunoglobulin molecules 
Three main categories of antigenic determinants are found on 
immunoglobulin molecules:-
1. Isotypes are antigenic determinants present on all molecules of each class and 
subclass of immunoglobulin heavy chains and on each type of light chain; they are 
10 
Fab arm waving 
x^<^^ 
Fc wagging 
Fig. 5 Flexibility of the IgG molecule. 
Source: (Brekke, etal, 1995). 
11 
defined serologically by antisera directed against the constant regions of H and L 
chains. The antisera are produced in animals which, upon injection of purified 
human immunoglobulins, recognize the structural differences between constant 
regions of H and L chains. 
• Isotypic determinants are common to all members of a given species; hence 
they cannot be used as genetic markers. Their practical importance results 
from the fact that they allow the identification of classes and subclasses of 
immunoglobulins through the heavy-chain and light-chain (K, X) isotypes. 
• The light-chain isotypes are shared by all classes and subclasses of normal 
immunoglobulins. 
2. Idiotypes are antigenic determinants associated with hypervariable regions. The 
antigen combining site in the V region of the immunoglobulin molecule, in addhion 
to determining specificity for antigen binding, can also act as an antigen and induce 
production of antibodies against it (anti-idiotypic antibodies). Antibodies of the 
same specificity share idiotypes. 
3. Allotypes are hereditary antigenic determinants of Ig polypeptide chains that may 
differ between individuals of the same species. Because of their heterogeneity, they 
can be used as genetic markers. 
• The loci controlling allotypic determinants are codominant (i.e., both are 
expressed phenotypically in a heterozygote) autosomal genes that follow 
Mendelian laws of heredity. 
• All allotypic markers that have so far been identified on human 
immunoglobulin molecules, with one exception, are present in the C regions 
of H chains of IgG, IgA, IgE, and on K-type L chains. 
General functions of immunoglobulins 
a) Antigen binding - Each immunoglobulin actually binds to a specific antigenic 
determinant. Antigen binding by antibodies is the primary function of antibodies and 
can result in protection of the host. 
Valency - The valency of antibody refers to the number of antigenic determinants 
that an individual antibody molecule can bind. The valency of all antibodies is at 
least two and in some instances more. 
b) Effector functions - Often the binding of an antibody to an antigen has no direct 
biological effect. Rather, the significant biological effects are a consequence of 
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secondary "effector functions" of antibodies. The immunoglobulins mediate a 
variety of these effector functions. 
• Fixation of complement - lysis of cells, release of biologically active 
molecules. 
• Binding to various cell types - phagocytic cells, lymphocytes, platelets, mast 
cells, and basophils have receptors that bind immunoglobulins and the 
binding can activate cells to perform some function. Some immunoglobulins 
also bind to receptors on placental trophoblasts. The binding results in 
transfer of the immunoglobulin across the placenta and the transferred 
maternal antibodies provide immunity to the fetus and newborn. 
Disulfide bonds 
Most IgG molecules have four interchain disulfide bonds—two connecting 
the two H chains at the hinge region and the other two connecting the two L chains 
to the H chains (Janeway et al, 2001). Exceptions do exist. Two disulfide bonds 
were found in IgGl and IgG4 linking the two heavy chain in the hinge region but 
four in IgG2 (Zhang and Czupryn, 2002). In IgGl MAb, HC is linked to the LC 
between the fifth Cys (C217) of HC and C213 on the LC. In IgG2 and IgG4 MAbs, 
it is the third Cys of HC (CI23) linking to the LC (Zhang and Czupryn, 2002). A 
disulfide bond between HC CI28 and LC C214 was found for mouse catalytic 
monoclonal antibodies (IgG2a) (Ruzheinikov et al., 2003). IgGs have four 
intrachain disulfide bonds, residing in each domain of the H and L chains, 
stabilizing these domains. The intrachain disulfide bonds in VH and VL are required 
in functional antigen binding (Glockshuber et al, 1992). Native IgG MAbs should 
not have any free sulfhydryl groups (Zhang and Czupryn, 2002). However, detailed 
examination of the free sulfhydryl groups in recombinant MAbs (one IgGl, two 
IgG2, and one IgG4) suggests presence of a small portion of free sulfhydryl group 
(approximately 0.02 mol per mole of IgG2 or IgG4 MAb and 0.03 for IgGl (Zhang 
and Czupryn, 2002). In rare cases, a free cysteine is found. A nondisulfidebonded 
Cys at residue 105 was found on the heavy chain of a mouse monoclonal antibody, 
0KT3 (IgG2a) (Kroon et al, 1992). 
Oligosaccharides 
Immunoglobulins contain carbohydrates (Fig. 6 & 7) at conserved N-
glycosylation sites located in the constant regions of their heavy chains (Sutton and 
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Fig. 6 An alpha carbon backbone representation of the IgG molecule. Each 
light chain (reddish-orange) is folded to give of two P-barrel domain 
structures. Each heavy chain (blue) is folded to give four such 
domains. There is domain "pairing" i.e. interaction through 
non-covalent bonds, except for the CH2 domains where the internal 
space is occupied by the oligosaccharide chains (white). 
Source: (http://www.ii.bham.ac.uk/webs/RoyJefferis/croatia/slide2.html). 
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Fig. 7 Interactions between domains in the separate chains of an immunoglobuHn 
molecule are critical to its quaternary structure, (a) Model of IgG molecule, 
based on x-ray crystallographic analysis, showing associations between 
domains. Each solid ball represents an amino acid residue; the larger tan 
balls are carbohydrate. The two light chains are shown in shades of red; the 
two heavy chains, in shades of blue, (b) A schematic diagram showing the 
in- teracting heavy- and light-chain domains. Note that the CH2/CH2 
domains protrude because of the presence of carbohydrate (tan) in the 
interior. The protrusion makes this domain more accessible, enabling it to 
interact with molecules such as certain complement components. 
Source: (Goldsby et ai, 2006). 
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Phillips, 1983). The oligosaccharides present at this site are highly heterogeneous, 
and are known to affect the biological and physicochemical properties of IgGs 
(Mizuochi, et ai, 1982; Fujii et al, 1990). Glycosylation of these sites seems to 
have little, if any, effect on antigen binding (Donadel et al, 1994). There is one 
oligosaccharide chain in IgGs (Janeway et al., 2001). This N-linked biantennary 
sugar chain resides mostly on the conserved Asn 297 (Fig. 8), which is buried 
between the CH2 domains (Wright and Morrison, 1997; Harris et al, 2004). For 
example, the oligosaccharide resides on Asn-297 of the CH2 domain of chimeric 
IgGl and IgG3 molecules (Tao and Morrison, 1989) but on Asn 299 in a 
monoclonal antibody, 0KT3 (IgG2a) (Kroon et al, 1992). The oligosaccharide, 
often microheterogeneous, is typically fucosylated in antibodies produced in CHO 
or myeloma cell lines (Harris et al, 2004) and may differ in other cell lines (Wright 
and Morrison, 1997; Roque et al, 2004). There are many factors that dictate the 
nature of the glycan microheterogenity on IgGs. These include cell line, the 
bioreactor conditions and the nature of the downstream processing. An additional 
oligosaccharide can be found in rare cases. A human IgG produced by a human-
human-mouse heterohybridoma contains an additional oligosaccharide on Asn 75 in 
the variable region of its heavy chain (Leibiger et al, 1999). In addition, 0-linked 
carbohydrates could also exist in this antibody. 
Proper glycosylation is critical for correct functioning of antibodies (Wright 
and Morrison, 1997). It was demonstrated that removal of the oligosaccharide in 
IgGs (IgGl and IgG3) made them ineffective in binding to Clq, in binding to the 
human FcgRI and activating C; and generally more sensitive to most proteases than 
their corresponding wild-type IgGs (one exception) (Tao and Morrison, 1989). This 
is because the binding site on IgG for Clq, the first component of the complement 
cascade, is localized in the CH2 domains (Wright and Morrison, 1997). 
Furthermore, the glycosylation can affect the antibody conformation (Tao and 
Morrison, 1989). 
The sugar composition of the oligosaccharide is also critical in antibody 
functions. It has been shown that a low fucose (Fuc) content in the complex-type 
oligosaccharide in a humanized chimeric IgGl is responsible for a 50-fold higher 
antibody-dependent cellular cytotoxicity (ADCC) compared with a high Fuc 
counterpart (Shinkawa et al, 2003). Some antibodies have also been reported with 
N - glycosylation sites in the variable regions (Leung er o/., 1995; Khuranae/a/., 
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Fig. 8 Diagram of the IgG molecule illustrating the carbohydrate sequence and site 
of attachment on heavy chain. The oligosaccharide, attached at asparagine 
297, is of the complex biantennary type. In the figure the continuous lines 
identify a "core" oligosaccharide structure and additional sugar residues that 
may be attached are indicated by the dotted lines. It is not known whether 
individual IgG molecules bear the same or different oligosaccharide 
structures on the heavy chains. 
Source: (Griffiths and Lunec, 1989). 
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1997). The light chain- linked oligosaccharides are presumed to be present on the 
variable regions (Sox and Hood, 1970; Decourt et ai, 1996). The presence of large, 
bulky carbohydrates on the surfaces of the variable regions of an immunoglobulin 
contributes to, and probably alters, the conformation of the protein at this site. 
Therefore, glycosylation in the variable domains often seems to interfere with the 
antigen-binding properties of these antibodies (Wallik et al, 1988; Wright et al., 
1991; Leung et al, 1995). There is limited information concerning the structures of 
Fab-linked oligosaccharides. The N-linked carbohydrate structures found in the 
variable regions seem to differ from those present in the constant region of IgG 
(Savidou et al., 1984; Rademacher et al., 1988; Tachibana et al., 1997). In addition 
to N linked oligosaccharides, 0-linked oligosaccharides have been determined in a 
human light chain (Chandrasekaran et al., 1981). 
IgG Fc reactions with other proteins 
The human IgG subclasses bind to other proteins by non-Fab-mediated 
reactions. Protein A from Staphylococcus aureus binds to human IgG at a site 
between their CY2 and Cy3 domains (Kronvall and Williams, 1969). A single 
substitution of arginine for histidine at amino acid residue no. 435 in the Fc region 
prevents IgG3 binding to Protein A. The interaction of Protein A with human IgG 
has been successfully used in affinity chromatography (Recht et al., 1981). Human 
rheumatoid factors (RF) are IgG, IgA or IgM antibodies that bind to the Fc of 
immunoglobulins (Munthe and Natvig, 1972). In most cases, IgG is also the antigen 
for RF. Human rheumatoid factors react most strongly with IgGl myeloma proteins 
followed by IgG2 and IgG4. IgG3 appears to be unreactive with RF (Torrigiani and 
Roitt, 1967; Normansell and Stanworth, 1968). Human rheumatoid factors (RF) 
have been defined as antibodies, most commonly IgM, that are found predominantly 
in individuals with rheumatic diseases (Kunkel et al, 1961; Robbins et al., 1987). 
RF binds to determinants primarily on the Fc of autologous (individual's own), 
isologous (other human), or heterologous (other species) IgG in either a native or 
denatured state. In clinical assays for rheumatoid factor the agglutination of rabbit or 
human IgG-coated latex particles is used to estimate the amount of RF activity in 
serum. IgG rheumatoid factors have been measured by immunoassay with 
monoclonal anfibodies (McDougal et al, 1985). It has not been possible to 
determine the subclass(es) of IgG RF that bind to human IgG, owing to the 
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unavailability of documented monoclonal antibodies that react only with 
determinants in the Fab region of each IgG subclass molecule. Anti-immunoglobulin 
antibodies (rheumatoid factors) may represent the single most important interfering 
factor in serum that can falsely increase the amount of analyte detected in 
immunometric assays (Bock et al, 1985; Boscato and Stuart, 1986). 
Characteristics of immunogen 
Many different substances can induce immune responses. The following 
characteristics have an important influence in the ability that a substance has to 
behave as an immunogen. 
A. Foreigness: As a rule, only substances recognized as "non-self will trigger the 
immune response. Microbial antigens and heterologous proteins are obviously "non-
self and are strongly immunogenic. 
B. Molecular size: The most potent immunogens are macromolecular proteins 
[molecular weight (M.W.) > 100,000]. Molecules smaller than 10,000 daltons are 
weakly immunogenic. 
C. Chemical structure and complexity: Proteins and polysaccharides are among 
the most potent immunogens, although relatively small polypeptide chains, nucleic 
acids, and even lipids can, given the right circumstances, be immunogenic. 
1. Proteins: Large heterologous proteins expressing a wide diversity of 
antigenic determinants are potent immunogens. 
a. The immunogenicity of a protein is strongly influenced by its chemical 
composition. Positively charged (basic) amino acids, such as lysine, arginine, and 
histidine are repeatedly present in the antigenic sites of lysozyme and myoglobin, 
while aromatic amino acids (such as tyrosine) are found in two of albumin's six 
antigenic sites. Therefore, it appears that basic and aromatic amino acids may 
contribute more strongly to immunogenicity than other amino acids; basic proteins 
with clusters of positively charged amino acids are strong immunogens. 
b. There appears to be a direct relationship between antigenicity and chemical 
complexity: aggregated or chemically polymerized proteins are much stronger 
immunogens than their soluble monomeric counterparts. 
2. Polysaccharides: Polysaccharides are among the most important natural 
antigens. Pure polysaccharides or the sugar moieties of glycoproteins, 
lipopolysaccharides, glycolipid-protein complexes, etc., are immunogenic. Many 
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microorganisms have polysaccharide-rich capsules or cell walls, and a variety of 
mammalian antigens, such as the erythrocyte antigens (A, B, Le, H), are short-chain 
polysaccharides (oligosaccharides). 
3. Polypeptides: Hormones such as insulin and other polypeptides, although 
relatively small in size (M.W. 1500), are usually immunogenic when isolated from 
one species and administered over long periods of time to an individual of a 
different species. 
Immunogenicity of IgG 
The ability of a protein to react specifically with the functional binding site 
of a complementary antibody is known as its antigenic reactivity or antigenicity. The 
portion of a protein antigen that is recognised by an antibody molecule is given the 
status of an antigenic determinant or epitope of the protein. The situation is quite 
different with immunogenicity which is the ability of the protein to induce an 
immune response in a competent host. Whereas antigenicity can be reduced to the 
level of chemistry, such a reduction is not achievable in the case of immunogenicity 
which depends on many complex interactions with various elements of the host 
immune system (Van Regenmortel, 2001). Immunogenicity depends on extrinsic 
factors such as the host immunoglobulin repertoire, self-tolerance, the production of 
cytokines and various cellular and regulatory mechanisms, definable only in the 
context of a particular host (Berzofsky, 1985). The immunogenicity of 
immunoglobulin idiotypes in syngeneic systems is a rather rare phenomenon. 
(Lopez-Requena et al., 2007). 
Since immunoglobulins are glycoproteins, they can act as an antigen, 
eliciting an immune response that generates anti-immunoglobulin antibodies. 
However, the structural (three-dimensional) features that define isotypes are not 
immunogenic in an animal of the same species, since they are not seen as "foreign". 
For example, the five human isotypes, IgA, IgD, IgG, IgE and IgM are found in all 
humans and a result, injection of human IgG into another human would not generate 
antibodies directed against the structural features (determinants) that define the IgG 
isotype. However, injection of human IgG into a rabbit would generate antibodies 
directed against those same structural features. Previous investigations have 
demonstrated that antigenic determinants are surface features of proteins and 
indicate that they are frequently found on regions of a molecule that have an 
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unusually high degree of exposure to solvent-i. e., regions which project into the 
medium (Atassi, 1975; Reichlin, 1975). This, together with the fact that charged, 
hydrophilic amino acid side chains are common features of antigenic determinants, 
Free radicals 
The presence of free radicals in biological materials was discovered less than 
56 years ago (Commoner et al., 1954.). In 1956, free radicals were described as a 
Pandora's box of evils that may account for gross cellular damage, mutagenesis, 
cancer, and, last but not least, the degenerative process of biological aging (Harman, 
1956, 1981). A free radical is any chemical species capable of independent 
existence, possessing one or more unpaired electrons. (Vallyathan and Shi, 1997). 
There exists a delicate balance between the advantageous and detrimental effects of 
free radicals. Chemical reactions, including oxidation and reduction of molecules, 
occur in every cell. These reactions can lead to the production of free radicals. 
Reactive oxygen species (ROS) are known mediators of intracellular signaling 
cascades. Excessive production of ROS may, however, lead to oxidative stress 
(Fisher-Wellman and Bloomer, 2009), loss of cell function, and ultimately apoptosis 
or necrosis. (Nordberg and Amer, 2001), Free radicals react with organic substrates 
such as lipids, proteins, and DNA. Through oxidation free radicals cause damage to 
these molecules, disturbing their normal function, and may therefore contribute to a 
variety of diseases. 
Free radicals and non-radical reactive molecules (derived from free radicals) 
have been listed in Table 4-6. Nitrogen monoxide (NO), superoxide anions and 
related reactive oxygen (ROS) and nitrogen (RNS) species, however, also play 
important modulating roles in certain signal transduction pathways. Several ROS-
mediated reactions protect the cell from oxidative stress and serve to stabilize redox 
homeostasis. In more developed organisms NO and ROS act as signal transducing 
molecules, modulating vascular tone, monitoring oxygen pressure and production of 
erythropoietin, as well as playing a role in signal transduction pathways involving 
membrane receptors as part of various physiological processes. 
Specific markers show that oxidative damage occurs. Certain biomarkers 
well characterize the cell damage in vitro. 8-Hydroxy-2-deoxyguanosine (8-OHdG) 
and 8-hydroxyadenine measured in urine are characteristics for DNA damage, 
lipid peroxides and other end products of the peroxidation process like isoprostanes 
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Table 4: Reactive oxygen species (ROS) as free radicals 
Hydroxyl 
Superoxide 
Nitric oxide 
Thiyl 
Peroxyl 
OH-
0-2" 
NO-
RS-
RO-2 
Table 5: Non-radical reactive oxygen species 
Peroxynitrite 
Hypochlorous acid 
Hydrogen peroxide 
Singlet oxygen 
Ozone 
Lipid peroxide 
ONOO-
HOCl 
H2O2 
-O2 
O3 
LOOH 
Table 6: Reactive nitrogen species (RNS) 
Nitrous oxide 
Nitrosyl cation 
Peroxynitrite 
Nitrogen dioxide 
Peroxynitrous acid 
Dinitrogen trioxide 
Nitroxyl anion 
Nitrous acid 
Nitryl chloride 
N2O 
NO^ 
OONO' 
NO-2 
ONOOH 
N2O3 
NO" 
HNO2 
NO2CI 
Source of Tables 4-6: (Somogyi et al., 2007). 
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(8-epi-prostaglandine), malondialdehyde or diene conjugation shows lipid damage, 
while nitrotyrosine is useful index for assessing protein damage. Antioxidants delay 
or inhibit the oxidation of a substrate (Somogyi et al., 2007; Chacko et ah, 2010). 
Reactive nitrogen species 
Reactive nitrogen species (RNS) are a family of antimicrobial molecules 
derived from nitric oxide produced via the enzymatic activity of inducible nitric 
oxide synthase 2 (NOS2) (Nathan and Shiloh, 2000; Fang, 2004). 
Nitric oxide (NO') 
Since its discovery as a biologic messenger molecule just over a decade ago, 
NO' has become well recognized for its participation in diverse biologic processes in 
nearly all aspects of life, including vasodilation, bronchodilation, neurotransmission, 
inhibition of phagocyte and platelet aggregation, and antimicrobial activity 
(Moncada, et al., 1991). Nitric oxide is produced by a wide variety of cell types by 
both constitutive and inducible nitric oxide synthases (Knowles and Moncada, 
1994). There are three isoforms of NOS: neuronal NOS (nNOS), identified in brain, 
inducible NOS (iNOS), identified in macrophages, and endothelial NOS (eNOS) 
identified in endothelial cells (Ghafourifar et al, 2001). It has many physiological 
functions ranging from regulation of vascular tone to neurotransmission and 
modulation of inflammatory processes (Moncada and Higgs, 1993). Induction of 
NO' synthesis during inflammatory processes represents a defense mechanism 
against invading microorganisms, but excessive formation of NO' has also been 
implicated in host tissue injury (Moncada and Higgs, 1993; Anggard, 1994; 
Beckman and Koppenol, 1996). Increased NO production by induction of iNOS has 
been recommended as a major mechanism by which cytokines mediate 
inflammatory responses and development of autoimmune diseases. (Turko and 
Murad, 2002). 
Although NO' is a free radical, it has selective reactivity and reacts 
predominantly with other paramagnetic species, including ferrous or ferric iron in 
heme proteins or iron-sulfur centers, and other radical species such as molecular 
oxygen (O2), superoxide anion (O2" "), and lipid or protein radicals (Stamler et al, 
1992; Kharitonov et al, 1994; Eiserich et al, 1995; Pryor and Squadrito, 1995; 
Rubbo et al, 1996). Autoxidation of NO by reaction with O2 results in the 
formation of nitrite (NO2"" ) as the primary end- product (Ignarro et al, 1993) 
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although at physiological concentrations of NO and O2, this reaction may be too 
slow to be of major importance in vivo (Kharitonov et al, 1994; Beckman and 
Koppenol, 1996). 
In the vascular system, NO is rapidly oxidized by reaction with oxyhemoglobin 
(Hb02), resulting in formation of methemoglobin (Hb^^) and nitrate (NOs") (Doyle 
and Hoekstra, 1981). Excess reactive nitrogen species (RNS) has been associated 
with vascular lesion formation and functional defects (Puddu et al, 2009). Nitric 
oxide also reacts with Hb'^ '^  to form a complex (Hb-NO), which can hydrolyze to 
Hb^ "^  and NOa" (Radi, 1996). Nitric oxide also reacts at a near diffusion- limited rate 
with O2' ~ to yield peroxynitrite (0N00~), a powerful oxidizing species, and many 
of the cytotoxic properties of NO have in fact been attributed to the formation of 
0 N 0 0 ~ (Beckman and Koppenol, 1996). Reaction of 0 N 0 0 ~ or its conjugate acid, 
ONOOH, with a wide variety of biomoleculesalso resuhs in concomitant production 
of NO2"' (Pryor and Squadrito, 1995). Hence, irrespective of the mechanisms 
involved, N02~ is a major oxidation product derived from NO , and increased N02~ 
levels can often be detected in situations where NO production is elevated. 
In healthy human subjects, N02~ can be detected at levels of 0.5-3.6 ^M in 
plasma (Leone et al, 1994; Ueda et al, 1995). Increased N02~ levels have been 
detected in synovial fluids of patients with rheumatoid arthritis (Farrell et al, 1992) 
and serum N02~ levels of 36|iM have been reported in human immunodeficiency 
virus-infected patients with interstitial pneumonia (Torre et al., 1996). Increased 
N02~ levels have been detected in condensed exhalates from patients with asthma 
(Hunt et al, 1995). Although NO2'" is a major end product of NO metabolism, it 
does not accumulate in vivo but is rapidly oxidized to NOs" (Parks et al, 1981). 
Nitrite can be oxidized by Hb02 or oxymyoglobin to form methemoglobin or 
metmyoglobin and NOs" (Martin and Huisman, 1963; Doyle et al, 1985), by 
catalase (Heppel and Porterfield, 1949; Cohen et al, 1964) by inflammatory 
oxidants such as hypochlorous acid (HOCl) (Klebanoff, 1993; Huie, 
1994). Oxidation of NOj" by HOCl results in the production of reactive nitrogen 
intermediates (Eiserich et al, 1996). Nitrite can also be oxidized by heme 
peroxidases in the presence of hydrogen peroxide (H2O2) (Haas and Lee, 1924; 
Chance, 1952; Shibata et al, 1995), resulting in reactive nitrogen intermediates 
(Shibata et al, 1995). Depending on the microenvironment, NO can be converted to 
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various other reactive nitrogen species (RNS) sucii as nitrosonium cation (NO*), 
nitroxyl anion (NO") or peroxynitrite (0N00~) (Stamler et al., 1992). 
Peroxynitrite (PON) 
Peroxynitrite is a powerful oxidant produced in biological systems from 
superoxide (O2* ' ) and nitric oxide (NO*) (Beckman et al, 1990; Radi et al, 1991a; 
Pryor and Squadrito, 1995; Khan et al, 2009; Shaw et al, 2009; Curtis et al, 2010; 
Hulvey et al, 2010). This is a diffusion-controlled reaction with a second order rate 
constant {kl) occuring at a very rapid reaction rate (0.38-1.9 x lO'^ M"' s"') and it is 
essentially irreversible due to its highly exothermic nature with a (Huie and 
Padmaja, 1993; Goldstein and Czapslci, 1995; Koppenol, 1998). This rate is almost 
10 times faster than the reaction between O2" ~ and superoxide dismutases (SODs, 
1-2 X 10^  M"^  s"^ ). The sites of peroxynitrite formation are assumed to be spatially 
associated with the sources of superoxide (such as the plasma membrane NAD(P)H 
oxidases or the mitochondrial respiratory complexes) because although NO is a 
relatively stable and highly diffusible free radical, superoxide is much shorterlived 
and has restricted diffusion across biomembranes. (Szabo et al, 2007). Various cell 
types such as macrophages, Kupffer cells, and endothelial cells that simultaneously 
produce and release O2' " and NO can produce peroxynitrite (Beckman et al, 1990; 
Radi et al, 1991a; Pryor and Squadrito, 1995). 
Although peroxynitrite is relatively stable, its conjugated acid, peroxynitrous 
acid (ONOOH, pKa = 6.8), decays rapidly, with an apparent rate constant of 0.9 s"' 
at 37°C (pH 7.4). Peroxynitrite has the potential to cause DNA-strand break, lipid 
peroxidation, oxidation, and nitration of nucleotides and proteins, or diverse 
modification of small biomolecules such as the oxidation of thiols or methionine, 
and the oxidation and nitration of tyrosine (Pryor and Squadrito, 1995; 
Ischiropoulos, 1998; Greenacre and Ischiropoulos, 2001; Zhou et al, 2009; Dixit et 
al, 2010). Peroxynitrite has also been implicated in an increasing list of diseases, 
including atherosclerosis, inflammation, and neurodegenerative diseases 
(Ischiropoulos, 1998; Greenacre and Ischiropoulos, 2001). Formation of 3-N02Tyr 
in the plasma proteins of rats given a nitrating agent was first observed by Ohshima 
et al, 1990. 3-N02Tyr has been widely utilized as a biomarker for production in a 
wide range of human and animal diseases (Huie and Padmaja, 1993; Pryor and 
Squadrito, 1995). Studies have suggested that peroxynitrite formed from NO' and 
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Oi' " can be a significant source of 3-N02Tyr (Reiter et al., 2000; Sawa et ai, 
2000). The rates of peroxynitrite production in vivo in specific compartments have 
been estimated to be as high as 50-100 fiM per min (Alvarez et ai, 2004). 
Peroxynitrite is a short-lived oxidant species with a short half-life of -10 ms at 
physiological pH (Szabo et al, 2007). 
Under physiological conditions, both NO and O2' ~ exist at very low 
concentrations. However, at loci near cells that produce both O2' ~ and NO, the 
local concentrations of the two should be significant and the formation of 0N00~ 
appears likely (Pryor and Squadrito, 1995). A landmark paper (Beckman et al., 
1990) suggested that these two radicals could combine to form ONOO" (Equation), 
holding enormous implications for the understanding of free radicals in biological 
systems. ONOO" will be generated as a consequence of the simultaneous 
production of O2' " and NO*, a condition almost invariably occurring at sites of 
active inflammatory-immune processes. 
02"~ + N0 ' - > ONOO" 
Peroxynitrite is not a free radical because the unpaired electrons on O2* ~ and 
NO* have combined to form a new N - 0 bond in peroxynitrite, but it is a strong one 
or two electron oxidant and nitrating agent (Gebicka and Didik, 2009). Even at 
physiological pH, the relative stability of ONOO' allows it to diffuse for a 
considerable distance on a cellular scale, and even to cross cell membranes 
(Beckman et al., 1994). Peroxynitrite can react rapidly with proteins (Moreno and 
Pryor, 1992; Ischiropoulos and Al-Mehdi, 1995; Pietraforte and Minetti, 1997; Sies 
and Arteel, 2000), lipids (Rubbo et al., 1994) and DNA (Epe et al., 1996; Ahmad 
et al., 2009). Moreover, sulphydryl groups on cell structures are also targets of 
ONOO", and either affect the function of signalling systems or result in the 
production of tissue-derived NO "-releasing compounds (Radi et al., 1991b; Wu 
et al., 1994; White et al., 1999; Crow, 2000). 
Like NO , ONOO" has been associated with both deleterious and beneficial 
effects (Moro et al., 1994; Vinten-Johansen, 2000). A review of the literature 
suggests that the effects of ONOO" do show a dependency on the environment in 
which the anion is present (Ronson et al., 1999; Ma et al., 2000). Moreover, the 
physiological effects of ONOO" are also dependent on its concentration. For 
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instance, Mallozzi et ah, (1997) demonstrated that 0N00~ at low concentrations 
(10-100 i^ mol/1) stimulates a metabolic response in human erythrocytes, leading to a 
rise of tyrosine phosphorylation proteins and an enhancement of lactate production, 
whereas 0N00~ at high concentrations (200-1000 |imol/l) inhibits tyrosine 
phosphorylation and glycolysis. This concentration-dependent effect is in agreement 
with two other independent studies, in which cardioprotection of isolated rat hearts 
occurs in the presence of low concentrations of ONOO" (2-A |imol/l) but not with 
40 |imol/l ONOO~(Schulz et al, 1997; Nossuli et al, 1998). Measuring ONOO" is 
problematic in that it cannot be measured directly; thus the surrogate measures of 
nitrotyrosine footprints are frequently used as an assay for ONOO" (Beckman et al., 
1994). The nitration (addition of aNOi group) of protein tyrosine residues gives rise 
to 3-nitrotyrosine which represents a protein modification specific for ONOO" 
formation in vivo (Beckman, 1996). Although considerably increased levels of 
nitrotyrosines have been found in tissues of several pathological conditions 
(Ischiropoulos, 1998; Reiter et al, 2000), the possible role of tyrosine nitration in 
cellular function has not been fully explored. It has been speculated that ONOO" 
formation is a primary pathway of NO metabolism (Pryor and Squadrito, 1995). 
One supposed mediator of tissue injury during reperfusion is peroxynitrite (Wang 
and Zweier, 1996). At high micromolar and low millimolar concentrations, 0N00~ 
promotes DNA strand breakage (Ischiropoulos and Al-Mehdi, 1995) and nitration of 
phenolic-containing substances (Gow et al., 1993.), resulting in cellular dysfunction. 
The peroxynitrite anion shows maximum absorption at 302 nm with an 
extinction coefficient of 1670 M~'cm~' (Hughes and Nicklin, 1968). Peroxynitrite 
can react with carbon dioxide to form a peroxynitrite-carbon dioxide adducts 
(nitrosoperoxocarboxylate, ONOOCOi"), which also has a very high reactivity with 
biological materials and an increasing of nitrated and decreasing of oxidized 
products (Uppu et al, 1996;Lymar et al, 1996; Yermilov et al, 1996; Wink and 
Mitchell, 1998; Radi, 2004). Since relatively high concentrations of bicarbonate 
(approx. 25 mM in blood plasma) and carbon dioxide (1.3-1.5 mM) in equilibrium 
with it are always present in intracellular and intercellular fluids, the peroxynitrite-
carbon dioxide adduct may be the ultimate chemical species that mediates O2* ~ and 
NO chemistry in vivo. Since the lifetime of the adduct is estimated to be less than 
1 s (Merenyi and Lind, 1997), the adduct decomposes into 67% nitrite and 33% NO2 
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and carbonate radical (CO3' ") immediately (Lymar and Hurst, 1998; Hodges and 
Ingold, 1998; Bonini et al, 1999). 
Beneficial role of PON 
Two important findings lend support to the contention that 0N00~ may 
actually be beneficial rather than cytotoxic. First, physiologically achievable 
concentrations of ONOO" significantly attenuated neutrophil-endothelium 
interactions in an in vivo rat mesentery preparation (Lefer et al, 1997). Second, at 
low micromolar concentrafions, ONOO" decreased the extension of necrotic tissue 
in vivo (Nossuli et al, 1997). Some studies have demonstrated that ONOO" at high 
nanomolar to low micromolar concentrations exerts beneficial effects similar to 
those of NO, including vasodilation of human (Ku, et al, 1995.) coronary arteries 
and inhibifion of leukocyte-endothelium interactions (Lefer et al, 1997; Nossuli et 
al, 1997). A potential molecular mechanism that may account for the beneficial 
effects of ONOO" is the formation of 5-nitrosothiols (Wu et al, 1994). 
iS-nitrosothiols have previously been shown to relax vascular smooth muscle by 
activation of guanylyl cyclase (Ignarro et al, 1981.) and protect in the setting of 
ischemia-reperfusion (Delyani, et al, 1996). 
Biochemistry of peroxynitrite: reaction targets and fate 
The oxidant reactivity of peroxynitrite is highly pH-dependent and both 
peroxynitrite anion (0N00~) and peroxynitrous acid (ONOOH) can participate 
directly in one- and two-electron oxidation reactions with biomolecules 
(Fig. 9 a&b). A fundamental reaction of ONOO" in biological systems is its fast 
reaction with carbon dioxide (in equilibrium with physiological levels of bicarbonate 
anion; (c), which leads to the formation of carbonate and nitrogen dioxide ('NOi) 
radicals (yield approximating 35%), which are good one-electron oxidants (d) that 
can readily oxidize amino acids such as cysteine and tyrosine to yield the 
corresponding cysteinyl and tyrosyl radicals. In addition, 'NO2 can undergo 
diffusion-controlled termination reactions with biomolecule-derived radicals, 
resulting in nitrated compounds (d). Alternatively, ONOOH can undergo hemolytic 
fission to generate one-election oxidants hydroxy! ('OH) and 'NO2 radicals (with a 
30% yield; e). However, this reaction is slow in biological systems compared with 
the other reactions of ONOO" and ONOOH and therefore is a modest component of 
the in vivo reactivity of peroxynitrite in aqueous compartments. However, ONOOH 
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RS" + ONOOH -^ RSOH + NO2-
RSOH + RS" -^ RSSR' 
Me"^X + ONOO" ^  0 = Me^"^"^X + "NOi 
ONOOH -> NO3 (isomerization, 70% yield) 
ONOOH ^ "NOj + 'OH (homolysis, 30% yield) 
ONOOCO2" -^ N03"+ CO2 (isomerization, 65% yield) 
ONOOCO2" -^ 'NO2 + CO3' (homolysis, 35% yield) 
Fig. 9 Biochemistry of peroxynitrite: reaction targets and fate 
(a) Peroxynitrite anion (ONOO") is in equilibrium with peroxynitrous acid 
(ONOOH; p^a = 6.8) and either one can undergo direct reactions with 
biomolecules as indicated (Se-GPx, Selenium-containing glutathione 
peroxidase). 
(b) Pathways in the decomposition of peroxynitrite. 
Source: (Szabo et al, 2007). 
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readily crosses lipid bilayers (f) and its decomposition to 'OH and 'NO2 radicals 
seems to become relevant in hydrophobic phases to initiate lipid peroxidation and 
lipid and protein nitration processes (g). Moreover, ONOOH in the membranes may 
undergo direct reactions with metal centres such as hemin or membrane associated 
thiols. 
Peroxynitrite reactions and formation in mitochondria 
Mitochondria constitute a primary locus for the intracellular formation and 
reactions of peroxynitrite, and these interactions are recognized to contribute to the 
biological and pathological effects of both nitric oxide (*N0) and peroxynitrite 
(Fig. 10). Extra- or intramitochondrially formed peroxynitrite can diffuse through 
mitochondrial compartments and undergo fast direct and free radical-dependent 
target molecule reactions. These processes result in oxidation, nitration, and 
nitrosation of critical components in the matrix, inner and outer membrane, and 
intermembrane space. Mitochondrial scavenging and repair systems for 
peroxynitrite-dependent oxidative modifications operate but they can be 
overwhelmed under enhanced cellular 'NO formation as well as under conditions 
that lead to augmented superoxide formation by the electron transport chain. 
Peroxynitrite can lead to alterations in mitochondrial energy and calcium 
homeostasis and promote opening of the permeability transition pore. The effects of 
peroxynitrite in mitochondrial physiology can be largely rationalized based on the 
reactivities of peroxynitrite and peroxynitrite-derived carbonate, nitrogen dioxide, 
and hydroxyl radicals with critical protein amino acids and transition metal centers 
of key mitochondrial proteins (Radi et ai, 2002). Nitric oxide can freely diffuse to 
or be formed in mitochondria, while the Q-cycle is a key source of 
intramitochondrial O2'. Peroxynitrite arising from extramitochondrial sites or 
formed intramitochondrially undergoes reactions in the different mitochondrial 
compartments and small amounts may even diffuse to the cytosol. In mitochondria, 
peroxynitrite can trigger processes that affect mitochondrial physiology, including 
inhibition in energy metabolism, disruption of calcium homeostasis, and opening of 
the permeability transition pore (PTP). 
Reactions of peroxynitrite with proteins 
Reactions of peroxynitrite with cysteine 
Peroxynitrite may alter protein structure and function by reacting with various 
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0MnSO^ 
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Fig. 10 Overview of peroxynitrite formation/reactions in mitochondria. 
Source: (Szabo et al., 2007). 
31 
amino acids in the peptide chain. The most prevalent reaction is that with cysteine, 
making thiol oxidation a major modification introduced by peroxynitrite. The 
reaction of peroxynitrite with the thiols of free cysteine and albumin was the first 
direct reaction of peroxynitrite that was reported (Radi et al., 1991b) and cysteine is 
the amino acid that reacts the fastest with peroxynitrite. The reaction of peroxynitrite 
with thiols yields the corresponding disulfides and nitrite (Table 7). An intermediate 
sulfenic acid (RSOH) is formed, which reacts with another thiol forming the 
corresponding disulfide. The sulfenic intermediates have been detected in the case of 
proteins such as peroxiredoxin (Bryk et ah, 2000) and albumin (Carballal et al., 
2003). In addition to low molecular weight molecules, thiol oxidation by 
peroxynitrite has also been shown in a number of proteins, and in many cases, 
attributed to loss of function. The oxidation of the thiol may interfere with 
downstream events, as is the case of thiol-containing tyrosine phosphatases, 
transcription factors and cysteine proteases. Disulfides do not react directly with 
peroxynitrite, with the exception of reactive disulfide in lipoic acid (Trujillo and 
Radi, 2002). 
Reactions of peroxynitrite with methionine 
The nucleophilic sulfur atom in the side chain of methionine is suscepfible to 
oxidation. The main reactive species appears to be peroxynitrous acid. The products 
formed are methionine sulfoxide (Table 7) and nitrite, with the minor contribution of 
one-electron pathways to yield secondary products such as ethylene (Jensen et al, 
1997; Perrin and Koppenol, 2000). The oxidation of methionine by peroxynitrite has 
also been observed in proteins such as a 1-antitrypsin inhibitor and glutamine 
synthetase in vitro (Moreno and Pryor, 1992; Berlett et al, 1998). 
Reactions of peroxynitrite with histidine 
Histidine does not react directly with peroxynitrite (Alvarez et al., 1999) but 
it can be modified by secondary radicals. Exposure histidine to peroxynitrite leads to 
the formation oxo-histidine, nitrohistidine and histidinyl radical. In histidine-
containing peptides, the formation of both oxo- and nitro-derivatives can be detected 
through mass spectrometry. The fact that histidine is present as metal ligand in a 
number of proteins makes it a likely candidate for site-specific modification by 
peroxynitrite, most likely via histidinyl radical. 
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Table 7: Products and intermediates detected in peroxynitrite-damaged 
amino acids 
Amino acid Product 
Cysteine Disulfide (RSSR) 
Sulfenic acid (RSOH) 
Sulfmic acid (RSO2H) 
Sulfonic acid (RSO3H) 
Nitrosocysteine (RSNO) 
Nitrocysteine (RSNO2) 
Thiyl radical (RS') 
Bisulphide radical anion (RSSR*") 
Sulfinyl radical (RSO') 
Methionine Methionine sulfoxide 
Tyrosine 3-Nitrotyrosine 
3 -Hydroxytyrosine 
Dityrosine 
3,5-Dinitrotyrosine 
Tyrosyl radical 
Phenylalanine 0-, m- and p-Tyrosine 
Nitrophenylalanine 
Nitrotyrosine 
Dityrosine 
Histidine Oxo-histidine 
Nitrohistidine 
Histidinyl radical 
Source: (Alvarez and Radi, 2003). 
Reactions ofperoxynitrite with phenylalanine 
Phenylalanine does not react directly with peroxynitrite either (Alvarez et al., 
1999). Nevertheless, its exposure to peroxynitrite leads to the formation of p-,m- and 
o-tyrosine, as well as nitrophenylalanine (van der Vliet et al., 1994). 
D-Phenylalanine has been used as a probe for reactive species formation in 
microdialysis experiments of neurotoxic damage. The formation of 0- and m-
tyrosine, as well as nitrophenylalanine and nitrotyrosine, was interpreted as 
indicative of peroxynitrite formation (Ferger et al., 2001). 
Reactions of peroxynitrite with tryptophan 
In contrast to the extensive studies on nitration of tyrosine and tyrosine 
residues in proteins, a few studies on have been carried out on peroxynitrite-
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tryptophan interactions. Padmaja et al., (1996) reported that formation of 6-
nitrotryptophan (6-N02Trp) and 5-nitrotryptophan (5-N02Trp) was major products 
in the reaction between peroxynitrite and tryptophan with minor nitration products 
(4- or 7-nitrotryptophan). Alvarez et ah, (1996) also reported formation of a nitrated 
tryptophan at low concentration (0.5 mM) and additional formation of two other 
minor nitrated tryptophans, hydroxytryptophan, and N-formylkynurenine or 
dihydrotryptophan at higher concentrations of peroxynitrite (5-10 mM). Kato et al, 
(1977) reported the reaction between tert-butoxycarbonyl-Ltryptophan (Boc-Trp) 
and peroxynitrite. They found three oxidized products, N-formylkynureine, 
oxindole, and hydropyrroloindole. Sala et al, (2004) have found nitrated products at 
the positions of 4-, 6-, 7-, and 1- of the indole ring and nitrosation at the position 1. 
Although composition of the products mixture might have depended on the nitrating 
agents, all products were always observed regardless of nitrating agents. Reaction 
between various peroxynitrite and N-acetyl-L-tryptophan (N-Ac-Trp) resulted in 
four major products, which are N-acetyl-NO-formylkynurenine (N-Ac-NOFK), 
6N02~ N-acetyl-tryptophan (6N02-N-AcTrp), lN02-N-acetyl tryptophan (INO2-N-
AcTrp), and INO-N-acetyl tryptophan (INO-N-AcTrp) (Suzuki et al, 2004). 
Reactions of peroxynitrite with tyrosine 
Protein tyrosine nitration is a covalent protein modification resulting from 
the addition of a nitro (-NO2) group adjacent to the hydroxy 1 group on the aromatic 
ring of tyrosine residues (Gow et al, 2004.). Tyrosine nitration affects protein 
structure and function, resulting in the generation of antigenic epitopes, changes in 
the catalytic activity of enzymes, altered cytoskeletal organization, and impaired cell 
signal transduction (Schopfer et al, 2003.), and is thus increasingly considered as a 
central aspect of peroxynitrite- mediated cytotoxicity. Tyrosine does not react 
directly with peroxynitrite. Instead, tyrosine nitration occurs through a radical 
mechanism (Fig. 11) in which a hydrogen atom is first abstracted from tyrosine to 
form a tyrosyl radical that quickly combines with NOa' to produce 3-nitrotyrosine. 
This competes with a secondary reaction where combining with another tyrosyl 
radical to form dityrosine (Beckman and Koppenol, 1996; Beckman, 1996; 
Ischiropoulos, 2003.). Nitration is promoted by exposure of the tyrosine, its location 
on a loop, its association with a neighboring negative charge and absence of 
proximal cysteines (Souza et al, 1999). Also, nitration is enhanced in hydrophobic 
environments, possibly because of the partition and longer half-life of nitrogen 
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Fig. 11 The free radical pathways of tyrosine nitration. 
Source: (Radi, 2004). 
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dioxide radical (Zhang et al., 2001). Since free radicals mediate the process, the 
stability of the tyrosyl radical should be critical as well (Guittet et al., 1998). 
Pathways mediated by carbonate radical are expected to nitrate superficial tyrosines, 
while the initial reaction of peroxynitrite with an enzymic metal may lead to 
nitration of tyrosines close to the active site. 
Nitration is also enhanced in the presence of transition metals due to the 
formation of secondary radicals at the metal center plus N02' (Alvarez and Radi, 
2003; Aulak et al, 2001.). Metalloproteins such as heme-containing proteins (e.g., 
prostacyclin synthase) or Cu,Zn- and Mn-SOD may thus catalyze peroxynitrite-
mediated tyrosine nitration (Radi, 2004.). A second mechanism of tyrosine nitration 
relies on the generation of the N02' radical by various heme-peroxidases (mainly 
myeloperoxidase and eosinophil peroxidase) in the presence of hydrogen peroxide 
(Wu et al., 1999; Gaut et al., 2001). This may serve as a recycling mechanism to 
reuse products formed from superoxide and NO production. Therefore, nitrotyrosine 
formation technically must be considered a marker of "nitrative" stress. The advent 
of proteomic analyses has confirmed that nitration is a highly selective process, 
limited to specific tyrosine residues on a surprisingly small number of proteins 
(Aulak et al, 2001; Gow et al., 2004; Kanski et al, 2005a; Kanski et al., 2005b). 
Nitration on specific tyrosine residues is promoted by the exposure of the 
aromatic ring to the surface of the protein, the location of the tyrosine on a loop 
structure, its association with a neighboring negative charge, and absence of 
proximal cysteines (Souza et al., 1999). Tyrosine nitration may also be favored in 
hydrophobic environment, which is a relevant issue, considering that peroxynitrous 
acid can readily pass through lipid membranes (Turko and Murad, 2002; Van der 
Vliet et al., 1997). Protein(s) located proximally to the site of generation of a 
nitrating agent encounter the nitrating agent(s) first and therefore have a higher 
probability of being nitrated. In a variety of human and experimental models of the 
disease, nitrated proteins have been detected only at the site of injury and only 
within specific cell types (Greenacre and Ischiropoulos, 2001; Turko and Murad, 
2002), suggesting that proximity to the sites of nitrating agent generation may 
determine the targets modified by nitration. Recent data also indicated that 
hydrophobicity might also play a role in directing the site of nitration in model 
peptides by different nitrating species (Zhang et al., 2003). Peroxynitrite-mediated 
36 
tyrosine nitration plays a key role in inflammation and pain. Human evidence of 
nitration is seen in several diseases (Table 8). 
Reactive carbonyl formation in proteins 
Increased oxidative/nitrosative stress generally describes a condition in 
which cellular antioxidant defenses are inadequate to completely inactivate the 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated 
because of excessive production of ROS/RNS, loss of antioxidant defenses, or both. 
A major consequence of oxidative/nitrosative stress is damage to nucleic acid bases, 
lipids, and proteins, which can severely compromise cell health and viability or 
induce a variety of cellular responses through generation of secondary reactive 
species, ultimately leading to cell death by necrosis or apoptosis. Oxidative damage 
of any of these biomolecules, if unchecked, can theoretically contribute to disease 
development. Indeed, an increasing amount of evidence suggests that 
oxidative/nitrosative stress is linked to either the primary or secondary 
pathophysiologic mechanisms of multiple acute and chronic human diseases 
(Halliwell and Gutteridge, 1999; Halliwell, 2001; Dalle-Donne et al., 2003a; 
Klaunig and Kamendulis, 2004; Stocker and Keaney, 2004; Dalle-Donne et al., 
2005). 
Protein carbonyls may be generated by the oxidation of several amino acid 
side chains (e.g., in Lys, Arg, Pro, and Thr; Dalle-Donne et al., 2006). The 
formation of carbonyl compounds is the most general and widely used marker of 
severe protein oxidation both in vitro and in vivo, with several assays developed for 
the quantification of these species (Winterbourn and Buss, 1999; Levine et al., 
2000). The chemical stability of protein carbonyls makes them suitable targets for 
laboratory measurement and is also useful for their storage: their stability during 
storage for 10 years at -80 °C has been demonstrated (Stadtman and Levine, 2003). 
As a marker of oxidative damage to proteins, carbonyls have been shown to 
accumulate during aging, ischemia/reperfusion injury, chronic inflammation, cystic 
fibrosis, and many of age-related diseases in a variety of organisms (Kettle et al., 
2004; Levine, 2002). Specific carbonylated proteins have been detected in both the 
brain tissue and plasma of Alzheimer disease (AD) patients (Butterfield and 
Castegna, 2003). The observation of carbonylated proteins in plasma—a body fluid 
easily obtainable without invasive procedures and, more importantly and unlike 
brain samples, before the death of the patient—suggests that these oxidized species 
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Table 8: Peroxynitrite and human diseases 
Disease 
Circulatory shock 
Type 1 diabetes 
Diabetic complications 
Chronic heart failure 
Neuro-inflammatory 
diseases 
Local inflammatory 
diseases (arthritis, 
colitis) 
Stroke and central and 
peripheral nervous 
system trauma 
Myocardial infarction 
Neurodegenerative 
diseases 
Organ transplantation, 
transplant rejection 
Human evidence of nitration 
• There is an increase in plasma nitrotyrosine in patients with 
chronic renal failure and septic shock 
• Plasma nitrotyrosine levels correlate with the severity of septic 
shock 
• Specific myocardial and skeletal muscle proteins show 
nitration in human sepsis (including inducible NOS 
• Diabetic islets show elevated levels of 3-nitrotyrosine 
• Human pancreatic p-cells are sensitive to the toxic effect of 
peroxynitrite 
• The presence of AEOL-10150 during human islet preservation 
improves islet function and preserves pancreatic islet mass 
• Kidneys of patients with diabetic nephropathy and 
microvessels of diabetic patients show evidence of tyrosine 
nitration 
• There is marked placental tyrosine nitration in diabetes 
• Circulating leukocytes also show signs of tyrosine nitration 
• SERCA nitration is increased in human heart failure 
• Cardiomyocyte and skeletal muscle tyrosine nitration is 
increased in patients with heart failure 
• Overexpression of inducible NOS in human myocytes induces 
depression of cardiac contractility by a mechanism that probably 
involves peroxynitrite (can be inhibited by NOS inhibitors as 
well as by antioxidants) 
• Increased oxidative stress and increased 'NO breakdown 
products in the cerebrospinal fluid of multiple sclerosis patients 
• Increased tyrosine nitration in post-mortem analysis of CNS 
lesions from muhiple sclerosis patients 
• Increased oxidative stress, increased 'NO breakdown products 
and elevated tyrosine nitration in synovial fluid from arthritic 
patients 
• Increased oxidative stress, increased 'NO breakdown products 
and elevated tyrosine nitration in brain sections from patients 
who died of stroke 
• Increased oxidative stress, increased 'NO breakdown products 
and elevated tyrosine nitration in cardiac tissues from patients 
with lethal heart attacks 
• Human evidence for the nitration and oxidative dimerization of 
tau protein, tyrosine hydroxylase and ]-synuclein 
• Human evidence for nitrated manganese superoxide dismutase 
in kidney transplants 
AEOL-10150, manganese(III) tetrakis[A^-N'-diethylimidazolium-2-yl]porphyrin; 
NOS, nitric oxide synthase, SERCA, sarco/endoplasmic reticulum 
Source: (Szabo et ah, 2007). 
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may be useful as diagnostic biomarkers for (possibly early) AD. 
Biomarkers of oxidative/nitrosative stress are significantly higher in patients 
with diabetes and hypercholesterolemia, chronic kidney disease, (Oberg et ah, 
2004), acute pancreatitis (Winterbourn et al., 2003), asthma, lung cancer, 
aceruloplasminemia (Dalle-Donne et al., 2005), diabetes (types 1 and 2), chronic 
renal failure, sepsis. Acute respiratory distress syndrome (ARDS) (Dalle-Donne et 
al., 2003a), preeclampsia, bronchopulmonary dysplasia (Levine, 2002), cystic 
fibrosis (Kettle et al, 2004), idiopathic pulmonary fibrosis (Rottoli et al., 2005), 
juvenile chronic arthritis (Levine, 2002; Renke et al, 2000), meningitis (Schaper et 
al., 2002), sarcoidosis (Rottoli et al., 2005), crohn disease, uremia, systemic 
amyloidosis, chronic hepatitis C, rheumatoid arthritis, psoriasis, helicobacter pylori 
infection, inflammation and cataractogenesis (Dalle-Donne et al., 2003b) 
Oxygen free radicals are produced as byproducts of many endogenous and 
exogenous sources including UV light, radiation, neutrophil activity, and 
metabolism (Stadtman et al., 1992; Dean et al., 1997; Beckman and Ames, 1998; 
Pollack and Leeuwenburgh, 1999). Oxidative stress leads to lipid, nucleic acid, 
carbohydrate, and protein modifications. Protein oxidation and modification have 
been shown to increase during aging and exacerbate many pathological processes, 
such as atherosclerosis and human cataracts (Stadtman, 1992; Stadtman et al., 1992; 
Pollack and Leeuwenburgh, 1999). Oxidation of proteins can lead to the formation 
of oxidized amino acids, such as dityrosine, 3-nitrotyrosine, 3-chlorotyrosine, 
oxohistidine, and altered amino acid side chains containing reactive carbonyls 
(Uchida and Kawakishi, 1993; Hazell et al., 1994; Hazen and Heinecke 1997; 
Leeuwenburgh et al., 1997a; Leeuwenburgh et al., 1997b; Leeuwenburgh et al., 
1997c; Heinecke et al., 1999). Oxidation of proteins can result in the loss of 
catalytic function, increased sensitivity to denaturation, and increased susceptibility 
to proteolysis (Stadtman et al., 1992; Dean et al., 1997; Beckman and Ames, 1998). 
The accumulation of oxidized proteins is often measured by the content of reactive 
carbonyls (Stadtman and Oliver, 1991; Stadtman et al, 1992). Spectrophotometric 
assays for the appearance of carbonyl groups on proteins have been developed to 
quantify oxidative protein damage using 2,4-dinitrophenylhydrazine (DNPH) 
(Levine, et al., 1994; Reznick and Packer, 1994; Burcham and Kuhan,1996). 
Moreover, protein carbonyls can be measured by antibodies to DNPH by 
immunoblot analysis (Shacter et al., 1994; Nakamura and Goto, 1996). However, 
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the spectrophotometric methods using DNPH still remain one of the primary ways to 
identify reactive carbonyl groups on proteins (Levine et al, 1994; Reznick and 
Packer, 1994) since this assay is convenient, fast, and inexpensive. One major 
pathway believed to generate protein carbonyls in vivo is the metal-catalyzed protein 
oxidation pathway (Stadtman and Oliver, 1991; Stadtman, 1992; Stadtman et al., 
1992). The spectrophotometric protein carbonyl assay is used as an indicator of 
protein damage by free radical reactions in vitro and in a variety of pathologies. 
Nitrotyrosine 
Tyrosine nitration is a widely used marker of peroxynitrite (0N00~) 
(Herrero et al, 2001; Crisafulli et al, 2010). N02Tyr (3-Nitrotyrosine) is a modified 
amino acid that is formed by nitric oxide-derived species (Kell, D.B. 2009) and has 
been implicated in the pathology of diverse human diseases. Nitration of active-site 
tyrosine residues is known to compromise protein structure and function. Although 
free N02Tyr is produced in abundant concentrations under pathological conditions, 
its capacity to alter protein structure and function at the translational or 
posttranslational level is unknown (Eiserich et al, 1999). 0N002 can decay 
spontaneously to form hydroxyl radical and nitrogen dioxide (Beckman et al., 1990). 
Autoimmunity 
Autoimmunity is the failure of an organism to recognize its own constituent 
parts as self, which allows an immune response against its own cells and tissues. 
Any disease that results from such an aberrant immune response is termed an 
autoimmune disease. The concept of autoimmunity was first predicted by Nobel 
Laureate Paul Ehrlich at the start of the twentieth century, and he described it as 
'horror autotoxicus' (Hestvik, 2010). His experiments led him to conclude that the 
immune system is normally focused on responding to foreign materials and has an 
inbuilt tendency to avoid attacking self tissues. But when this process goes wrong, 
the immune system can attack self tissues resulting in autoimmune disease. The 
perplexing issue of what allows the immune system to attack self tissues is a 
continuing focus of research. 
In healthy individuals the immune system is "tolerant" of its host ("self) but 
attacks foreign ("non-self) constituents such as bacteria and viruses. The ability to 
distinguish self from non-self is considered to be the determining factor in whether 
the immune system responds to a suspected challenge. Possible discriminators 
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between "self and "non(not)-self' include recognition of infection (Medzhitov and 
Janeway, 2002) or identification of danger signals (Matzinger, 2002). The outcome 
of the debate on self/non-self discrimination not withstanding, autoimmunity 
represents an obvious disruption to the mechanism by which the immune system 
regulates its activities. Importantly, the responsible effector mechanisms appear to 
be no different from those used to combat exogenous infective reagents and include 
soluble products such as antibodies (humoral immunity) as well as direct cell-to-cell 
contact resuhing in specific cell lysis (cell-mediated immunity). No single 
mechanism has been described that can account for the diversity of autoimmune 
responses, or the production of autoantibodies. The most perplexing and challenging 
aspect of autoimmunity and autoantibody elicitation is the identification of the 
events involved in the initiation of the response. Although these early events are 
poorly understood for most autoimmune diseases, it is thought that an exogenous 
trigger can provide the first step in the initiation of some autoimmune responses. 
Autoantibodies in autoimmunity 
A classic features of autoimmune diseases is the presence of autoantibodies 
(Davidson and Diamond, 2001), though not all autoantibodies detected in humans 
are abnormal. Natural autoantibodies can at low levels be found in all humans, and 
they are considered abnormal only at excessively high concentrations (Tomer and 
Shoenfeld, 1988). Natural autoantibodies are usually non-organ specific, while so 
called organ-specific antibodies, react only with specific organ components. Both 
have been implicated in tissue damage and the induction of autoimmune diseases 
(Davidson and Diamond, 2001), though the function of low level natural 
autoantibodies has remained largely unknown (George et al, 1997; Lacroix-
Desmazes et al, 1998; Tomer and Shoenfeld, 1988; Baumgarth et al, 2005). The 
diseases associated with autoantibodies can be divided into two broad groups: the 
organ-specific autoimmune diseases, in which autoantibodies have the ability to 
react with autoantigens from a particular organ or tissue, and the multi-system 
autoimmune diseases, in which autoantibodies react with common cellular 
components that appear to bear little relevance to the underlying clinical picture. In 
both cases particular autoantibody specificities can serve as diagnostic markers 
(Table 9). 
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Table 9: Examples of clinical diagnostic specificity of autoantibodies 
Autoantibody specificity ^^  Molecular specificity ' 
Organ-specific autoimmune diseases 
Anti-acetylcholine 
receptor* 
Anti-TSH receptor* 
Anti-thyro globulin * 
Anti-thyroid peroxidase* 
Anti-mitochondria* 
Anti-keratinocyte* 
Anti-keratinocyte * 
Anti-GAD65 
Acetylcholine receptor 
TSH receptor 
Thyroglobulin 
Thyroid peroxidase 
Pyruvate dehydrogenase 
complex 
Desmoplakin I homologue 
Desmoglein 
Glutamic acid 
decarboxylase 65 kDa 
Multi-system autoimmune diseases 
Anti-double-stranded 
DNA* 
Anti-Sm* 
Anti-nRNP 
Anti-SS-A/Ro 
Anti-SS-B/La 
Anti-Jo-1* 
Anti-fibrillarin* 
Anti-RNA polymerase 1 * 
Anti-DNA topoisomerase 1 
(anti-Scl-70)* 
Anti-centromere* 
cANCA 
Anti-CCP* 
B form of DNA 
B, B', D, and E proteins of 
Ul,U2,andU4-U6 
snRNP 
70-kDa A and C proteins 
ofUl-snRNP 
60- and 52-kDa proteins 
associated with hYl-Y5 
RNP complex 
47-kDa phosphoprotein 
complexed with RNA 
polymerase III transcripts 
Histidyl tRNA synthetase 
34-kDa protein of C/D 
box-containing snoRNP 
(U3, U8, etc.) 
SubunitsofRNA 
polymerase 1 complex 
100-kDaDNA 
topoisomerase I 
Centromeric proteins 
CENP-A, -B, and -C 
Serine proteinase 
(proteinase 3) 
Cyclic citrullinated peptide 
Clinical association 
Myasthenia gravis 
Graves' disease 
Chronic thyroiditis 
Chronic thyroiditis 
Primary biliary cirrhosis 
Bullous pemphigoid 
Pemphigus foliaceus 
Type 1 diabetes 
SLE 
SLE 
MCTD, SLE 
SS, neonatal lupus, SLE 
SS, neonatal lupus, SLE 
Polymyositis 
Scleroderma 
Scleroderma 
Scleroderma 
CREST (limited 
scleroderma) 
Wegener's vasculitis 
Rheumatoid arthritis 
a) Disease-specific diagnostic marker antibodies indicated by asterisk. 
Abbreviations: SLE=systemic lupus erythematosus; MCTD=mixed connective tissue 
disease; SS=Sjogren's syndrome; cANCA=cytop!asmic anti-neutrophil cytoplasmic 
antibody; TSH=thyroid-stimulating hormone; CREST=calcinosis, Raynaud's phenomenon, 
esophageal dysmotility, sclerodactyly, telangiectasia. 
Source: (Pollard, 2006). 
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Autoimmune diseases 
A disease is defined as autoimmune if the tissue injury is caused by an 
adaptive immune response to self-antigen (Hestvik, 2010). Development of the 
disease by transferring the active component of the immune response to an 
appropriate recipient (usually an animal model, or in some instances matemo-fetal 
transfer of autoantibody) is the best proof that a disease is caused by autoimmunity. 
Autoimmune diseases can be considered on a continuum between those which are 
organ specific, and those which are non-organ specific (Fig. 12) (Brogana and 
Dillon, 2005). Autoimmune diseases, with the exception of rheumatoid arthritis and 
autoimmune thyroiditis, are individually rare, but together they affect approximately 
5 percent of the population in Western countries (Sinha et al, 1990; Jacobson et al., 
1997). For many years, the central dogma of immunology focused on the clonal 
deletion of autoreactive cells, leaving a repertoire of T-cells and B-cells that 
recognize specific foreign antigen. However, present view acknowledges that a low 
level of auto reactivity is physiologic (Dighiero and Rose, 1999) and crucial to 
normal immune function. Autoantigen helps to form the repertoire of mature 
lymphocytes, and the survival of naive T-cells (Goldrath and Bevan, 1999) and B-
cells Gu et al., 1991) in the periphery requires continuous exposure to autoantigens. 
Since there is no fundamental difference between the structure of self antigens (or 
autoantigens) and that of foreign antigens, lymphocytes evolved not to distinguish 
self from foreign, as some have speculated, but to respond to antigen only in certain 
microenvironments, generally in the presence of inflammatory cytokines (Silverstein 
and Rose, 2000). Since autoreactivity is physiologic, the challenge is to understand 
how it becomes a pathologic process and how T-cells and B-cells contribute to 
tissue injury. 
Alterations that lower the threshold for the survival and activation of 
autoreactive B-cells often cause the production of multiple autoantibodies, as in the 
case of the antinuclear and anti-DNA antibodies in systemic lupus erythematosus 
(Takahashi et al, 1994). Changes in the repertoire of T-cells may cause a systemic 
illness or organ-specific abnormalities. There is a tendency for more than one 
autoimmune disorder to occur in the same individual and when this happens the 
associafion is often between diseases within the same region of the autoimmune 
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Organ-specific 
Hashimoto's thyroiditis 
Thyrotoxicosis 
Pernicious anaemis 
Addison's disease 
Insulin dependent Diabetes Mellitus 
Myasthenia gravis 
Acute disseminated encephalomyelitis (ADEM) 
Goodpasture's syndrome 
Mesangiocapillary glomerulonephritis 
Gullain Barre syndrome 
Myasthenia gravis 
Pemphigus 
Pemphigoid 
Autoimmune haemolytic anaemia 
Idiopathic thrombocytopenic purpura 
Autoimmune leucopenia 
Chronic active hepatitis 
Coeliac disease 
Autoimmune enteropathy 
Autoimmune polyendocrinopathy 
Autoimmune lymphoproliferative syndrome (ALPS) 
Scleroderma 
Sjogren's syndrome 
Dermatomyositis 
Systemic vasculitides 
Mixed connective tissue disease 
Antiphospholipid syndrome 
Systemic lupus erythromatosis 
Non-Organ specific 
Fig. 12 Autoimmune diseases are considered broadly under the headings of 
organ-specific or non-organspecific diseases. In reality, there is a 
continuum between the two. 
Source: (Roitt and Delves, 2001). 
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spectrum. Thus patients with autoimmune thyroiditis (Hashimoto's disease or 
primary myxedema) have a much higher incidence of pernicious anemia than would 
be expected in a random population matched for age and sex (10% as against 0.2%). 
Conversely, both thyroiditis and Graves' disease are diagnosed in pernicious anemia 
patients with an unexpectedly high frequency (Roitt et al, 2001). As an autoimmune 
disease progresses from initial activation to a chronic state there is often an increase 
in the number of autoantigens targeted by T-cells and antibodies ("epitope 
spreading") (Moudgil and Sercarz, 1994; Lanzavecchia, 1995) and, in some cases, a 
change in participating cells, cytokines, and other inflammatory mediators. Both 
autoreactive T-cells and B-cells contribute to epitope spreading. 
Mechanism of autoantibody production 
Majority of endogenous antigens are non-immunogenic due to 
immunological tolerance at the T-cell and/or B-cell levels. However, self-proteins 
are rendered immunogenic if they are chemically modified posttranslationally under 
various physiologic or pathologic conditions (Utz and Anderson, 1998; Doyle and 
Mamula, 2001). In inflamed tissues or apoptotic cells, a variety of structurally 
modified proteins have been shovm to occur (Piacentini and Colizzi, 1999; Ohmori 
and Kanayama, 2003). Such protein modifications may lead to the generation or 
unmasking of new antigenic epitopes that will serve to activate B-cells and/or T-
cells, thereby impairing or bypassing immunological tolerance (Casciola-Rosen et 
al, 1999; Ohmori and Kanayama, 2003). Despite muhiple mechanisms to remove 
autoreactivity, a level of weakly autoreactive B-cells are continually exported to the 
periphery in normal individuals (Liu, 1997). The excluded B-cells are short-lived 
(1-2 days), and require stronger signals for activation than non-autoreactive B-cells, 
thereby decreasing the risk of autoimmune responses (Liu, 1997; Townsend et al, 
1999). Strict clonal deletion for establishing immunological tolerance may result in 
the formation of "holes" in the lymphocyte repertoire. Individuals with such "holes" 
will be susceptible to the attack by pathogens that possess self-mimicking epitopes. 
Thus, the leakiness of the central tolerance may be important to overcome the hole 
problem in the B cell repertoire (Townsend et al, 1999). If the autoreactive B-cells 
present in the periphery are activated, and recruited to the affinity maturation 
pathway, this may lead to the generation of pathogenic auto-Abs (Kouskoff et al, 
2000). 
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Post-translational modification of self-proteins as a mechanism of 
generating new antigenic epitopes 
Post-translational protein modifications play an important role in the 
regulation of protein function through the modulation of protein structure, activity, 
turnover, localization, and the nature of protein-protein complexes. It is an 
important biologic tool for the production of various protein species from a single 
gene, which may vary in conformation, function, biologic half-life and complex 
formation with other proteins (Schoneich, 2006). Today more than 200 different 
post-translational modifications are known (Khidekel and Hsieh-Wilson, 2004), 
which are the result of both enzymatic and non-enzymatic processes. There is 
increasing evidence that post-translational modifications of specific proteins 
accompany pathologic processes. Such studies could eventually lead to the 
discovery of specific biomarkers for diagnostic purposes and/or the design of 
therapies or preventive measures. 
Reactivation of silenced self-reactive B-cells is one of the critical 
mechanisms triggering auto-Ab production. B-cell tolerance has been shown to be 
disrupted when an appropriate T-cell help is provided at the time of the encounter 
with self-antigens Fulcher et al., 1996; Seo et ah, 2002). T-cell tolerance has been 
suggested to be broken or bypassed if new antigenic epitopes are created on self-
proteins (Casciola-Rosen et al, 1997; Mevorach et al, 1998; Utz and Anderson, 
1998; Amoura et al, 1999; Burkhardt et al, 2001; Doyle and Mamula, 2001). In 
apoptotic or inflamed tissues, a variety of post-translationally modified self-proteins 
have been shown to accumulate (Burkhardt et al, 2001). These modifications 
include, for instance, transglutamination, isomerization to isoaspartyl, deamidation, 
deimination (citruUination), glycosylation, oxidation, phosphorylation, and nitration 
(Scho"neich, 2006). When mice were injected with apoptotic autologous thymocytes 
containing a variety of modified proteins, pathogenic auto-Abs to nuclear proteins, 
cardiolipin and single stranded DNA (ssDNA) were efficiently induced (Mevorach 
et al, 1998). Thus, post-translational protein modification may be an important 
mechanism generating new antigenic epitopes to which T-cells and/or B-cells are 
not usually rendered tolerant. 
In the past, autoimmune diseases have been studied on the basis of the organ 
affected, but in recent years the focus has switched to a more cross-disciplinary 
approach with a view to providing a better understanding of the common 
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mechanisms underlying the pathogenesis of these diseases (Bell and Bird, 2005). 
Autoimmune diseases (AIDs) are a clinically important entity, consisting of at least 
70 known or suspected diseases. Altogether 3-5% of the general population is 
affected by these diseases. Many AIDs are common in most populations and 
characteristically women are more frequently affected than men (typically 3:1 sex 
ratio). The aetiology of most AIDs is multifactorial, with a complex polygenic 
genetic background interacting with triggering environmental factors, most of which 
are unknown (Ulmanen et al., 2005). 
Immunogenicity of NT-carrying self-proteins 
Protein tyrosine nitration is widely recognized as a hallmark of inflammation 
that is associated with the up-regulation of inducible NO synthase (Evans et al., 
1996; Ischiropoulos, 1998; Aulak et al., 2001). Activated macrophages produce 
superoxide O2* " and NO, which are converted to peroxynitrite (0N00~), a 
powerful nitrating agent that forms proteins carrying 3-nitrotyrosine (NT) as shown 
in Fig. 13 (Xia and Zweier, 1997; Ischiropoulos, 1998). NT formation is also 
catalyzed by a class of peroxidases utilizing nitrite and hydrogen peroxide as 
substrates (Pfeiffer et al., 2001). Tyrosine residues in a variety of proteins have been 
reported to be nitrated by peroxynitrite both in vitro and in vivo. These include, for 
instance, glutamine synthase, p34cdc2 kinase, bovine serum albumin, manganese 
superoxide dismutase, phosphatidylinositol 3-kinase, and tyrosine hydroxylase 
(Ischiropoulos, 1998). The formation of NT proteins has been detected 
histochemically in inflamed or infected tissues. In influenza virus-infected mice, 
alveolar macrophages and neutrophils are intensely stained with an anti-NTAb 
(Akaike et al, 1996). Macrophages in human lymph nodes obtained from surgical 
resection for lung and colonic cancers contained NT-immunopositive proteins in the 
cytoplasm (Brito et al, 1999). Synovial fluids from patients with rheumatoid 
arthritis contained higher concentrations of NT-carrying IgG compared with 
osteoarthritic specimens (Uesugi et al, 2000). 
The NT moiety is considered to serve as a hapten to stimulate NT-specific B-
cells, since anti- NT Abs are easily induced when animals are immunized with NT-
bearing heterologous proteins (Ye et al, 1996). It has been seen that NT-bearing 
mouse IgG (NT-IgG) as a model of NTself proteins is immunogenic to induce 
DNA-crossreactive anti-NT Abs in autologous normal mice. Anti-NT IgM and IgG 
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Natvesef-proteins 
(nofumnunogenc) 
NT- s&f-proleins 
Fig. 13 Generation and immunogenicity of NT-carrying self-proteins. 
Protein tyrosine residues are nitrated by the reaction with 
peroxynitrite that is formed by activated inflammatory cells, yielding 
NT-carrying self-proteins. NT-containing peptides (shown in red) 
may serve as B cell and T cell epitopes. Silenced B-cells specific for 
a native epitope on NT-proteins (shown in green) might be activated 
by helper T-cells recognizing NTcontaining epitopes. 
Source: (Ohmori and Kanayama, 2005). 
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responses elicited after the third immunization with NT-IgG, concomitant with an 
increase of anti-ssDNA titer. NT-IgG can also provide antigenic epitopes for T-cells 
because NT-IgG-primed splenic T-cells show a proliferative response to the 
inducing antigen in vitro (Ohmori et al., 2005). Another interesting finding is that 
NT-IgG primed splenic cells also prolifere in response to native IgG, suggesting a 
type of epitope-spreading during the immune response. Cooperation between B-cells 
and T-cells primed with NT-IgG may have led to the production of ssDNA-
crossreactive anti-NT antibodies. It may be also possible that silenced B-cells 
specific for a native determinant are reactivated by helper T-cells recognizing 
NTepitopes (Seo et al., 2002). Effectiveness of an NT-containing peptide as a T-cell 
epitope has been shown in other experiments (Bimboim et al., 2003). Further 
investigations on how posttranslationally modified self-proteins including NT 
proteins impair immunological tolerance may lead to more profound understanding 
of the onset of autoimmune responses. 
Tyrosine nitration target proteins in vivo: structural consequences 
Pathologic and aging tissue often shows increased levels of 3-nitrotyrosine 
(Greenacre and Ischiropoulos, 2001; Turko and Murad, 2002; Ischiropoulos, 2003; 
Ischiropoulos and Beckman, 2003). In addition, 3-NT levels may serve as an 
indicator for the progression of cardiovascular disease and its modulation by stafin 
therapy (Shishehbor et al., 2003). In general, the formafion of 3-NT is taken as 
evidence that tissue is exposed to some sort of oxidative (or nitrative) stress. 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is the most common inflammatory arthritis, 
affecting 0.5-1% of the population. (Orozco and Olsen, 2006; Mirshafiey and 
Mohsenzadegan, 2008). Rheumatoid arthritis (RA) is a systemic inflammatory 
disease that is characterized by chronic and erosive polyarthritis or by abnormal 
growth of synovial tissue (pannus) and causes irreversible joint disability 
(Westwood et al., 2006). Recent studies show that joint injury in RA patients 
progresses within two years from onset, and aggressive treatments from the early 
stage can prevent the progression of the disease. Hence, the necessities of early 
diagnosis and early treatment have been emphasized. However, RA patients do not 
always show typical symptoms at the early stages and are often difficult to diagnose 
since they may not fulfill the classification criteria for RA. Since the pivotal studies 
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of Waaler (1940), RA is also categorized among systemic autoimmune diseases 
because of the presence of rheumatoid factor (RF), autoantibodies against the Fc 
portion of IgG, and other autoantibodies. 
As with other autoimmune conditions women are affected more than men in 
the ratio of 3:1. The disease occurs at any age with the peak onset being the fourth 
and the fifth decade of life. The aetiology of RA is not clear. It is postulated a 
genetically susceptible host is exposed to an unknown pathogen and this interaction 
gives rise to a persistent immunological response. Studies in families show that first 
degree relatives of RA patients develop the disease at a higher rate than the general 
population indicating genetic predisposition. Multiple genetic factors are involved as 
Mendelian inheritance pattern is not seen (Deighton et al, 1992). Studies in twins 
show a higher concordance rate of RA in monozygotic as compared to dizygotic 
twins (Aho et al, 1986). The most definite genetic association with RA is with 
human leucocyte antigen alles (HLA) of the major histocompatibility complex 
(MHC). The HLA-DR4 allele which is found at the HLA-DRBl locus is associated 
with the development and severity of RA. Studies have also revealed variation of the 
genes for various proteins known to drive inflammatory process in RA. 
Infectious agents or viruses and bacteria such as Epstein-Barr virus, 
parvovirus, lentivirus and bacterial organism such as Mycoplasma, Mycobacteria 
and Yersinia infect the host cells and alter the reactivity and responsiveness of the T-
cells of the immune system sufficiently to trigger the disease. Another causative 
agent may be Heat shock proteins (HSP), a family of proteins produced by cells of 
all species in response to stress. Antibodies and T-ceils recognize epitopes shared by 
the HSP of both the infectious agent and the host. This facilitates cross-reactivity of 
lymphocytes with host cells triggering an immunological reaction referred to as 
'molecular mimicry' (Buch and Emery, 2002). RA can be diagnosed by clinical 
signs of disease activity, systemic indices of inflammation, such as the erythrocyte 
sedimentation rate (ESR) and serum C-reactive protein (CRP), rheumatoid factor 
(RF) positivity, HLA-DBRl genotypes and radiographic damage. American 
Rheumatism Association Revised Criteria for RA Classification is given in 
Table 10. 
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Table 10: American Rheumatism Association revised criteria for RA 
classification 
Criteria 
Morning Stiffness 
Arthritis of 3 or 
more joint areas 
Arthritis of hand 
joints 
Symmetric arthritis 
Rheumatoid nodules 
Serum rheumatoid 
factor 
Radiographic 
changes 
Description 
Morning stiffness in and around the joints, lasting at least 
one hour before maximal improvement. 
At least 3 joint areas (out of 14 possible areas; right or 
left PIP, MCP, wrist, elbow, knee, ankle, MTP joints) 
simultaneously have had soft-tissue swelling or fluid (not 
bony overgrowth alone) as observed by a physician. 
At least one area swollen (as defined above) in a wrist, 
MCP, or PIP joint. 
Simultaneous involvement of the same joint areas (as 
defined above) on both sides of the body (bilateral 
involvement of PIPs, MCPs, or MTPs, without absolute 
symmetry is acceptable). 
Subcutaneous nodules over bony prominences or 
extensor surfaces, or in juxta-articular regions as 
observed by a physician. 
Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which the result has 
been positive in less than 5% of normal control subjects. 
Radiographic changes typical of RA on posterior or 
anterior hand or wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in, 
or most marked adjacent to, the involved joints 
(osteoarthritis changes alone do not qualify). 
*Note: For classification purposes, a patient has RA if at least four of these 
criteria are satisfied (the first four must have been present for at least six 
weeks). 
**MCP - metacarpophalangeal, PIP - proximal interphalangeal, 
MTP - metatarsophalangeal 
Source: {Amett etal., 1988). 
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Autoantibodies in RA 
Autoantibodies are a common and characteristic feature of rheumatic 
autoimmune diseases (Table 11). Although the majority of autoantibodies do not 
seem to play a major pathogenetic role in these disorders, some of them have proven 
extremely useful as diagnostic tools and indicators of disease activity (von Muhlen 
and Tan, 1995). Only a few autoantibodies are truly disease specific, however, and 
their prevalence, or sensitivity, in the respective disorders is usually < 50%. The 
lack of a specific marker antibody is particularly true for rheumatoid arthritis (RA). 
Rheumatoid factors (RF), the immunologic hallmark of RA, have modest RA 
disease specificity (up to 66%) (Smolen, 1996). This has stimulated a search for 
novel antibodies and their respective target molecules that could be useful for the 
diagnosis of RA. Among the autoantibodies described in recent years, several are 
promising candidates as diagnostic indicators for RA and may soon become part of 
the diagnostic repertoire. The ability to predict onset and prognosis of RA would 
enable therapy to be directed and initiated without unnecessary delay. The 
association of HLA-DRw4 with RA was first reported in 1978. Subsequent clinical 
studies led to the 
Table 11: Novel autoantibodies of potential diagnostic relevance in rheumatoid 
arthritis 
Antibody (year) 
Antikeratin(1979) 
Anti-RA33 (1989) 
Anti-Sa(1994) 
Anti-p68(1995) 
Antigen (year) 
Filaggrin(1993) 
AnticitruUinated peptides 
(1998) = deiminated 
arginine identified in 
filaggrin (1999) and in 
fibrin (2001) 
hnRNP-A2(1992) 
50 kDa protein, 
unidentified 
BiP/grp78 (2001) 
Sensitivity (%) 
40 
53* 
32 
42 
40 
Specificity 
(%) 
92-99 
96 
90-96t 
98 
96 
BiP, immunoglobulin binding protein; grp78, glucose-regulated protein 78 kDa; 
hnRNP-A2, heterogeneous nuclear ribonucleoprotein A2. * In rheumatoid factor-
negative patients, approximately 15%. t Specificity of anti-RA33 when a diagnosis 
of systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD) 
can be excluded, or in the absence of autoantibodies associated with SLE or MCTD 
(anti-DNA, anti-Sm, anti-Ul RNP, anti-Ro, anti-La). 
Source: (Steiner and Smolen, 2002). 
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hypothesis that susceptibihty was due to a sequence of amino acids encoded by 
particular HLA-DRBl alleles - 'the shared epiptope (SE)' (Saleem et ah, 2006). 
Rheumatoid factor in RA 
RF, autoantibodies that react with the Fc portion of IgG, have been on the 
rheumatologic stage for longer than 60 years and are still the only established 
serologic marker of RA (Tighe and Carson, 1997). RF can be detected in 60-80% of 
RA patients and are thus fairly sensitive in diagnosing RA. However, the specificity 
of RF as a diagnostic indicator for RA is substantially inferior to that of 
autoantibodies used for the diagnosis of other rheumatic autoimmune diseases. 
Moreover, RF occur less frequently or are of low titer in early disease stages when a 
clear diagnosis is often not yet possible. Apart from RA, high-titer RF are also 
present in the majority of patients with primary Sjogren's syndrome and can be 
found in lower proportions (and usually also in lower titers) in all other rheumatic 
autoimmune diseases, as well as in a number of non-autoimmune conditions such as 
osteoarthritis or chronic infections (Smolen, 1996; Tighe and Carson, 1997). The 
disease specificity of RF for rheumatic diseases is dependent on the concentration 
(titer) used as a cut-off and is considerably higher at elevated titers, albeit at the 
expense of sensitivity. Furthermore, RF can be a prognostic indicator because they 
are related to increased severity of RA, such as the presence of erosive disease, more 
rapid disease progression, and worse outcome. Although RF may be involved in RA 
pathogenesis, their role is still not entirely clear. Interestingly, RF do not occur in 
experimental models of RA. Only MRL/lpr mice that suffer from lupus-like disease 
with anti-dsDNA and anti- Sm antibodies express RF (Eisenberg et al, 1979). In 
addition, these mice present with arthritis, which may become erosive, as well as 
other overlapping disease features (Koopman and Gay, 1988). 
Conformationally altered IgG has been detected in rheumatoid serum and 
synovial fluid (Johnson et al., 1974). IgG monomers and aggregates with fluorescent 
properties believed to be characteristic of free radical-induced damage have also 
been identified in rheumatoid sera and synovial fluids (Lunec et al., 1985). IgG 
aggregates with evidence of oxidative modification have been found in the synovial 
fluids of patients with rheumatoid arthritis. Previous work has also indicated that the 
majority of articular cartilage specimens obtained from patients with rheumatoid 
arthritis contained ICs and complement that were tightly bound and sequestered on 
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the pannus-free articular surface. It was suggested that these complexes gave rise to 
the phenomenon of frustrated phagocytosis on the cartilage surface, resulting in the 
egestion of noxious neutrophil granular component such as ROS and proteases 
(Uesugi et ah, 1998). Articular chondrocytes generate large amounts of nitric oxide 
(NO) when appropriately stimulated with cytokines or bacterial products (Stadler et 
ai, 1991; Stefanovic-Racic and Evans, 1993). 
Antigenic targets (epitopes) and rheumatoid factor 
An important antigenic target for RFs is the CY2-CY3 interface in the Fc 
region on the immunoglobulin molecule (Artandi et ai, 1992), thus making RFs the 
ultimate autoantibody, since there is no shortage of IgG antigen to form immune 
complexes. In addition, other potential RF epitopes have been identified via epitope 
mapping studies (Williams and Malone, 1994; Peterson et al, 1995; Williams et ai, 
1997). The target sites do not seem to have any special autoimmune potential as the 
main epitopes for autoantibodies appear to be adjacent to, or overlap with, those 
recognized by antibodies from other species when immunized with human IgG. For 
instance, epitopes defined by murine anti-IgO antibodies bind at or adjacent to RF 
antigenic hot spots (Nelson et ai, 1996; Nelson et ai, 2003). Certainly, monomeric 
IgG is a poor activator of RF^ B-lymphocytes compared with immune-complexed 
IgG: the structure of these immune complexes appears to be significant, as the 
antibodies need to be bound to strictly ordered antigens rather than irregularly 
arranged, to promote efficient induction of RFs (Fehr et al, 1997). A quesfion to be 
asked: 'Is the target for RF the normal immunoglobulin molecule or is it an altered 
molecule that is the important inducer and binder of RF?' 
In RA, the detection of agalactosyl immunoglobulins is a characterisfic 
feature. The absent galactose within the Fc region of IgG allows access to RF-
binding epitopes that are either exposed, or revealed as a consequence of 
conformational changes (Westwood et al., 1994). Other RF-binding epitopes have 
been shown to be independent of the oligosaccharides (Soltys et al., 1994). Proteins 
may be modified by the binding of glucose [e.g. in diabetes, where haemoglobin is 
glycated (HbAlc) and HbAlc levels are used as an indicator of glycaemic control]. 
Likewise, IgG also may be modified, and autoantibodies against advanced glycated 
end (AGE)-damaged IgG have also been detected and shown to be highly 
significantly associated with RFs (Newkirk et al., 2003). 
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Reactive nitrogen species and RA 
Cartilase/collas.en effect 
Modification of amino acids by oxidation, nitrosylation, nitration, and 
chlorination can alter protein structure and impair biological function, leading to cell 
death. ROS impair chondrocyte responses to growth factors and migration to sites of 
cartilage injury; RNS, in particular NO, interfere with interactions between 
chondrocytes and the extracellular matrix (Clancy et al, 1997). NO can also 
increase chondrocyte apoptosis. Oxygen and nitrogen radicals inhibit the synthesis 
of matrix components including proteoglycans by chondrocytes. In particular, NO 
and 02 seem to inhibit type II collagen and proteoglycan synthesis and the sulfation 
of newly synthesized glycosaminoglycans. Oxygen radicals can cause low levels of 
collagen fragmentation and enhanced collagen fibril cross-linking. Oxygen radicals 
have also been shown to fragment hyaluronan and chondroitin sulfate (Rees et al., 
2003, 2004) and damage the hyaluronan binding region of the proteoglycan core 
protein, thereby interfering with proteoglycan-hyaluronan interactions (Panasyuk et 
al., 1994). In addition, ROS and RNS can damage the components of the 
extracellular matrix indirectly through the activation and upregulation of matrix 
metalloproteinases. Numerous studies carried out on patients with rheumatoid 
arthritis revealed increased endogenous NO synthesis. A number of cells within the 
joint, including endothelial cells of synovial capillaries, mesenchymal cells, 
neutrophils, fibroblasts, lymphocytes, mast cells and macrophages are able to 
generate substantial quantities of NO (van't Hof and Ralston, 2001). Overproduction 
of NO may be important in the pathogenesis of RA. NO produced in the inflamed 
joint may contribute to the peri-articular bone-loss observed in RA (van't Hof and 
Ralston, 2001). For example, iNOS deficient mice are resistant to IL-1-induced bone 
resorption (van't Hof et al., 2000). Anti-TNF-a therapy was reported to reduce 
iNOS overexpression and iNOS enzyme activity in the PBMC of patients with RA 
(Perkins et al., 1998). Evidence from rodent models supports the fact that inhibition 
of NO synthesis may have a therapeutic role in RA. 7VG-monomethyl-L-arginine, an 
inhibitor of NOS, given systematically to rats with experimental arthritis lowered 
joint indices and inflammation (McCartney-Francis, 1993). A traditional herbal 
remedy tripterygium wilfordii Hook F (TWHF) was also reported to be effective in 
the treatment of rheumatoid arthritis (Wang et al., 2004). The major active 
component of TWHF triptolide significantly inhibited NO %ro<iuaion of activate 
peritoneal macrophages and decreased the level of iNOS mRIv^ugge^ffiigrthaf^^ 
specific inhibition of the iNOS gene may be responsible for the anti-Inflammatory 
effects of TWHF. Peroxynitrite causes cartilage destruction and SOD is protective 
(Fig. 14). 
Diabetes mellitus 
Diabetes mellitus is a complex metabolic disorder characterised by persistent 
hyperglycaemia resulting from defects in insulin secretion, insulin action or both. 
The two main types of diabetes mellitus are type 1 (formerly known as insulin-
dependent diabetes), and type 2 (formerly known as non-insulin-dependent 
diabetes). Type 1 diabetes is caused by the autoimmune destruction of the P-cells of 
the pancreatic islets, whereas type 2 diabetes results from both impaired insulin 
secretion and resistance to the action of insulin. Diabetes is associated with 
premature mortality, predominantly through atherosclerotic vascular disease (World 
Health Organization, 1999). Microvascular complications, which affect the small 
blood vessels in the eye, kidney and nerves, are associated with considerable 
morbidity. 
Type 2 diabetes 
Diabetes mellitus is one of the most prevalent (the estimated lifetime risk of 
developing diabetes for individuals bom in 2000 is 32.8% for males and 38.5% for 
females) chronic diseases, which significantly reduces life expectancy (Narayan et 
ah, 2003). Type 2 diabetes is a heterogeneous disorder that resuhs from an 
interaction between a genetic predisposition and environmental factors. It accounts 
for around 90% of all cases of diabetes. The incidence of diabetes increases with 
age, with most cases being diagnosed after the age of 40 years. This equates to a 
lifetime risk of developing diabetes of 1 in 10 (Neil et al, 1987). The prevalence of 
diabetes is increasing rapidly. The World Health Organization has predicted that the 
global prevalence (for all age groups) would rise to 4.4% in 2030, more than 
doubling the number of persons affected, from 171 million to 366 million (Sicree 
and Shaw, 2007). 
Type 2 diabetes usually affects overweight individuals (Mozaffari et al, 
2009), and most cases are diagnosed in those over 40 years old (Jonsson, 2002). 
Around half of patients with type 2 diabetes are diagnosed as a result of the typical 
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Fig. 14 Role of peroxynitrite and protective effects of SOD on cartilage. 
Source: (Afonso et al, 2007). 
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diabetic symptoms of polyuria, nocturia, thirst, tiredness and blurred vision; a 
further 16% of patients are diagnosed after presenting with an infection (UK 
Prospective Diabetes Study Group, 1988). Diabetes is associated with a number of 
chronic microvascular complications, which affect the eyes, kidneys and nervous 
system, and macrovascular complications, which lead to an increased risk of 
myocardial infarction, stroke and peripheral vascular disease. 
Protein oxidation in diabetic patients 
Proteins are an important target for oxidative challenge (Bloomer et al, 
2009). Reactive oxygen species modify amino acid side chains of proteins such as 
arginine, lysine, threonine and proline residues to form protein carbonyls. Protein 
carbonyl content is the most widely used marker of oxidative modification of 
proteins and suggested to be a reliable marker of oxidative stress (Chevion et al., 
2000). Elevated protein carbonyl levels were detected both in type 1 and type 2 and 
also in experimental diabetes (Dominguez et al, 1998; Cakatay et al., 2000; Jang et 
al, 2000). Furthermore, protein carbonyl content is well correlated with the 
complications of diabetes (Altomare et al., 1997). 
In addition to lipid and protein oxidation, oxidative damage of DNA has 
been reported in diabetic patients. Type 1 and type 2 DM patients have significantly 
higher levels of 8-hydroxydeoxyguanosine, indicator of oxidative damage of DNA, 
in mononuclear cells (Dandona et al, 1996). These changes might contribute to 
atherogenesis in DM and to the microangiopathic complications of the disease. 
Pathogenesis of diabetic endothelial dysfunction: role of nitrosative stress 
and peroxynitrite 
Peroxynitrite attacks various biomolecules, leading to cardiovascular 
dysfunction via multiple mechanisms (Pacher et al, 2005a). Accumulating evidence 
supports the hypothesis that diabetes is associated with increased nitrosative stress 
and peroxynitrite formation in numerous tissues, both in experimental animals and 
in humans (Pacher et al, 2005b). For example, increased nitrotyrosine plasma levels 
are detectable in type 2 diabetic patients (Ceriello, 2001) and iNOS-dependent 
peroxynitrite production is increased in platelets from diabetic individuals (Tannous 
et al., 1999). Hyperglycemia induces increased nitrotyrosine formation in the artery 
wall of monkeys (Pennathur et al., 2001 and in diabetic patients during a period of 
postprandial hyperglycemia (Ceriello et al., 2002a, 2002b). 
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Increased nitrotyrosine immunoreactivity has also been demonstrated in the 
microvasculature of type 2 diabetic patients, which correlates with fasting blood 
glucose, endothelial dysfunction, and increased levels of HbAlc, intracellular 
adhesion molecule and vascular cellular adhesion molecule (Szabo et al., 2002). 
Toxic actions of peroxynitrite and/or nitrotyrosine in the cardiovascular system are 
also supported by evidence showing that the degree of cell death and/or dysfunction 
correlates with levels of nitrotyrosine in endothelial cells, myocytes and fibroblasts 
from heart biopsies of diabetic patients (Frustaci et al, 2000), hearts of 
streptozotocin-induced diabetic rats (Kajstura et al., 2001) and working hearts of 
rats during hyperglycemia (Ceriello et al, 2002c). Nitrotyrosine is directly harmful 
to endothelial cells (Mihm et al, 2000), and high glucose-induced oxidative and 
nitrosative stress pathologically alters the prostanoid profile of human endothelial 
cells (Zou et al., 2002; Cosentino et al, 2003) 
It has recently been suggested that there may be several phases in the 
pathogenesis of high glucose induced endothelial injury: the short-term effect 
appears to depend upon combined oxidative and nitrosative stress with peroxynitrite 
formation, whereas the long-term effect is related to the generation of reactive 
oxygen species. In both cases, protein kinase C ultimately mediates the changes in 
vascular permeability (Pricci et al, 2003). Peroxynitrite might also be involved in 
the pathogenesis of primary diabetes (Szabo et al., 2002), diabetic microvascular 
injury in retinopathy (Du et al, 2002; El-Remessy et al., 2003a, 2003b), 
nephropathy (Onozato et al, 2002; Thuraisingham et al., 2000) and neuropathy 
(Obrosova et al, 2005a, 2005b, 2005c). 
Reactive nitrogen species and diabetes mellitus 
RNS are increased in Type 2 diabetes mellitus (Zou et al, 2004) and could 
contribute to protein misfolding. Growing evidence implicates both ROS and RNS 
(such as the reaction of superoxide anion (O2' ") with nitric oxide (NO) to form 
peroxynitrite and other RNS) as important molecules in the development of diabetes 
(Adeghate and Parvez et al, 2000; Turko et al, 2001; Hayden and Tyagi, 2002; 
Adeghate, 2004; Cowell and Russell, 2004). In other conformational diseases, such 
as Alzheimer's disease and Parkinson's disease, abnormal NO production is involved 
in protein misfolding leading to aggregates and proteasome dysfunction on 
ubiquinated material (Emerit et al, 2004). Peroxynitrite reacts relatively slowly with 
most biological molecules and as a result becomes a potent selective oxidant. 
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Peroxynitrite specifically modifies tyrosine in proteins/polypeptides to create 
nitrotyrosine, which leaves an indelible footprint detectable in vivo (Agbani et ah, 
2009). Nitrotyrosine and nitrosylated arginine (nitroarginine), known biomarkers of 
redox stress, are capable of competing with the natural substrate L- arginine for the 
production of endothelial nitric oxide (eNO) via the endothelial nitric oxide synthase 
(eNOS) reaction (Zou et ai, 2002). The presence of RNS in the plasma of diabetic 
patients suggests a possible involvement of peroxynitrite in the development of 
diabetic complications (Ceriello et al., 2001). Could RNS-induced protein 
modifications also increase the propensity for Islet amyloid polypeptide (lAPP) to 
become misfolded? Post-translational events, such as nitrosylation, can affect the 3-
dimensional configuration of proteins (Hess et al., 2001). Nitrosylation of various 
amino groups could therefore result in prevention of the proper folding of lAPP. 
Objectives of the present study 
The present study had three objectives. The first objective was to analyse the 
effect of peroxynitrite on IgG isolated from normal human sera. Peroxynitrite 
induced physicochemical changes in IgG have been studied by UV-visible 
spectroscopy, fluorescence, CD and FTIR spectroscopy, HPLC and SDS-PAGE. 
The second objecfive was to check whether peroxynitrite-modified IgG is more 
immunogenic in experimental animals compared to native IgG. The third objective 
was to study the binding profile of autoantibodies in the sera of rheumatoid arthritis 
patients as well as type-2 diabetes patients with native and peroxynitrite-modified 
IgG. In view of the projected possible role of reactive nitrogen/oxygen species in the 
onset/progression of rheumatoid arthritis and development of secondary 
complications in diabetes, a detailed study on the binding properties of 
experimentally produced antibodies against peroxynitrite-modified IgG and 
autoantibodies derived from rheumatoid arthritis and diabetes patients was also 
planned. 
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Bovine serum albumin (BSA), 3-nitrotyrosine, vitamine E, dithiothreitol 
(DTT), superoxide dismutase (SOD), milk powder, 2,4-dinitrophenylhydrazine 
(DNPH), glutathione (reduced), cysteine, calf thymus DNA, anti-human & anti-
rabbit IgG-alkaline phosphatase conjugate, p-nitrophenyl phosphate, uric acid, 
ascorbic acid, Tween-20, coomassie brilliant blue (G-250 & R-250), sodium dodecyl 
sulphate. Freund's complete & incomplete adjuvants, agarose, Diethylenetriamine 
pentaacetic acid (DTPA), carboxy-PTIO [2-(4-carboxyphenyl)-4,4,5,5-
tetramethylimidazoline-l-oxyl-3-oxide], sodium azide and dialysis tubing, 5,5'-
dithiobis-2-nitrobenzoic acid (DTNB), l-anilinonaphthalene-8-sulfonic acid (ANS) 
and Protein-A agarose were purchased from Sigma Chemical Company, USA. 
Milex syringe filters (0.45 m^) were purchased from Millipore Inc., USA. Folin-
Ciocalteau reagent was purchased from Centre for Biochemical Technology, New 
Delhi. Silver nitrate, formaldehyde, methanol, glacial acetic acid, iso-propanol, 
sodium chloride, sodium carbonate, sodium bicarbonate, magnesium chloride, 
potassium chloride, guanidinium chloride, sodium hydroxide, EDTA (disodium 
salt), hydrogen peroxide, sucrose and ammonium persulphate were obtained from 
Qualigens, India. Flat bottom polysorp ELISA modules were purchased from 
NUNC, Denmark. Acrylamide, bisacrylamide, ammonium persulphate, N,N,N ,N -
tertramethylethylenediamine (TEMED) were from Bio-Rad Laboratories, USA. All 
other reagents/chemicals were of highest analytical grade available. 
Collection and processing of blood samples 
Normal human sera were obtained from healthy subjects. Diabetic sera (n=50) 
were collected from patients attending the medicine outdoor clinic and /or those 
admitted in the medicine ward, Faculty of Medicine, J. N. Medical College, Aligarh 
Muslim University, India. Rheumatoid factor positive sera (Tested by Rhelax RF-
slide test for rheumatoid factors) of arthritis patients (n=50) were collected from the 
Department of Microbiology. Verbal consent of patients as well as healthy subjects 
was obtained before taking blood samples. They were told that the blood samples 
would be used only for the purpose of research. Samples were collected in a glass 
test tube and left for clotting for 30 min at 37°C. Serum was separated by 
centrifugation at 3000 rpm for 10 min. Serum samples were heated at 56°C for 
30 min to inactivate complement proteins and stored in aliquots at -20°C. 
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Equipments 
ELISA microplate reader (Labsystem Multiskan EX, Finland), Shimadzu's 
spectrophotometer (UV-1700) with programmable melting device and 
spectrofluorometer (RF-5301), ELICO pH meter (Ll-120), polyacrylamide gel 
electrophoresis assembly (Genei, India), Avanti 30 table top high speed refrigerated 
centrifuge (Beckman, USA), HPLC-Duo flow (Bio-Rad Laboratories, USA), CI8 
HPLC column (Supelco discovery, USA), spectropolarimeter (Jasco, USA) attached 
to a microcomputer and FT-IR Spectrometer (Perkin Elmer Spectrum RXI 4000cm'' 
- 450 cm'', USA) were the major equipments used in this study. 
METHODS 
Determination of protein concentration 
Colorimetric estimation of proteins was proteins was carried out by the 
method of Lowry et ai, (1951). Protein estimation by this method utilizes alkali (to 
keep the pH high), Cu^ "^  ions (to chelate proteins) and tartarate (to keep the Cu "^  ions 
in solution at high pH). 
(a) Folin-Ciocalteau reagent 
The reagent was purchased from Centre for Biochemical Technology, New 
Delhi and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) 2 percent sodium carbonate in 100 mM sodium hydroxide, 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components 
(i) and (ii) in the ratio of 50:1. 
(c) Procedure 
To 1.0 ml of protein sample was added 5.0 ml of alkaline copper reagent and 
incubated for 10 min at room temperature. One ml of working Folin-Ciocalteau 
reagent was added and the tubes were read at 660 nm after 30 min. 
The concentration of protein in unknown sample was determined from a standard 
plot of bovine serum albumin. 
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Isolation of IgG by Protein A-agrose column 
IgG from human and rabbit sera were isolated by affinity chromatography on 
Protein A-agarose column. Serum (0.3 ml) diluted with equal volume of PBS (pH 
7.4) was applied on top of Protein A-agarose column equilibrated with the same 
buffer. The wash through was recycled 2-3 times. Unbound matter was removed by 
extensive washing with PBS, pH 7.4. The bound IgG was eluted with 0.58% acetic 
acid in 0.85% sodium chloride (Coding, 1978) and neutralized in a tube containing 
1.0 ml of IM Tris-HCl, pH 8.5. Three ml fractions were collected and read at 278 
nm. IgG concentration was determined considering 1.4 OD278 = 1.0 mg IgG/ml. The 
isolated IgG was dialyzed against PBS, pH 7.4, and stored at -20°C with 0.1 % 
sodium azide. 
Polyacrylamide gel electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis was performed according to the 
procedure described by Laemmli (1970) with slight modifications. 
(i) Acrylamide-bisacrylamide (30:0.8): A stock solution was prepared by 
dissolving 30 gm of acrylamide and 0.8 gm bis-acrylamide in distilled water to a 
final volume of 100 ml. 
(ii) Resolving gel buffer: A stock solution was prepared by dissolving 36.3 gm Tris 
in 48.0 ml of IN HCl. The contents were mixed, pH adjusted to 8.8 and the final 
volume brought to 100 ml with distilled water. 
(iii) Electrode buffer: 3.03 gm Tris and 14.4 gm glycine were dissolved in distilled 
water and pH was adjusted to 8.3. SDS (1.0 g) was added and volume made up to 
one litre. 
(iv) Procedure: Cleaned glass plates, separated by 1.5 mm thick spacer, were sealed 
from the bottom and sides with \% agarose. The 7.5% resolving gel mixture was 
prepared by mixing the components and poured into the space between the glass 
plates and allowed to solidify. Protein samples mixed with sample dye (10%) 
glycerol, 2% SDS, 0.5 M Tris pH 6.8 and 0.002% bromophenol blue) were applied 
into the wells and electrophoresis was carried out at 50-80V for 3 to 8 hr. The 
electrophoresed proteins were visualized by staining with silver nitrate. 
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Composition of 7.5% resolving gel: The following solutions were mixed and 
instantly poured between the glass plates; 
Component 
Distilled water 
Acrylamide - bisacrylamide 
Resolving gel buffer 
10%SDS 
1.5% ammonium persulphate 
TEMED 
Volume 
4.8 ml 
2.5 ml 
2.5 ml 
0.1ml 
0.1ml 
6^1 
SDS-PAGE under non-reducing conditions 
Native and peroxynitrite-modified IgG samples were subjected to 
electrophoresis on 7.5% polyacrylamide gel. The samples were mixed with one-
tenth volume of sample dye and electrophoresed at 80 V for 3-8 hr in Tris-glycine 
buffer (pH 8.3) containing 0.1% SDS. Protein bands were located by staining with 
silver nitrate. 
Silver nitrate staining of gel 
Silver staining of the gel was done as described by Merril et al., (1981). 
After electrophoresis, the protein bands were fixed by rapidly immersing the gel in a 
mixture (40%) methanol and 13.5%) formaldehyde) for 15 min with intermittent 
shaking. The gel was then washed with distilled water twice and transferred to 
0.02% sodium thiosulphate (Na2S203) solution and incubated for 2 min. This gel 
was again rinsed twice with distilled water. This was followed by treatment with 
0.1%) AgNOs solution for 20 min. The gel was washed with distilled water briefly 
and then immersed in a developer solution (3% sodium carbonate solution 
containing 0.5%) formaldehyde and 0.02% Na2S203) for 15 min or until the gel was 
properly stained. The reaction was stopped by transferring the gel to a stopper 
solution (25% isopropanol solution containing 10% glacial acetic acid) and left for 5 
min. The gel was washed twice with distilled water and finally stored in distilled 
water. 
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Determination of hexose content of IgG 
The neutral hexose content of normal human IgG was determined by the 
method of Dubois et al, 1956. One ml protein solution was added to 1ml of 5% 
phenol and mixed thoroughly. Five ml of concentrated sulphuric acid was added on 
the surface of the solution, to produce desired mixing. The orange-yellow colour 
developed was read at 490 nm against the reagent blank. The hexose content of 
protein was determined by computing the absorbance with that of standard curve, 
drawn with glucose. 
Laboratory synthesis of peroxynitrite 
Peroxynitrite was synthesized by rapid quenched flow process (Beckman et 
al, 1996). Solutions of sodium nitrite (0.6 M in 50 mM sodium phosphate buffer, 
pH 7.4), hydrogen peroxide (0.6 N in 0.7 N HCl) and sodium hydroxide (1.2 M in 
distilled water) were prepared and chilled for few minutes prior to use. The 
schematic representation of laboratory that were assembled to synthesize 
peroxynitrite is shown in Fig. 15. A flow rate of 10 ml/min was adjusted to get a 
concentrated solution of peroxynitrite. The peroxynitrite was collected in 1.2 M 
NaOH and kept at -20°C. The concentration of stored peroxynitrite was assessed 
each time it was used by recording absorbance at 302 nm using molar extinction 
coefficient of 1670 M"'cm'' (Radi et al, 1991b). 
Modification of IgG by peroxynitrite 
The modification was carried out by incubating 1.7 ^M of IgG with 100 |iM 
of diethylene triamine penta-acetic acid (DTPA, a metal ion chelator) and 0.4, 0.8 
and 1.2 mM peroxynitrite at 37°C for 45 min. 
Spectroscopic analysis of native and peroxynitrite-modified IgG 
Absorption spectra of native and peroxynitrite-modified IgG were recorded 
on Shimadzu spectrophotometer in the wavelength range of 250-500 nm using 
quartz cuvette of 1 cm path length. 
Fluorescence measurements 
Fluorescence emission was recorded on spectrofluorometer. Fluorescence of 
tyrosine residues of native and peroxynitrite-modified IgG were monitored in the 
wavelength range of 280-430 nm after excitation at 275 nm. Similarly, fluorescence 
of tryptophan residues of native and peroxynitrite-modified IgG were read in the 
wavelength range of 300 - 400 nm after excitation at 295 nm. Loss in emission 
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.,^, Bypass tube 
^ To vacuum 
Fig. 15 Assembly for laboratory synthesis of peroxynitrite. The assembly was 
operated under vacuum and the bypass tube directed to the waste bottle 
initially. Once a steady flow was observed the tube was manually 
twisted to collect the peroxynitrite. Except waste container, all flasks 
were covered with ice. 
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intensity was calculated using the following formula; 
Percent loss in _ F. I. of native IgG - F. I. of peroxynitrite modified IgG v 100 
fluorescence F. I. of native IgG 
intensity(F.I.) 
Emission profile of anilinonaphthalene sulfonic acid 
Fluorescence properties of ANS were exploited to study hydrophobic patches 
(or regions) in native and peroxynitrite-modified IgG. The ANS and IgG ratio was 
kept at 1:20 and emission spectra were recorded in the wavelength range of 400-600 
nm after excitation at 380 nm. Increase in fluorescence intensity (F.I.) was 
calculated using the following formula; 
F.I. of peroxynitrite modified IgG - F.I. of native IgG 
Percent increase in F.I. = ~ ~ 7~. ,._ , ^ ^ x 100 
F.I. 01 peroxynitrite modiried IgG 
Circular dichroism measurements 
All circular dichroism (CD) measurements were carried out at 25°C on 
spectropolarimeter using SPL-430A SEKONIC plotter, with a thermostatically 
controlled cell holder attached to an RTE 110 NESLAB water bath with an accuracy 
of ± 0.1 °C. Far-UV CD spectra of native and peroxynitrite-modified IgG samples 
were recorded in the wavelength range 200-250 nm. A scan speed of 20 nm/min and 
response time of 1 sec was chosen to record CD spectra. The MRE (mean residual 
ellipticity) expressed in deg cm^ mof' was calculated. MRE = CD/10 x n x 1 x Cp 
where CD is in millidegree, n is the number of amino acid residues (1288), 1 is the 
path length of the cell (1mm/ 0.1 cm) and Cp is the mole fraction. (3 sheet content 
and helical content were calculated using MRE equation; MRE = CD/1287 x 0.1 x 
0.00000167 X 10 = CD X 465.27. K2D estimation of proteins' secondary structure 
was done from CD profile. 
Fourier transformed-infra red (FT-IR) spectroscopy 
Native and peroxynitrite-modified IgG samples were lyophilized and 
analyzed on FT-IR spectrometer. Pellets were prepared by mixing lyophilized 
samples with potassium bromide, to absorb remaining moisture under pressure, in an 
attenuated total reflection (ATR) cell attached to a thermostat. This was followed by 
spectra recording (Jovanovic, 2008). 
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Determination of 3-nitrotyrosine in native- and peroxynitrite-modified 
IgG and patients' sera by HPLC 
Detection and quantification of nitrotyrosine in IgG samples as well as in 
patients' sera was achieved on a Biologic Duo Flow System (Bio-Rad, Hercules, 
CA, USA). Samples of native and peroxynitrite-modified IgG were subjected to 
HPLC analysis for 3-nitrotyrosine after pronase treatment (Kaur and Halliwell, 
1994). The retention time of commercially available 3-nitrotyrosine (3-NT) was 
taken as reference for comparison. Brief descriptions of the sample preparation are 
as follows; pronase protease was first dialyzed against 0.1 M sodium acetate buffer, 
pH 7.2, and added to IgG samples (1.7 )iM) present in 20 mM Tris buffer (pH 7.4). 
The IgG:pronase ratio was 5:1. The assay tubes were then kept at 50°C for 16 hr to 
ensure complete hydrolysis. The hydrolyzed samples were passed through 0.42 ^M 
Milex for ultrafiltration. The filtrate was diluted 1:2 with eluant buffer (500 mM 
potassium phosphate, pH 3.0 containing 10% methanol). The material was then 
injected into C-18 reverse phase column (25 cm x 4.6 mm). Elution was carried 
out at a flow rate of 0.8 ml/min. The absorbance of the fractions was monitored at 
274 nm (pH > 3.5) on UV-visible multiple wavelength detector. The absorbance of a 
series of known concentrations of standard 3-NT at acidic pH (pH 3.5) was used as 
reference to determine the concentration of 3-NT in the serum samples. 
Nitrotyrosine in healthy and patients' sera (DM and RA) was also determined. 
Carbonyl estimation 
Carbonyls contents in native & peroxynitrite-modified IgG and patients' 
sera were analyzed according to Levine et al., (1994) with slight modifications. It is 
known that exposure of proteins to peroxynitrite leads to oxidation resulting in 
modification of the side chain of certain amino acid residues due to generation of 
2,4-dinitrophenylhydrazine (DNPH) reactive carbonyls. Quantitative estimation of 
carbonyl groups in proteins is carried out by DNPH reagent and analyzed 
spectrophotometricaly. Native and peroxynitrite-modified IgG were precipitated 
with 10% (v/v) ice-cold trichloroacetic acid (TCA). After 10 min of incubation at 
4°C, the samples were centrifuged at 11,000 x g for 3 min. The formed pellet was 
re-suspended in 0.5 ml of 10 mM DNPH dissolved in 2 M HCl. The assay tubes 
were then placed in a sample holder and continuously vortexed at room temperature 
for 1 hr and precipitated with 0.5 ml of 20% (v/v) TCA followed by centrifugation at 
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11,000 X g for 3 min. The pellet was washed with 1 ml of 1:1 (v/v) mixture of 
ethanol-ethyl acetate to get rid of any extra DNPH reagent. Samples were incubated 
for 10 min at room temperature and then centrifuged at 11,000 x g for 5 min. The 
supernatant was discarded and the pellet was washed twice with ethanol-ethyl 
acetate mixture. The protein pellet was finally suspended in 1 ml of 6 M 
guanidinium chloride dissolved in 2 mM potassium phosphate buffer (pH 2.3, 
adjusted with trifluoroacetic acid). The samples were incubated at 37°C for 15-30 
min for complete dissolution of proteins. Samples having difficulties going into 
solution were briefly sonicated and incubated at an elevated temperature, up to 
70°C. All samples were then centrifuged to remove any insoluble material. The 
concentration of DNPH was determined by recording absorbance at 360 nm against 
guanidinium chloride (used as blank) using the molar extinction coefficient of 
22,000 M"'cm"'. IgG concentration in the samples was determined by their 
absorbance at 278 rmi. Carbonyl contents were expressed as rmiol/mg protein. 
Quenching studies 
Quenching studies were performed to evaluate effect of enzymatic and non-
enzymatic inhibitors on macromolecule nitration by incubating the quenchers with 
the nitrating reaction mixture (Yoshie and Ohshima, 1997). The absorbance at 420 
nm shown by peroxynitrite-modified IgG was taken as control and effect of various 
quenchers was evaluated. Nitric oxide trapping agent (carboxy-PTIO, 10 mM), 
hydroxyl radical scavengers (SOD; 500 units/ml, mannitol; 10 mM), antioxidants 
(ascorbic acid, uric acid, glutathione and vitamin E, 1 OmM each) and 10 mM each 
of dithiothreitol & desferrioxamine were used for quenching studies. 
Absorption-temperature scan 
Thermal denaturation profile of native and peroxynitrite-modified IgG 
(dissolved in PBS, pH 7.4) were monitored at 278 nm on spectrophotometer 
equipped with a temperature programmer and controller assembly (Alam et al, 
1993). Percent denaturation of individual sample was computed using the following 
equation; 
Percent denaturation = ^ ~ °^ X100 
' ^ m a x - ' ^ 3 0 
where. AT = Absorbance at a temperature T °C. 
Amax = Final maximum absorbance on the completion of 
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denaturation (95 °C). 
A30 = Initial absorbance at 30 °C. 
Immunization of rabbits 
Fresh rabbits (1-1.5 Kg) were selected for immunization and it was insured 
that the rabbits were infection free. A dose of fifty microgram of native IgG or 
peroxynitrite-modified IgG was used for immunizing the animals in duplicate 
(Ohmori et al., 2005). The immunogen was first emulsified with an equal volume of 
Freund's complete adjuvant for first injection. Intramuscular injections were given 
at multiple sites. The animals were boosted with immunogens in Freund's 
incomplete adjuvant at weekly intervals for 5 weeks with the same amount of 
antigen (Rasheed et al, 2006; Rasheed, 2008). During the course of immunization 
each animal received a total of 300 \ig of immunogen. One week after the last dose, 
marginal ear veins of immunized animals were punctured and blood was collected 
carefully. Prior to immunization blood was collected from all the animals. Sera were 
separated and decomplemented by heating at 56°C for 30 min. Sera were stored in 
small aliquots at -20 °C with 0.1% sodium azide as preservafive. 
Detection of antibodies by enzyme immunoassay 
Pre-immune and immune sera obtained from rabbits were tested for 
antibodies against native and peroxynitrite-modified IgG by enzyme linked 
immunosorbent assay (ELISA). Sera of diabetes mellitus and rheumatoid arthritis 
patients were processed in a similar way. 
Buffers and reagents 
The following reagents were prepared in distilled water and used in enzyme 
immunoassay. 
Protein coating buffer: 15 mM sodium carbonate, 35 mM sodium bicarbonate, 
pH9.6 
Tris-buffered saline (TBS): 10 mM Tris, 150 mM NaCl, pH 7.4 
Iris-buffered saline containing Tween 20 (TBS-T): 20 mM Tris, 144 mM NaCl, 
2.68 mM KCl, pH 7.4 containing 500 i^ l Tween-20 per litre. 
Carbonate-bicarbonate buffer: 15 mM sodium carbonate, 35 mM sodium 
bicarbonate, pH 9.6 containing 2 mM magnesium chloride. 
Substrate: 500 }ig p-nitrophenyl phosphate (p-NPP) per ml of carbonate-
bicarbonate buffer. 
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Procedure of ELISA 
Enzyme linked immunosorbent assay (ELISA) was performed on flat bottom 
polystyrene polysorp modules (or polysorb 96 well plates) according to procedure 
described earlier (Ali and Alam, 2002). Wells were coated with 100 ^L of native or 
peroxynitrite-modified IgG antigens (20 i^ g/ml) in protein coating buffer for 2 h at 
37°C and overnight at 4°C (Stone et al., 1987). Samples were coated in duplicate 
and half of the wells served as control devoid of antigen only. The wells were 
washed with TBS-T and unoccupied sites were blocked with 2% fat free milk in 
TBS for 4-6 h at 37°C. Again, the wells were washed and filled with test sera 
serially diluted in TBS-T or affinity purified antibodies (100 |xL/well) and left for 2 
h at 37°C and overnight at 4°C. Bound antibodies were assayed with anti-rabbit 
alkaline phosphatase conjugate using p-nitrophenyl phosphate as substrate. The 
absorbance (A) of each well was monitored at 410 nm on an automatic microplate 
reader. Each sample was run in duplicate. The control wells were treated similarly 
but were devoid of antigen. Resuhs were expressed as a mean oi Atest Acontroi-
Procedure of inhibition ELISA 
The antigenic specificity of the antibodies was determined by inhibition 
ELISA (Alam et al, 2007). Varying amounts of inhibitors (0-20 |ag/ml) were mixed 
with a constant amount of patients' sera/antisera or IgG. The mixture was incubated 
at room temperature for 2 hr and overnight at 4°C. The immune complex thus 
formed was coated in the wells of antigen-coated plates instead of the serum/IgG 
and the residual antibody level was detected by ELISA. The remaining steps were 
the same as in direct binding ELISA. Percent inhibition was calculated using the 
following formula; 
^inhibited 
Percent inhibition =1 — x 100 
Auninhibited 
Statistical analysis 
Data have been presented as mean ± SD. Statistical significance of the 
results were evaluated by student's 'Y'-test (SPSS-15). A p value of <0.05 was 
considered as statistically significant. 
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Purification of Immunoglobulin G 
Immunoglobulin G (IgG) was isolated from healthy human sera by affinity 
chromatography on Protein A-agarose column. The IgG eluted in a single peak (Fig. 
16). In SDS-polyacrylamide gel, purified IgG migrated as a single band (Inset to 
Fig. 16). The concentration was determined considering 1.38 OD278=1-0 mg IgG/ml 
(Fig. 17) and stored at -20 °C after dialysis against PBS (pH 7.4). 
Determination of hexose content of IgG 
Phenol in presence of sulfuric acid can be used for the quantitative 
colorimetric determination of sugars and their methyl derivatives. The method is 
sensitive and particularly useful for the determination of small quantities of sugars. 
Simple sugars, oligosaccharides and polysaccharides (and their derivatives) give an 
orange-yellow color when treated with phenol and concentrated sulfuric acid. 
The neutral hexose content in human IgG was determined by the 
development of orange-yellow colour, which was read at 490 nm against the reagent 
blank. The hexose content of IgG was determined from standard curve of glucose 
(Fig. 18). Under our experimental conditions, the hexose content in IgG was found 
to be 3%. 
Generation and characterization of peroxynitrite 
Peroxynitrite was synthesized in our laboratory by rapid quenched flow 
method. It was identified by a characteristic yellow colour having A,max at 302 
nm (Fig. 19). The stock solution was stored at -20°C and before each use its 
concentration was determined by recording absorbance at 302 nm and using 
molar extinction coefficient of 1670 M''cm"' 
UV spectroscopy of native- and peroxynitrite-modified IgG 
Preliminary experiments were carried out to work out the optimum 
concentration of peroxynitrite needed for the modification of IgG. Varying 
concentration of peroxynitrite (0.4, 0.8 and 1.2 mM) was incubated with IgG (1.7 
l-iM) and subjected to spectrophotometric analysis. Control IgG (native IgG) showed 
an absorbance peak at 278 nm (Fig. 20). Upon modification with peroxynitrite, the 
absorbance at 278 nm was found to be increasing. Furthermore, with increasing 
concentrations of peroxynitrite we observed bathochromic shift in 278 nm peak. 
Compared to 278 nm absorbance value of control IgG, the hyperchromicities shown 
by 0.4, 0.8 and 1.2 mM peroxynitrite-modified IgG were 21%, 52% and 74%) 
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Fraction number 
11 13 
Fig. 16 Elution profile of human serum IgG on Protein-A 
agarose column. Inset: SDS-PAGE of purified IgG 
in 7.5% polyacrylamide gel. 
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Fig. 17 Absorption spectrum of normal human IgG. 
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Fig. 18 Standard curve of glucose. 
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Wavelength (nm) 
390 
Fig. 19 Absorption profile of freshly synthesized peroxynitrite. 
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250 
Fig. 20 
300 350 400 
Wavelength (nm) 
450 500 
Absorbance profile of native IgG (—•—) modified by 
0.4mM (-n-) , 0.8mM ( - A - ) and 1.2mM (-A-) 
peroxynitrite. Inset: shows appearance of new peak at 
420 nm in peroxynitrite-modified conformers of IgG. 
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respectively. Though the peroxynitrite-modified conformers exhibited 
hyperchromicity but the overall sharpness of the peaks was maintained. UV 
aborption characteristics of native-and peroxynitrite-modified IgG are given in 
Table 12. 
An interesting observation was the appearance of yellow colour in 
peroxynitrite-modified samples of IgG and birth of new peak at 420 nm (Inset to 
Fig. 20). This appears to be the consequence of peroxynitrite-mediated nitration of 
mainly tyrosine residues because a standard solution of 3-nitrotyrosine processed 
under identical conditions showed a peak at the same wavelength (Fig. 21). 
Quantitative estimation of nitrotyrosine, using molar extinction coefficient of 4400 
M"'cm'', was carried out in peroxynitrite-modified samples of IgG and the resuhs 
are summarized in Table 13. 
Effect of quenchers on peroxynitrite-mediated nitration of IgG 
Peroxynitrite is an oxidizing as well as a nitrating agent. Quenching studies 
were performed with equimolar concentrations of dithiothreitol (DTT), glutathione, 
mannitol, SOD, uric acid, ascorbic acid, vitamin C and desferrioxamine to evaluate 
their potential in prevention of peroxynitrite-mediated nitration of IgG. The 
absorbance at 420 nm given by peroxynitrite-modified IgG was taken as control and 
effect of above quenchers was assessed in comparison to the control. Results are 
compiled in Fig. 22 and Table 14. 
Fluorescence spectroscopy of native- and peroxynitrite-modified IgG 
Emission profiles of tyrosine residues in native- and peroxynitrite-modified 
IgG samples were recorded after excitation at 275 nm and the results are presented 
in Fig. 23. For all samples, the maximum fluorescence intensity was observed at 
336 nm. However, all samples of PON-modified IgG showed an additional kink at 
305 nm but the emission intensity kept decreasing with increasing concentrations of 
peroxynitrite which may be attributed to nitration of IgG's tyrosine residues. 
Table 15 summarizes the fluorescence characteristics of native- and peroxynitrite-
modified IgG excited at 275 nm. 
Interaction of ANS (l-aniIinonaphthalene-8-sulfonic acid) fluorescence 
with native- and peroxynitrite-modified IgG 
Fluorescent dyes are highly sensitive and versatile tools for protein 
characterization and applied in various fields of protein analysis. Interaction of ANS 
Table 12 
UV absorption characteristics of native- and peroxynitrite-modified IgG 
IgG Absorbance at 278nm Percent hyperchromicity 
Native 0.340 
Modified by 0.4 mM PON 0.398 21 
Modified by 0.8 mM PON 0.747 52 
Modified by 1.2 mM PON .299 74 
78 
Wavelength (nm) 
Fig. 21 Absorption spectrum of standard 3-nitrotyrosine. 
Table 13 
Nitrotyrosine content of IgG modified with peroxynitrite 
IgG Nitrotyrosine (|J.M) 
Native 
Modified by 0.4 mM PON 
Modified by 0.8 mM PON 
Modified by 1.2 mM PON 
7.5 
9.7 
13.6 
79 
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Fig. 22 
Quenchers 
Effect of some quenchers on peroxynitrite-induced nitration 
oflgG. shows peroxynitrite-induced nitration of IgG in 
absence of any quencher 
Table 14 
Effectiveness of quenchers in preventing nitration of IgG 
Quencher tested Percent quenching 
DTT 
Carboxy-PTIO 
Glutathione 
Mannitol 
SOD 
Uric Acid 
Ascorbic Acid 
Vitamin E 
Desferrioxamine 
30 
64 
42 
13 
25 
78 
59 
47 
33 
80 
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430 
Fig. 23 Emission profile of native IgG ( ) modified by 0.4mM ( ), 
0.8mM ( ) and 1.2mM ( ) peroxynitrite respectively. The 
samples were excited at 275 nm. 
Table 15 
Fluorescence characteristics of native- and peroxynitrite-
modifled IgG excited at 275 nm 
IgG Intensity (A.U.) 
384 
88 
59 
42 
Percent loss in intensity 
after modiflcation 
~ 
77 
84.6 
89 
Native 
Modified by 0.4 mM PON 
Modified by 0.8 mM PON 
Modified by 1.2 mM PON 
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with hydrophobic sites (regions) in protein causes enhancement in the fluorescence 
intensity accompanied by blue shift of the peak. Effect of peroxynitrite modification 
on hydrophobic clusters in peroxynitrite-modified IgG were probed with ANS dye 
and the resuhs are summarized in Fig. 24, Table 16. The data indicate that the 
peroxynitrite-modification of IgG has gradually exposed the hydrophobic sites 
which are available for ANS-binding as indicated by increase in fluorescence 
intensities and shift in the emission maximum wavelength. 
Evaluation of dityrosine content in peroxynitrite-modified IgG samples 
Peroxynitrite reaction generates phenoxyl radicals which can form C-C 
covalent bond between tyrosine residues. Amount of dityrosine in peroxynitrite-
modified IgG samples was calculated from absorbance values at 330 nm (A,max for 
dityrosine) and using extinction coefficient of 4000 M"'cm"' (Table 17). Increasing 
concentration of peroxynitrite produced more dityrosine compared to native IgG 
which was devoid of dityrosine. To further assess the formafion of dityrosine, 
emission profiles of peroxynitrite-modified IgG samples were recorded after 
excitation at 325 nm and the results are shown in Fig. 25, Table 18. Modified 
samples showed peak at 400 nm. The intensity of the peaks (A.U.) was directly 
proportional to concentration of peroxynitrite. 
CD spectroscopy of native- and peroxynitrite-modified IgG 
Circular dichroism (CD) is a spectroscopic technique that can be used to 
determine the secondary structural content of proteins and may be defined as the 
differential absorbance of left circularly polarized light and right circularly polarized 
light. The electronic transitions of polypeptide backbone peptide bonds in different 
conformations produce differential absorption spectra for left- and right-handed 
circularly polarized light in the far UV. To be "CD active", a molecule must be 
structurally asymmetric and exhibit absorbance. Asymmetry can result from chiral 
molecules such as the peptide backbone of proteins, a non-chiral molecule 
covalently attached to a chiral molecule (aromatic amino acid side chains), or a non-
chiral molecule in an asymmetric environment (e.g., a chromophore bound to a 
protein). Increased relative absorption of left polarized light results in a positive CD 
signal, while a negative signal is the result of right polarized light being more highly 
absorbed. Proteins are CD active (all amino acids except glycine contain a chiral 
carbon, thus are asymmetrical), and the resulting CD signals are sensitive to protein 
82 
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Fig. 24 Emission profile of ANS alone (—), native IgG treated with 
ANS (-D-) and ANS treated IgG modified with 0.4 mM ( - • - ) , 
0.8 mM (—A—) and 1.2 mM (—A—) peroxynitrite respectively. 
Table 16 
ANS-binding characteristics of native- and peroxynitrite-modified IgG 
IgG Fluorescence ^max 
intensity (nm) 
(A.U.) 
Shift in Xmax Percent increase 
compared to •" ANS binding 
native IgG compared to 
(nm) native IgG 
Native 73.0 487 
Modified by 0.4 mM PON ^2.0 482 
Modified by 0.8 mM PON 96.0 480 
Modified by 1.2 mM PON 1 ^ ^ -O ^79 
5.0 
7.0 
8.0 
10.9 
23.9 
33.6 
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Table 17 
Quantitation of dityrosine in peroxynitrite-modified IgG 
IgG Dityrosine (^M) 
Native 
Modified by 0.4 mM PON 
Modified by 0.8 mM PON 
Modified by 1.2 mM PON 
Nil 
39.5 
103.5 
218.25 
200 
325 350 375 400 425 450 
Wavelength, nm 
475 500 
Fig. 25 Emission profile of IgG treated with 0.4mM (—), 0.8mM (—) 
and 1.2mM (—) peroxynitrite respectively. The profiles were 
recorded after exciting the samples at 325 nm. 
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Table 18 
Fluorescence characteristics of native- and peroxynitrite-
modified IgG excited at 325 nm 
IgG Increase in intensity (A.U.) 
Native — 
Modified by 0.4 mM PON 74.6 
Modified by 0.8 mM PON 128.4 
Modified by 1.2 mM PON 143.3 
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secondary and tertiary structure. Three common secondary structure motifs (alpha-
helix, beta sheet, and random coil) may be seen in proteins. A random polypeptide 
has a CD spectrum similar to that of a simple amide. The spectrum of the a-helix 
shows a large negative band at 222 nm and 208 nm and a positive band at 
approximately 192 nm. The CD spectrum of the antiparallel pleated sheet shows a 
negative band at 217 nm and a positive band at 195 nm in the far-UV range. 
The far-UV CD profiles of native- and peroxynitrite-modified IgG samples 
were recorded and results are summarized in Fig. 26, Table 19. Native IgG and 
those modified by 0.4 mM and 0.8 mM peroxynitrite showed large negative 
dichroism at 217 nm, which depicts typical p structure. IgG treated with 1.2 mM 
peroxynitrite did not show ellipticities at above mentioned wavelengths. 
FT-IR analysis of native- and peroxynitrite-modified IgG 
Fourier-transformed infrared (FT-IR) spectroscopy is a sensitive 
physicochemical analytical technique that identifies structural moieties of 
biomolecules on the basis of their IR absorption. FT-IR spectroscopy provides 
information about the secondary structure content of proteins, unlike X-ray 
crystallography and NMR spectroscopy which provide information about the tertiary 
structure. Each biomolecule possesses a unique structure and exhibits a 
characteristic FT-IR spectrum, representing the vibrations of its structural bonds. 
The technique works by shining infrared radiation on a sample and seeing which 
wavelengths of radiation in the infrared region of the spectrum are absorbed by the 
sample. Each compound has a characteristic set of absorption bands in its infrared 
spectrum. Characteristic bands found in the infrared spectra of proteins and 
polypeptides include the Amide I and Amide II. These arise from the amide bonds 
that link the amino acids. The absorption associated with the Amide I band leads to 
stretching vibrations of the C=0 bond of the amide, absorption associated with the 
Amide II band leads primarily to bending vibrations of the N—H bond. Because 
both C-0 and N—H bonds are involved in the hydrogen bonding both Amide I and 
Amide II bands are sensitive to the secondary structure content of a protein. Fig. 27 
represent the FT-IR profiles of native- and peroxynitrite-modified analogues of IgG. 
For native IgG, the maximum absorbance at 1600-1700 wavenumber is referred to 
as amide I region (Fig. 27 a). The spectra of peroxynitrite-modified IgG (Fig. 27 
b,c,d) showed decrease in peak absorbance in amide I region at 1638 cm"'compared 
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240 250 
Fig. 26 Far-UV CD spectra of native IgG ( ) and IgG 
modified with 0.4 mM ( ), 0.8 mM ( - • - ) and 
1.2 mM (—••—) peroxynitrite respectively 
Table 19 
CD characteristics of native- and peroxynitrite-modified IgG 
IgG Alpha-helix (%) p strand (%) 
Native 48 
Modified by 0.4 mM PON 
Modified by 0.8 mM PON 11 
44 
37 
Modified by 1.2 mM PON 
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Fig. 27 FTIR of native IgG (a) and 0.4 mM (b), 0.8mM (c) and 1.2 mM (d) 
peroxynitrite modified IgG. 
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to the native IgG. It means, the peroxynitrite-modified IgG contains lesser amount 
of p-structure. 
Thermal denaturation profile of native- and peroxynitrite-modified IgG 
Effect of peroxynitrite modification on the stability of IgG was studied by 
recording heat induced changes in absorbance values at 278 nm. The mid-point 
meltingtemperature (Tm) was calculated from absorbance values in the temperature 
range of 30-90°C. The thermal denaturation profiles of native- and peroxynitrite-
modified IgG samples are depicted in Fig. 28. Native IgG showed a Tm of 84°C. 
Modification of IgG by 0.4 mM peroxynitrite sharply decreased the melting 
temperatures. Furthermore, increasing concentrations of peroxynitrite had little 
effect on melting temperatures. Table 20 summarizes the Tm values of native- and 
modified samples of IgG. Treatment of IgG with peroxynitrite decreases thermal 
stability as shown by decrease in the melting temperatures of peroxynitrite-modified 
samples of IgG indicating that they are more vulnerable to heat treatment. 
SDS-poIyacrylamide gel electrophoresis of native- and modified IgG 
Native- and peroxynitrite-modified samples of IgG were subjected to non-
reducing polyacrylamide gel electrophoresis under denaturing conditions. Twelve fig 
each of native- and peroxynitrite-modified IgG samples were loaded into the wells 
of 7.5% polyacrylamide gels. The migration patterns of silver stained bands are 
shown in Fig. 29. Native IgG appeared as compact single band (lane 1). Band 
intensities of the modified IgG samples were found to be diminishing with 
increasing concentrations of peroxynitrite (lane 2-4). At the highest concentration of 
peroxynitrite (1.2 mM) the band intensity was very poor. Furthermore, we observed 
appreciable amount of aggregates in the wells (lane 2-4) which failed to enter the 
gel. 
Determination of carbonyl content in native-and peroxynitrite-modified 
IgG 
Protein carbonyls are indicator of protein damage by free radical reactions. 
Carbonylation of lysine, arginine, threonine and proline residues are markers of 
protein oxidation. Upon reaction with dinitrophenyl hydrazine, carbonyl groups 
form of 2,4-dinitrophenyl hydrazone which is measured spectrophotometrically at 
360 nm. 
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Fig. 28 Melting profile of native IgG (—•—) modified by 0.4 mM (—n—), 
0.8 mM (—A—) and 1.2 mM (—A—) peroxynitrite respectively. 
Table 20 
Melting temperature (Tm) of native- and peroxynitrite- modified IgG 
IgG Tm,°C 
Native 
Modified by 0.4 mM PON 
Modified by 0.8 mM PON 
Modified by 1.2 mM PON 
84 
58 
58 
60 
90 
Fig. 29 Pattern of silver stained bands of native IgG (lane 1) 
modified with 0.4mM, O.SmM and 1.2mM 
peroxynitrite respectively (lanes 2-4) in SDS 
polyacrylamide gel. 
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The carbonyl content (quantitated as dinitrophenyl hydrazone) in native IgG 
was found to be 8.4 nmole/mg of protein. Upon modification with peroxynitrite, the 
carbonyl content increased to 25.8, 40.0 and 59.1 nmole/mg of protein in IgG 
samples modified with 0.4 mM, 0.8 mM and 1.2 mM peroxynitrite respectively 
(Fig. 30). This corresponds to 67.4%, 79% and 85.7%) increase in carbonyl level 
compared to native IgG. 
Quantitation of nitrotyrosine in native- and peroxynitrite-modified IgG 
samples by HPLC 
First of all, HPLC profile of varying concentrations of standard 3-
nitrotyrosine was recorded and resuhs are shown in Fig. 31(a-e). Peaks 
corresponding to retention time of -7.2 min characterize 3-nitrotyrosine. A standard 
curve was generated from the above data (Fig. 32). Native IgG was devoid of 
nitrotyrosine because we did not observe any peak having retention time of-7.2 min 
(Fig. 33a). Concentration dependent peroxynitrite-induced generation of 
nitrotyrosine was observed in all samples of IgG modified by peroxynitrite 
(Fig. 33 b-d). A quantitative estimation of nitrotyrosine in peroxynitrite-modified 
IgG samples is given in Table 21. 
Immunogenicity of native- and peroxynitrite-modified IgG 
Effect of peroxynitrite modification on the immunogenicity of IgG was 
evaluated by inducing antibodies in rabbits. Antisera were tested by direct binding 
immunoassay on microtitre wells coated with respective immunogen. Being a 
protein, native IgG did elicit antibody response (Fig. 34 a) but its modification by 
low dose of peoxynitrite made it more immunogenic (Fig. 34 b). Further increase in 
peroxynitrite concentration did not enhance the antibody induction (Fig. 34 c&d). Of 
the three modified forms of IgG, the one modified with 0.4 mM peroxynitrite was 
most potent immunogen while modification with 1.2 mM peroxynitrite appears to 
have destroyed the conformational requirements for immunogenicity. This shows 
the effect of modification and requirements of minimum conformation for 
immunogenicity of protein antigens. The specificity of experimentally produced 
antibodies with corresponding immunogen was evaluated by inhibition assay (Fig. 
35 a-d). Inhibition in antibody binding to coated antigens at 20 }j.g/ml of inhibitors 
(the immunogen) was 60%) (for anti-native IgG antibodies) and 90%), 78%) and 58%o 
for antibodies against 0.4 mM, 0.8 mM and 1.2 mM peroxynitrite-modified 
IgG respectively. Thus, under our experimental conditions 0.4 mM peroxynitrite-
92 
IgGN IgGa IgGb IgGc 
Fig. 30 Quantitative estimation of carbonyls in native IgG (IgGN) 
modified with 0.4 mM (IgGa), 0.8mM (IgGb) and 1.2 mM (IgGc) 
peroxynitrite respectively. Each histogram represents the 
mean ± S.D. of 4 independent assays. 
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nitrotyrosine. 
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Fig. 32 Standard curve of 3-nitrotyrosine constructed from data in 
Fig. 31 (a-e). 
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Table 21 
Quantitative estimation of 3-nitrotyrosine in peroxynitrite-
modifled IgG samples 
IgG Nitrotyrosine (nM) 
Native Nil 
Modified by 0.4 mM PON 7.7 
Modified by 0.8 mM PON 10.0 
Modified by 1.2 mM PON 13.8 
100 
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Fig. 34 Direct binding ELIS A of experimentally produced antibodies 
against; 
(a) native IgG 
(b) 0.4 mM peroxynitrite-modified IgG 
(c) 0.8 mM peroxynitrite-modified IgG 
(d) 1.2 mM peroxynitrite-modified IgG 
The microtitre wells were coated with respective immunogens. 
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Fig. 35 Inhibition ELISA of binding of experimentally produced antibodies to; 
(a) native IgG 
(b) 0.4 mM peroxynitrite-modified IgG 
(c) 0.8 mM peroxynitrite-modified IgG 
(d) 1.2 mM peroxynitrite-modified IgG 
The inhibitor and coating antigens were same. 
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modified IgG is a powerful immunogen and induced antibodies are specific also. 
Therefore, further studies have been carried out with 0.4 mM peroxynitrite-modified 
IgG and experimentally produced antibodies against this form of modified IgG. 
Crossreactivity of anti- peroxynitrite-modified IgG antibodies 
The immunogen specificity of the experimentally produced antibodies (IgG 
type) against peroxynitrite (0.4 mM)-modified IgG was ascertained by inhibition 
assay. Antibody specificity for the immunogen was confirmed from 92.7% 
inhibition (Fig. 36 a). Native IgG showed 79.6% inhibition in antibody binding. This 
indicates polyspecific nature of induced antibodies capable of recognizing old 
epitopes on native IgG as well as peroxynitrite-induced neo-epitopes on modified 
IgG. Antibodies against peroxynitrite (0.4 mM)-modified IgG showed cross-reaction 
with an array of nitrated and non-nitrated proteins/amino acids (Fig. 36-38). Results 
of cross-reaction studies have been summarized in Table 22. It may be noted that the 
peroxynitrite-modified counterparts of the inhibitors are preferentially bound by the 
experimentally produced antibodies. Involvement of nitrotyrosine, besides other 
factors, in the immunogenicity of peroxynitrite (0.4 mM)-modified IgG is evident 
from ability of nitrotyrosine in inhibiting antibody binding to the extent of 73.0 
percent. 
Cross-reactivity of anti-native IgG antibodies 
The immunogen specificity of the experimentally induced antibodies (IgG 
type) against native IgG was characterized by inhibition assay. Antibody specificity 
for the immunogen was confirmed from 82.8%o inhibition (Fig. 39 a). The induced 
antibodies showed significant binding with peroxynitrite (0.4 mM)-modified IgG 
and 74.6% inhibition in antibody binding was observed (Fig. 39 a). Antibodies 
against native IgG showed cross-reaction with an array of non-nitrated and nitrated 
proteins/amino acids (Fig. 39 b-d and 40, 41). Results of cross-reaction studies have 
been summarized in Table 23. It may be noted that unmodified inhibitors are 
preferentially bound by the experimentally produced antibodies against native IgG. 
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Fig. 36 Inhibition ELISA of anti-peroxynitrite (0.4 mM)-modified IgG antibody 
binding by; 
(a) Native (—•—) and peroxynitrite (0.4mM)-modified IgG (—A—). 
(b) Peroxynitrite (0.8 mM)-modified IgG (—•—) and peroxynitrite 
(1.2 mM)-modified IgG (-A-). 
(c) Cysteine (—•—) and peroxynitrite (0.4mM)-modified cysteine (—A—). 
(d) Tyrosine (—•—) and commercially available 3-nitrotyrosine (—A—). 
The microtitre wells were coated with peroxynitrite (0.4mM)-modified 
IgG. 
104 
0.01 0.1 100 
20-
40 
60 
80 
no 
^ = = = 8 = = : 
i i i i m i l . 1 
=»:::;; 
1 1 
(b) 
0.01 0.1 10 ICO 
o 
^ 
c 
v 
u 
u 
0-
20-
40 
60 
80 
100 
^ -X=i; — I — . 
1 ' 
(c) 
" 1 ' ' 1 " 1 " 
aoi 0.1 1 10 100 
InhiMtorooiicentiation, jL^ni 
20-
40 
60 
80 
100-
' = ^ = x = ^ 
1 ' ' 
= ^ . ^ 
\ 
\ 
A 
0.01 0.1 1 10 100 
InhiUtDr oonoentratiQn, Mg/nfl 
Fig. 37 Inhibition ELISA of anti-peroxynitrite (0.4mM)-modified IgG antibody 
binding by; 
(a) Native DNA (—•—) and peroxynitrite (0.4mM)-modified DNA (—A—). 
(b) Tryptophan (—•—) and peroxynitrite (0.4mM)-modified 
tryptophan (—A—). 
(c) Phenylalanine (—•—) and peroxynitrite (0.4mM)-modified 
phenylalanine (—A—). 
(d) HSA ( - • - ) and peroxynitrite (0.4mM)-modified HSA (-A-). 
The microtitre wells were coated with peroxynitrite 
(0.4mM)-modified IgG. 
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Fig. 38 Inhibition ELISA of anti-peroxynitrite (0.4mM)-modified IgG antibody 
binding by; 
(a) H3 histone (—•—) and peroxynitrite (0.4mM)-modified H3 histone (—A—). 
(b) H2A histone (—•—) and peroxynitrite (0.4mM)-modified H2A 
histone (—A—). 
(c) LDL (—•—) and peroxynitrite (0.4mM)-modified LDL (—A—). 
(d) Trypsin (—•—) and peroxynitrite (0.4mM)-modified trypsin (—A—). 
The microtitre wells were coated with peroxynitrite (0.4mM)-modified 
IgG. 
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Table 22 
Cross-reaction of anti-peroxynitrite (0.4 mM)-modified IgG antibodies 
Inhibitor 
Native IgG 
Peroxynitrite (0.4 mM)-modified IgG 
Peroxynitrite (0.8 mM) -modified IgG 
Peroxynitrite (1.2 mM) -modified IgG 
Tyrosine 
3-nitrotyrosine 
Tryptophan 
Peroxynitrite (0.4 mM)-modified tryptophan 
Phenylalanine 
Peroxynitrite (0.4 mM)-modified phenylalanine 
Cysteine 
Peroxynitrite (0.4 mM)-modified cysteine 
HSA 
Peroxynitrite (0.4 mM)-modified HSA 
H2A Histone 
Peroxynitrite-modified H2A histone 
H3 Histone 
Peroxynitrite (0.4 mM)-modified H3 histone 
LDL 
Peroxynitrite (0.4 mM)-modified LDL 
Trypsin 
Peroxynitrite-modified trypsin 
DNA 
Peroxynitrite (0.4 mM)-modified DNA 
Maximum percent inhibition at 
20 ng/ml 
79.6 
92.7 
76.8 
74.2 
50.4 
73.0 
13.0 
31.4 
10.5 
19.3 
25.1 
37.0 
30.9 
61.4 
9.9 
12.5 
4.0 
45.8 
5.2 
20.9 
22.0 
50.0 
12.0 
40.0 
Wells were coated with 100 \iM peroxynitrite (0.4mM)-modified IgG. 
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Fig. 39 Inhibition ELISA of anti-native IgG antibody binding by; 
(a) Native IgG (—A—) and peroxynitrite (0.4 mM)-modified IgG (—•—). 
(b) 0.8 mM peroxynitrite-modified IgG (—A—) and 1.2 mM 
peroxynitrite-modified IgG (—•—). 
(c) Tyrosine (—A—) and peroxynitrite (0.4 mM)-modified tyrosine (—•—). 
(d) Tryptophan (—A—) and peroxynitrite (0.4 mM)-modified 
tryptophan (—•—). 
The microtitre wells were coated with native IgG 
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Fig. 40 Inhibition ELISA of anti-native IgG antibodies binding by; 
(a) Phenylalanine (—A—) and peroxynitrite (0.4 mM)-modified 
phenylalanine (—•—). 
(b) Cysteine (—A—) and peroxynitrite (0.4 mM)-modified cysteine (—•—). 
(c) HSA (-A-) and peroxynitrite (0.4 mM)-modified HSA ( - • - ) . 
(d) H2A (-A-) and peroxynitrite (0.4 mM)-modified H2A ( - • - ) . 
The microtitre wells were coated with native IgG. 
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Fig. 41 Inhibition ELISA of anti-native IgG antibodies binding by; 
(a) H3 histone (—A—) and peroxynitrite (0.4 mM)-modified H3 
histone (—•—). 
(b) LDL (—A—) and peroxynitrite (0.4 mM)-modified LDL (—•—). 
(c) Trypsin (—A—) and peroxynitrite (0.4 mM)-modified trypsin (—•—). 
(d) DNA (—A—) and peroxynitrite (0.4 mM)-modified DNA (—•—). 
The microtitre wells were coated with native IgG. 
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Table 23 
Cross reactions of anti IgG antibodies 
Inhibitor Maximum percent inhibition at 20 fig/ml 
Native IgG 
Peroxynitrite (0.4 mM)-modified IgG 
Peroxynitrite (0.8 mM)-modified IgG 
Peroxynitrite (1.2 mM)-modified IgG 
Tyrosine 
3-nitrotyrosine 
Native tryptophan 
Peroxynitrite (0.4 mM)-modified tryptophan 
Native phenylalanine 
Peroxynitrite (0.4 mM)-modified phenylalanine 
Native cysteine 
Peroxynitrite (0.4 mM)-modified cysteine 
Native HSA 
Peroxynitrite-modified HSA 
Native H2A histone 
Peroxynitrite (0.4 mM)-modified H2A histone 
Native H3 histone 
Peroxynitrite (0.4 mM)-modified H3 histone 
Native LDL 
Peroxynitrite (0.4 mM)-modified LDL 
Native trypsin 
Peroxynitrite (0.4 mM)-modified trypsin 
Native DNA 
Peroxynitrite (0.4 mM)-modified DNA 
82.8 
74.6 
62.9 
34.1 
11.0 
2.7 
8.4 
1.2 
10.8 
9.5 
12.4 
2.1 
25.9 
17.9 
12.0 
3.0 
10.0 
6.0 
19.8 
9.3 
35.1 
7.86 
10.28 
1.4 
Wells were coated with native IgG. 
I l l 
STUDIES ON SERA OF RHEUMATOID ARTHRITIS PATIENTS 
Direct binding ELISA of diabetes sera with native- and peroxynitrite 
(0.4 mM)-modified IgG 
Serum samples (n=50) were diluted 1:100 and subjected to direct binding 
ELISA on microtitre wells coated with equal amounts of native- and peroxynitrite 
(0.4 mM)-modified IgG (Fig. 42-45). Age- and sex- matched sera from healthy 
individuals served as control. Peroxynitrite (0.4 mM)-modified IgG was better 
recognized by autoantibodies in RA sera compared to native IgG. This shows 
abundance of autoantibodies against native/altered IgG. Statistical significance of 
the data was evaluated by employing students "/" test procedure (SPSS-15). A 
p value of <0.05 indicated that there existed significant difference between the 
means of the RA sera bindings with native- and peroxynitrite (0.4 mM)-modified 
IgG at 99% confidence interval. Significance of the binding of native- and 
peroxynitrite (0.4 mM)-modified IgG with normal human sera and RA sera 
respectively was found to be < 0.05 by students 'V" test procedure which is again 
significant. 
Inhibition ELISA of RA IgG with native- and peroxynitrite (0.4 mM)-
modified IgG 
IgG were isolated from 16 RA sera (Fig. 42-45, * marked). The isolated RA 
IgG were first subjected to direct binding assay on microtitre wells coated with 
peroxynitrite (0.4 mM)-modified IgG to check their binding activity and to evaluate 
the amount of antibody required for antigen saturation. Fig. 46 shows the result of 
direct binding assay of one of the RA IgG. 
Specificity of isolated RA IgG towards native- and peroxynitrite (0.4 mM)-
modified IgG was evaluated by inhibition ELISA and results are given in Fig. 47-50. 
Peroxynitrite (0.4 mM)-modified IgG appears to be better substrate for RA IgG 
because it was found to be better inhibitor (Table 24). Statistical analysis of the data 
was evaluated by employing students "f test procedure (SPSS), kp value of <0.05 
revealed that there existed significant difference between the means of the 
inhibitions of RA IgG binding with native- and peroxynitrite (0.4 mM)-modified 
IgG. 
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Fig. 42 Binding of 1:100 diluted Rheumatoid Arthritis sera to native IgG 
(—•—) and peroxynitrite (0.4 mM)-modified IgG (—•—). Pooled 
normal human sera (NH) showed negligible binding with native IgG 
but some binding with peroxynitrite (0.4 mM)-modified IgG. 
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Fig, 43 Binding of 1:100 diluted Rheumatoid Arthritis sera to native 
IgG (—•—) and peroxynitrite (0.4 mM)-modified IgG (—M—). 
Pooled normal human sera (NH) showed some binding with the 
coated antigens. 
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Fig. 44 Binding of 1:100 diluted Rheumatoid Arthritis sera to native 
IgG (—•—) and peroxynitrite (0.4 mM)-modified IgG (—•—). 
Pooled normal human sera (NH) showed some binding with coated 
antigens. 
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Fig, 45 Binding of 1:100 diluted Rheumatoid Arthritis sera 
to native IgG (—•—) and peroxynitrite 
(0.4 mM)-modified IgG (—•—). Pooled normal 
human sera (NH) showed negligible binding with 
coated antigens. 
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Fig. 46 Direct binding ELISA of a purified Rheumatoid Arthritis 
IgG (—A—) and normal human IgG (—A—) on 
microtitre wells coated with peroxynitrite 
(0.4 mM)-modified IgG. 
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Fig. 47 Inhibition of RA IgG (isolated from serum no. 1, 2, 7 and 8) binding 
by native IgG (—•—) and peroxynitrite (0.4 mM)-modified 
IgG (—A—). Microtitre wells were coated with peroxynitrite 
(0.4 mM)-modified IgG. 
118 
••4 
.a 
a 
0) 
u 
u 
9) 
RAIgG9 
ICXH— 
QQl 
TTTT] I T — t - i - i - m r , ' I I III 
Ql 1 10 IflO 
On 
20 
40i 
60^  
80 
lOO I T T l i i n i r 
RA 
- r - m i i l 1 
IgG 10 
w 
A 
\ 
i r o i i l I i - i i n n 
I 
o 
100 
aoi 0.1 1 10 100 
IhhiUtaroQnoentratiQn, |i^ni 
0 
20 
40 
60 
80 
100 
• 
-
• 
1 i i i i i i 
RA IgG 18 
• • . 
A 
\ 
aoi a i 1 10 100 
Inhibitar ooiioentratiiQn, ji^iil 
Fig. 48 Inhibition of RA IgG (isolated from serum no 9, 10, 16 and 18) 
binding by native IgG (—•—) and peroxynitrite (0.4 mM)-modified 
IgG (—A—). Microtitre wells were coated with peroxynitrite 
(0.4 mM)-modified IgG. 
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Fig. 49 Inhibition of RA IgG (isolated from serum no. 23, 24, 30 and 31) 
binding by native IgG (—•—) and peroxynitrite (0.4 mM)-modified 
IgG (—A—). Microtitre wells were coated with peroxynitrite 
(0.4 mM)-modified IgG. 
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IgG (—A—). Microtitre wells were coated with peroxynitrite 
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Table 24 
Inhibition of RA IgG binding by native- and 
peroxynitrite (0.4mM)-modified IgG 
IgG 
01(1) 
02(2) 
03(7) 
04(8) 
05(9) 
06 (10) 
07(16) 
08(18) 
09 (23) 
10 (24) 
11(30) 
12(31) 
13 (32) 
14 (37) 
15(47) 
16(48) 
Maximum percent inhibition at 20 ^ g/ml 
Peroxynitrite-modified IgG 
90.2 
88.5 
84.6 
89.0 
84.2 
72.1 
76.7 
75.0 
73.6 
72.6 
76.7 
66.1 
41.9 
60.0 
64.2 
52.0 
Native IgG 
34.9 
33.9 
53.9 
56.1 
60.0 
53.0 
50.0 
26.8 
27.3 
35.0 
55.0 
24.1 
25.0 
40.7 
29.7 
35.0 
MeaniS.D. = (72.96±13.63%) (40.02±12.59%) 
Microtitre plates were coated with 0.4 mM peroxynitrite 
modified IgG. Numbers in parentheses show the RA serum 
number in Fig. 42-45 which were used for isolation of IgG. 
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Estimation of protein carbonyl in RA sera 
Carbonyl contents in 16 RA sera (no. 1, 2, 7-10, 16, 18, 23, 24, 30-32, 37, 
47,48) and 10 normal human sera were estimated to assess the quantum of oxidative 
stress in normal subjects and RA patients. In normal subjects the average carbonyl 
content was found to be 1.88 ± 0.16 nmol/mg protein while in case of RA the 
average was 4.44 ± 0.39 nmol/mg protein (Fig. 51). Statistical analysis of data by 
students 'V" test revealed that RA serum samples had significantly higher content of 
carbonyls {p < 0.05) compared to normal sera. 
Estimation of nitrotyrosine in normal and RA sera by HPLC 
Ten serum samples of apparently normal human subjects were mixed in 
equal amounts and subjected to HPLC analysis in order to check the presence of 
nitrotyrosine in healthy individuals. (Fig. 52). Under our experimental conditions 
nitrotyrosine was not observed in control serum. HPLC chromatogram of 10 RA 
samples are given in Fig. 53-57. All tested RA samples were positive for 
nitrotyrosine because peaks were observed matching with the retention time of 
3-nitrotyrosine. The concentration of 3-nitrotyrosine in RA serum samples were 
calculated from the calibration curve of standard 3-nitrotyrosine given elsewhere 
in the thesis. The data is summarized in Table 25. 
STUDIES ON SERA OF TYPE-2 DIABETES MELLITUS PATIENTS 
Direct binding ELISA of diabetes sera with native- and peroxynitrite 
(0.4 mM)-modified IgG 
Serum samples (n=50) included in this study were pre-tested for fasting 
blood glucose and the average value was 267 ± 25.62 mg per 100 ml. Age- and sex-
matched sera from apparently normal subjects were included as control. 
All sera were diluted 1:100 and subjected to direct binding ELISA on 
microtitre wells separately coated with equal amounts of native- and peroxynitrite 
(0.4 mM)-modified IgG to detect presence of circulating autoantibodies (Fig. 58-
61). The results suggest that autoantibodies in type 2 diabetes are recognizing both 
native- and peroxynitrite (0.4 mM)-modified IgG but modified IgG is preferred for 
binding. Statistical significance of the data was evaluated by employing students "f 
test procedure. Ap value of <0.05 indicated that there existed significant difference 
between the means of the sera bindings with native- and peroxynitrite (0.4 mM)-
modified IgG at 99% confidence interval. Significance of the binding of native- and 
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NH RA Sera 
Fig. 51 Level of carbonyls in normal human sera (NH) and 
RA sera. Each histogram represents the mean ± S.D. 
of analysed samples. 
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Fig. 52 HPLC chromatogram of pooled sera often healthy subjects. The arrow 
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at retention time. 
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standard nitrotyrosine. 
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Fig. 55 HPLC chromatogram of RA serum sample number 16 (e) and number 
18 (f). The profile shows peak corresponding to the retention time of 
standard nitrotyrosine. 
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HPLC chromatogram of RA serum sample number 23 (g) and number 
30 (h). The profile shows peak corresponding to the retention time of 
standard nitrotyrosine. 
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Fig. 57 HPLC chromatogram of RA serum sample number 47 (i) and number 
48 (j). The profile shows peak corresponding to the retention time of 
standard nitrotyrosine. 
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Table 25 
Quantitation of nitrotyrosine in RA sera by HPLC 
RA serum sample number Absorbance at 274 nm Nitrotyrosine (fiM) 
1 0.280 0.520 
2 0.230 0.580 
7 0.365 0.700 
8 0.230 0.40 
16 0.275 0.510 
18 0.340 0.650 
23 0.275 0.510 
30 0.240 0.410 
47 0.238 0.438 
48 0.360 0.680 
Mean ± SD = (0.539 ± 0.109) nM 
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NH 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Diabetes Sera 
Fig. 58 Binding of 1:100 diluted sera to native (—•—) and peroxynitrite 
(0.4 mM)-modified IgG (—•—). Pooled normal human sera (NH) 
showed some binding with coated antigens. 
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NH 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
Diabetes Sera 
Fig. 59 Binding of 1:100 diluted sera to native (—•—) and peroxynitrite 
(0.4 mM)-modified IgG (—•—). Pooled normal human sera 
(NH) showed some binding with coated antigens. 
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Fig. 60 Binding of 1:100 diluted sera to native (—•—) and peroxynitrite 
(0.4 mM)-modified IgG (—•—). Pooled normal human sera (NH) 
showed some binding with coated antigens. 
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NH 46 47 48 49 50 
Diabetes Sera 
Fig. 61 Binding of 1:100 diluted sera to native (—•—) and 
peroxynitrite (0.4 mM)-modified IgG (—•—). 
Pooled normal human sera (NH) showed some 
binding with coated antigens. 
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peroxynitrite (0.4 mM)-modified IgG with normal human sera and DM sera 
respectively was also found to be < 0.05 by students "f test procedure which is 
again significant. 
Inhibition ELISA of diabetes IgG with native- and peroxynitrite (0.4 
mM)-modified IgG 
IgG were isolated from 16 diabetes sera (Fig. 58-61, § marked). The isolated 
diabetes IgG were first subjected to direct binding assay on microtitre wells coated 
with peroxynitrite (0.4 mM)-modified IgG to check their binding activity and to 
evaluate the amount of antibody required for antigen saturation. Fig. 62 shows the 
resuh of direct binding assay of one of the DM IgG. 
Specificity of isolated DM IgG towards nafive- and peroxynitrite (0.4 mM)-
modified IgG was evaluated by inhibition ELISA and resuhs are given in Fig. 63-66. 
Peroxynitrite (0.4 mM)-modified IgG appears to be better substrate {p < 0.05 by "f 
test) for DM IgG because it was found to be better inhibitor (Table 26). 
Estimation of protein carbonyl in DM sera 
Carbonyl contents in 16 DM sera (no. 1, 3, 7-9, 11, 16, 17, 20, 22, 23, 31, 32, 
47, 49, 50) and 10 normal human sera were estimated to assess the quantum of 
oxidative stress in normal subjects and DM patients. In normal subjects the average 
carbonyl content was found to be 1.88 ± 0.16 nmol/mg protein while in case of DM 
the average was 3.39 ± 0.45 nmol/mg protein (Fig. 67). Statistical analysis of data 
by students "/" test revealed that DM serum samples had significantly higher content 
of carbonyls (p < 0.05) compared to normal sera. 
Estimation of nitrotyrosine in normal and DM sera by HPLC 
Under our experimental conditions HPLC profile of control serum showed 
absence of nitrotyrosine (Fig. 52). HPLC chromatogram of 10 DM serum samples 
are given in Fig. 68-72. Tested diabetes samples were positive for nitrotyrosine 
because peaks were observed matching with the retention time of 3-nitrotyrosine. 
The concentration of 3-nitrotyrosine in DM samples were calculated from the 
calibration curve of standard 3-nitrotyrosine. The data has been given in 
Table 27. 
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IgG ^g/ml 
Fig. 62 Direct binding ELISA of a purified Diabetes Mellitus 
IgG (—•—) and normal human IgG (—A—) on 
microtitre wells coated with peroxynitrite (0.4 mM)-
modified IgG. 
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Fig. 63 Inhibition of DM IgG (isolated from serum no. 1, 3, 7 and 8) binding 
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(—A—). Microtitre wells were coated with peroxynitrite (0.4 mM)-
modified IgG. 
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Fig. 65 Inhibition of DM IgG (isolated from serum no. 20, 22, 23 and 31) 
binding by native IgG (—•—) and peroxynitrite (0.4 mM)-modified 
IgG (—A—). Microtitre wells were coated with peroxynitrite 
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Fig. 66 Inhibition of DM IgG (isolated from sera 32, 47, 49 and 50) 
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peroxynitrite (0.4 mM)-modified IgG. 
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Table 26 
Inhibition of DM IgG binding by native- and peroxynitrite 
(0.4mM)-modified IgG 
¥ / ^ 
IgG 
01(1) 
02(3) 
03(7) 
04(8) 
05(9) 
06(11) 
07(16) 
08(17) 
09 (20) 
10(22) 
11 (23) 
12(31) 
13 (32) 
14 (47) 
15(49) 
16 (50) 
Maximum percent inhibition at 20 |iig/ml 
Peroxynitrite-modified IgG 
66.5 
60.0 
62.0 
59.0 
74.5 
58.5 
54.0 
54.8 
48.8 
55.2 
45.6 
33.7 
34.3 
27.5 
33.6 
36.6 
Native IgG 
46.5 
38.0 
44.7 
36.6 
46.5 
48.0 
35.0 
33.7 
36.7 
24.4 
16.4 
14.7 
16.5 
12.5 
27.1 
22.2 
MeaniS.D. = (50.28±13.71%) (31.21±12.27%) 
Microtitre plates were coated with peroxynitrite (0.4 mM)-
modified IgG. Numbers in parentheses show the DM serum 
number in Fig. 58-61 which were used for isolation of IgG. 
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Fig. 67 Level of carbonyls in normal human sera (NH) and 
DM sera. Each histogram represents the mean ± S.D. 
of analysed samples. 
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Fig. 68 HPLC chromatogram of DM serum sample number 1 (a) and number 
3 (b). The profile shows peak corresponding to the retention time of 
standard nitrotyrosine. 
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Fig. 69 HPLC chromatogram of DM serum sample number 7 (c) and 
number 8 (d). The profile shows peak corresponding to the 
retention time of standard nitrotyrosine. 
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HPLC chromatogram of DM serum sample number 9 (e) and number 
11 (f). The profile shows peak corresponding to the retention time of 
standard nitrotyrosine. 
F r a c t i o n s 
146 
0 .40 
0 .35 
0 .30 
0 .25 
0.20 
0 .15 
0 .10 
0 .05 
0 .00 
-0 .05 
AU 
i .«J%M»l 
.«4 
3-nitrotyrosine 
A 
(g) 
" r ™ -T~ 
m 
0 .40 
0 .35 
0 .30 
0 .25 
0 .20 
0 .15 
0 .10 
0 .05 
0.00 
- 0 . 0 5 
AU 
**« i%f t* f f 
.-%$ 
- t ; t # -
3-nitrotyrosine 
^•j 
~i ^ r-
(h) 
m 
Retention time, min 
istt 
Fig. 71 HPLC chromatogram of DM serum sample number 16 (g) and 
number 17 (h). The profile shows peak corresponding to the retention 
time of standard nitrotyrosine. 
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Fig. 72 HPLC chromatogram of DM serum sample number 20 (i) and 
number 22 (j). The profile shows peak corresponding to the retention 
time of standard nitrotyrosine. 
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Table 27 
Quantitation of nitrotyrosine in DM sera by HPLC 
DM serum sample number Absorbance at 274 nm Niytotyrosine (^ iM) 
I 0.360 1.200 
3 0.230 0.400 
7 0.120 0.220 
8 0.060 0.100 
9 0.370 1.210 
II 0.200 0.280 
16 0.270 0.380 
17 0.230 0.400 
20 0.270 0.380 
22 0.190 0.310 
Mean ± SD = 0.488 (±0.389) fiM 
DISCUSSION 
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Nitric oxide (NO) and superoxide (O2* ~) are probably the most relevant free 
radicals in biology. Action of nitric oxide synthase (NOS) on arginine generates 
nitric oxide. Major sources of intracellular O2* " are uncoupling of mitochondrial 
electron transport and cytosolic oxidases (such as NADH/NADPH oxidase and 
xanthine oxidase). The superoxide anion is also generated in a number of 
biochemical reactions including cellular respiration, in activated polymorphonuclear 
leucocytes, macrophages, epithelial and endothelial cells (Salvemini et al., 2006). In 
vivo, the peroxynitrite anion (0N00~) is rapidly formed through reaction of the 
superoxide anion with nitric oxide (Beckman et al., 1990). Peroxynitrite is highly 
reactive and can modify biomolecules such as lipids, DNA or proteins. An excess of 
peroxynitrite is consequently involved in a number of pathological mechanisms 
including inflammation, cell damage (apoptosis and cytotoxicity), and may interfere 
with nitric oxide mediated signaling (Salvemini et al, 2006; Muijsers et al., 1997). 
Furthermore, cysteine, methionine and tryptophan can directly react with 
peroxynitrite, whereas tyrosine, phenylalanine and histidine are modified through 
intermediary secondary species (Ischiropoulos and al-Mehdi, 1995; Alvarez et al, 
1996; Alvarez et al., 1999; Alvarez and Radi, 2003). Sulfliydryls (Radi et al., 
1991b) and tyrosine residues are the major targets of peroxynitrite in proteins (van 
der Vliet et al., 1995; Beckman, 1996) and oxidation of thiols is faster than tyrosine 
nitration (Alvarez et al., 1999; Alvarez and Radi, 2003). Peroxynitrite chemistry is 
highly pH dependent and it is maximal at physiological pH (about pH 7.4). The 
hallmarks of the peroxynitrite-mediated attack on proteins is the formation of 
6-nitrotryptophan, 3-nitrotyrosine, and 3,3 dityrosine. Nitrotyrosine has been 
considered as a direct footprint of peroxynitrite activity. 
Protein tyrosine nitration is a well established post-translational modification 
(Greenacre and Ischiropoulos, 2001) which can affect protein structure and function. 
Furthermore, tyrosine nitration may change the rate of proteolytic degradation of 
nitrated proteins and favour either its faster clearance or the accumulation of nitrated 
proteins in cells. Cumulatively, this suggests that protein nitration may be involved 
in a variety of functions, possibly including disease initiation and progression. 
Increased 3-nitrotyrosine formation has been found in acute lung injury, sepsis, 
rheumatoid arthritis, Alzheimer's disease, liver transplantation, etc. (Beckman and 
Koppenol, 1996). Elevated levels of anti-nitrotyrosine antibodies have indeed been 
measured in synovial fluid of patients with rheumatoid arthritis and osteoarthritis 
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(Khan and Siddiqui, 2006), as well as in the serum of patients with systemic lupus 
erythematosus (a muhisystem autoimmune disease) (Khan and Siddiqui, 2006; Khan 
and Ali, 2006). 
Endogenous proteins are normally not immunogenic due to immunological 
tolerance. However, post-translational modifications of self-proteins can lead to 
generation or unmasking of epitopes, resulting in the triggering of an immune 
response, which may induce autoimmune phenomenon (Ohmori and Kanayama, 
2005). A variety of post-translationally modified proteins (including nitrated 
proteins) have been shown to accumulate in apoptotic or inflamed tissues (Ohmori 
and Kanayama, 2005). The accumulation in inflamed tissue of nitrotyrosine-
containing autologous proteins, that appear as foreign to the immune system, might 
induce an autoimmune response and sustain a chronic inflammatory response 
(Bimboim et al, 2003). 
Since antibodies are glycoproteins, they can themselves function as potent 
immunogens to induce antibody response. The antigenic determinants, or epitopes, 
on immunoglobulin molecules fall into three major categories namely - isotypic, 
allotypic, and idiotypic determinants, which are located in characteristic portions of 
the molecule. Human rheumatoid factors (RFs) are IgG, IgA or IgM antibodies that 
bind to the Fc portion of immunoglobulins (Munthe and Natvig, 1972). In most 
cases, IgG is the antigen for RF. 
In the present study, purified human IgG was modified by peroxynitrite and 
characterized by physicochemical methods. Addition of peroxynitrite to IgG caused 
hyperchromicity compared to native IgG. This may be attributed to 
peroxynitrite-induced modification of mainly aromatic amino acids (especially 
tyrosine residues) as well as unfolding of protein. Peroxynitrite-induced nitration 
was evident from appearance of yellow colour in peroxynitrite-modified IgG 
samples and the colour intensity was directly proportional to peroxynitrite 
concentration. Furthermore, in modified-IgG samples a new peak at 420 nm was 
clearly visible which may be due to generation of nitrotyrosine because a standard 
solution of 3-nitrotyrosine gave similar peak at 420 nm. HPLC resuhs further 
suggested the generation of nitrotyrosine in peroxynitrite-modified IgG samples. 
Tyrosine and tryptophan are natural fluorophores commonly found in 
proteins (Lakowicz, 1983). Although IgG has several tyrosine, tryptophan and 
phenylalanine residues, the fluorophoric property of tyrosine was taken into account 
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to analyze the modified-IgG structures in fluorescence terms. The emission profile 
of peroxynitrite-modified IgG samples exhibited fluorescence quenching (any 
process which reduces the lifetime of the excited state) compared to native IgG. In 
our case, it may be the result of peroxynitrite mediated addition of nitro group in the 
phenolic ring. 
Dityrosine is a fluorescent molecule (DiMarco and Giulivi, 2007) formed as 
a resuh of normal post-translational processing. It can also form as a result of UV 
irradiation, aging, y-irradiation, exposure to oxygen free radicals, nitrqgen dioxide 
and peroxynitrite. The mechanism of dityrosine formation begins with the 
generation of a tyrosyl radical which subsequently leads to the production of 
dityrosine involving two monomeric molecules of tyrosine, joined by intermolecular 
crosslinking, thus resuhing in the formation of protein dimmers (Giulivi et al, 
2003). In our studies, spectroscopic determination revealed generation of dityrosine 
in peroxynitrite-modified IgG samples. Here, it may be pointed out that dityrosine 
has been used as an important biomarker for oxijJative/nitrosative stress (Dimarco 
and Giulivi, 2007). In many structural proteins, dityrosine confers resistance to 
proteolysis. 
The surface hydrophobicity of a protein affects its physical stability, 
solubility, aggregation tendency as well as adsorption behaviour. The use of 
hydrophobic fluorescent dyes offer a spectroscopic approach to measure surface 
hydrophobicity of native and denatured proteins (Hawe et al, 2008). There are 
several factors that can alter protein surface hydrophobicity, e.g. it changes upon 
denaturation and folding, it can be altered by the binding of some ligand, and it has 
also been observed that oxidative modifications considerably alter surface 
hydrophobicity (Moller and Denicola, 2002). The surface of partially unfolded 
proteins is more hydrophobic than their native counterparts. ANS (1-
anilinonaphthalene-8-sulfonic acid) is an extensively utilized fluorescent probe for 
the characterization of protein surface hydrophobicity. 
The binding of ANS to native as well as peroxynitrite-modified IgG samples 
was investigated by spectrofluorimetry after excitation at 380 nm (Thiagarajan et al, 
2004; Hawe et al, 2008). The fluorescence emission spectrum of ANS mixed native 
or modified-IgG samples showed increase in the emission intensity as well as blue 
shift of the maximum emission wavelength. The surface hydrophobicity of 
peroxynitrite-modified IgG samples was found to increase, as modification 
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increased, resulting in higher ANS binding and hence more intense fluorescence. 
Thus, ANS binding study is a suitable way to show the existence of the surface 
hydrophobic patches as well as to detect non-native intermediate conformations of 
globular proteins (Semistonov et al, 1991). 
The accumulation of oxidized proteins is most commonly measured by the 
content of reactive carbonyls (Stadtman and Oliver, 1991; Stadtman et al, 1992). 
Oxidation of proteins can result in the loss of catalytic function, increased sensitivity 
to denaturation, and increased susceptibility to proteolysis (Stadtman et al, 1992; 
Grune et al, 1997). Quantitation of reactive carbonyl in peroxynitrite-modified IgG 
samples showed generation of carbonyls with increasing amount of peroxynitrite. 
The increase in carbonyl content in peroxynitrite-modified IgG samples may be 
attributed directly to oxidative action of peroxynitrite (Adams et al, 2001). 
The utility of CD in the determination of secondary structure of proteins is 
well documented (Nakanishi et al, 1994). This valuable tool was utilized for fur1:her 
evaluation of changes in secondary structures of native and peroxynitrite-modified 
IgG samples. Native IgG as well as its counterparts modified by 0.4 mM and 0.8 
mM peroxynitrite showed a large negative dichroism at 217 nm and earlier studies 
have taken it as a characteristic feature of p-sheet structure (Cathou et al, 1968; 
Ross and Jirgensons, 1970; Doi and Jirgensons, 1970). It has also been reported that 
CD spectrum of serum IgG from healthy volunteers is remarkably reproducible, 
despite the heterogeneous nature of IgG (Johnson et al, 1974). Gorga et al, (1989) 
have reported 3% a-helix in native IgG while under our experimental conditions it 
was found to be 4%. Upon treatment with peroxynitrite, IgG showed gradual 
decrease in P-sheet content and increase in a-helix. At higher concentration of 
peroxynitrite (1.2 mM) the IgG showed aggregates probably due to exposure of 
hydrophobic interior. At the interfaces between the building blocks of the aggregate, 
hydrogen bonds between peptide units in the polypeptide chain may be formed 
which induces the formation of a-helixes (Vermeer and Norde, 2000). Previous 
studies have reported that due to unfolding of IgG the P-sheet fractions decreases 
whereas a-helix conformations increases (Vermeer et al, 1998). Our results get 
support from it. 
Consequences of peroxynitrite-modification on the stability of IgG was 
studied by recording melting temperature. Treatment with peroxynitrite has 
decreased the Tm of peroxynitrite-modified IgG samples indicating their thermal 
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instability. It may be concluded that peroxynitrite has already partially denatured the 
structures of IgG during the course of modification. During temperature-induced 
denaturation, the protein absorbance changes with temperature until the process of 
unfolding is complete. The unfolding of immunoglobulin G is a complex process, in 
which the denatured state is obtained from the native protein through several, at least 
partly independent, intermediate states. Moreover, depending on the type of 
denaturing stress the denaturation process follows different paths, the Fab fragment 
is most sensitive to heat treatment. Peroxynitrite-induced nitration of tyrosine 
residues coupled with denaturation appears to be the reason for decreased melting 
temperatures of modified samples because the forces (or factors) responsible for 
maintaining the native structure of IgG are severely affected under the influence of 
peroxynitrite. 
Immunogenicity is the ability of a molecule to give rise to an immune 
response in certain hosts and this property depends on extrinsic factors such as the 
host immunoglobulin repertoire, self-tolerance, the production of cytokines and 
various cellular and regulatory mechanisms, definable only in the context of a 
particular host (Berzofsky, 1985). Most peptides are immunogenic in the sense that 
they readily elicit antibodies that react with the peptide immunogen. IgG is of high 
molecular weight and is therefore a potent immunogen. A direct conformational 
change of some of the IgG molecules might expose antigenic sites on the molecule 
and lead to autoantibody production (Johnson et al., 1974). The alteration is 
responsible for generating new epitopes on self proteins leading to immune reaction. 
In our studies, antibodies against native IgG as well as its peroxynitrite-modified 
forms were induced in rabbits. IgG modified by lowest concentration of 
peroxynitrite (0.4 mM) induced maximum antibody response. Use of higher 
concentrations of peroxynitrite proved detrimental for antibody response probably 
due to damage/masking of immunogenic epitopes. Although induced antibodies 
were immunogen specific but showed cross-reactivity with native and 
peroxynityrite-modified proteins/amino acids, a characteristic feature of 
polyspecific antibodies commonly associated with autoimmune diseases. 
Furthermore, peroxynitrite-modified proteins/amino acids showed better binding 
with anti-peroxynitrite (0.4 mM)-modified-IgG antibodies than their native 
counterparts. Involvement of nitrotyrosine as preferred substrate by experimentally 
produced antibodies against peroxynitrite (0.4 mM)-modified-IgG signifies the role 
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of nitrotyrosine in immunogenicity. Ohmori et al, (2005) suggested that NT-IgG is 
immunogenic in autologous hosts. NT IgG- primed spleen cells showed a significant 
proliferative response to NT-IgG, suggesting that NT-IgG provided effective 
epitopes for activating T-cells NT-IgG is a model of inflammation associated NT-
self proteins was immunogenic in autologous host, and induced DNA-cross-reactive 
anti-NT antibodies. 
Autoimmune diseases, with the exception of rheumatoid arthritis and 
autoimmune thyroiditis, are individually rare, and together they affect approximately 
5 percent of the population in Western countries (Sinha et al, 1990; Jacobson et al, 
1997). Autoimmune diseases are a clinical syndrome caused by the activation of T-
cells or B-cells (or both) in the absence of an ongoing infection or other discernible 
cause. A majority of endogenous antigens are non-immunogenic due to 
immunological tolerance at T- and/or B-cell level. However, autologous proteins 
may become immunogenic if they are modified post-translationally under 
physiologic or pathologic conditions (Doyle and Mamula, 2001; Utz and Anderson, 
1998). For many years, the central dogma of immunology focused on the clonal 
deletion of autoreactive cells, leaving a repertoire of T-cells and B-cells that 
recognize specific foreign antigen. However, a low level of autoreactivity is 
physiologic and crucial to normal immune function (Dighiero and Rose, 1999). 
Autoreactivity is physiologic, later it becomes a pathologic process contributing to 
tissue injury. When autoimmune disease progresses from initial activation to a 
chronic state there is often an increase in the number of autoantigens targeted by T-
cells and antibodies ("epitope spreading") (Moudgil and Sercarz, 1994; 
Lanzavecchia, 1995). Both autoreactive T-cells and B-cells contribute to epitope 
spreading. Autoantibodies also cause damage through mechanisms that include the 
formation of immune complexes, cytolysis or phagocytosis of target cells, and 
interference with cellular physiology. 
Rlieumatoid arthritis is an autoimmune disorder (Moran et al, 2009; Catalan 
et al, 2010) characterized by a chronic, longstanding inflammatory process within 
diarthrodial joints leading to tissue damage and functional incapacity (Jasin, 2000; 
Uhlig et al, 2010). Although the precise etiologic factors responsible for the chronic 
nature of the disease are not well understood, several features suggest that an 
autoimmune response within the synovial membrane may be responsible for the 
sustained inflammatory response. Rheumatoid factors (autoantibodies directed to 
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antigenic determinants on the Fc fragment of human and also other mammalian IgG 
molecules) are believed to play an important role in maintaining the inflammatory 
events leading to tissue damage in rheumatoid arthritis (Roitt et ah, 1982). Research 
has indicated that peptides containing nitrotyrosine, presumably as a result of 
exposure to peroxynitrite or other nitric oxide-derived radicals, may induce T-cell 
responses specific for the modified peptide in animals that are otherwise tolerant to 
the native peptide (Birnboim et al, 2003). It has been previously shown that RA 
synovial fluid contains proteins modified by oxygen radicals or peroxynitrite 
(Uesugi et al, 2000; Jasin, 1993) Investigation of the possibility that RA patients 
may have circulating T lymphocytes that are capable of reacting with IgG modified 
by hypochlorous acid or peroxynitrite suggest that RA lymphocytes recognize 
modified IgG in vitro by initiation of a proliferative response and secretion of IL-2, 
the hallmarks of an immune response to antigens. Results advocate that in RA 
patients there is a circulating autoreactive T lymphocyte population that is 
programmed to respond to oxidatively modified IgG, particularly N-IgG (Grinnell et 
al., 2005). Birnboim et al., (2003) showed that nitrotyrosine-containing peptides 
induced robust T cell responses in mice that had tolerance to the native molecule. 
Many autoantigen/ antibody systems have been described in RA, including 
antibodies to autoantigens with post-traslational modifications. Previous work 
(Uesugi et al, 2000; Jasin, 1993; Kaur and Halliwell, 1994) has shown the presence 
of proteins modified by chlorination and nitrosation in RA synovial fluid. Thus, 
inflammatory process is sustained by a local immune response to an autoantigen. 
Circulating RA lymphocytes recognize oxidatively modified IgG in vitro by 
initiating a proliferative response and secreting IL-2, the hallmarks of an immune 
response to antigens. 
Direct binding ELISA carried out on rheumatoid factor positive RA sera 
showed higher binding with peroxynitrite (0.4 mM)-modified-IgG compared to 
native IgG. Inhibition ELISA results with IgG isolated from above RA sera 
supported the results of direct binding immunoassay. Carbonyl level estimation in 
32% of randomly selected sera was found to be higher as compared to control sera. 
Proteins found in synovial fluid of RA patients have been found to be rich in 
carbonyl (Mantie et al, 1999; Chapman et al, 1989). The likely participation of 
peroxynitrite in modifying the protein structure (especially those in synovial 
membrane) during inflammation was supported from HPLC detection of higher 
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content of nitrotyrosine in 20 percent of RA sera. This points out the role of 
nitrotyrosine in disease initiation/progression and also the likely link between 
autoantibodies in RA sera and peroxynitrite-modified protein antigens. 
Diabetes mellitus (DM) is a global healthcare challenge, both in 
industrialised and developing nations. Estimates of future prevalence indicate that 
diabetes is reaching epidemic proportions worldwide (Chaabo, et ah, 2010; Kalra et 
al, 2010). DM is a chronic disorder resulting from a number of factors in which an 
absolute or relative deficiency of insulin or its function occurs. It is projected that by 
the year 2025, India alone would have 57 million diabetics mainly of type 2 diabetes 
constituting 90% of the diabetic population (King et al, 1998; Ramachandran et al, 
2002). Diabetes is usually associated with macrovascular and microvascular 
complications which are a significant cause of co-morbidity and mortality in people 
with diabetes. Tyrosine nitration has been demonstrated in diabetes mellitus 
(Greenacre and Ischiropoulos, 2001). In the pancreatic islets of spontaneous 
autoimmune diabetic mice, a significant increase in tyrosine nitration was found and 
the degree of beta-cell destruction showed a good correlation with the frequency of 
nitrotyrosine-positive beta cells. It can therefore be concluded that the intra-islet 
formation of peroxynitrite plays an active pathogenic role in the pathogenesis of 
diabetes mellitus (Suarez-Pinzon et al, 1997). Direct binding ELISA carried out 
with sera of confirmed cases of diabetes showed overall higher binding with 
peroxynitrite (0.4 mM)-modified IgG compared to native IgG. Inhibition ELISA 
results confirmed the preferential binding of peroxynitrite (0.4 mM)-modified IgG 
by autoantibodies in type 2 diabetes. These findings in diabetes may be important 
because the modified IgG might not work as an effective molecule to confer the 
required level of immunity and hence the patient is more prone to infection. 
Furthermore, the excessively formed free radicals (oxygen/nitrogen based) in early 
or late stages of type 2 diabetes can also alter IgG structure. The modified IgG can 
trigger immune reactions leading to induction of autoantibodies. 
Conclusions 
Under our experimental conditions, the physicochemical studies carried out 
on peroxynitrite-modified-IgG suggest generation of nitrotyrosine, formation of 
carbonyls and changes in secondary structures. IgG modified by 0.4mM, 0.8 mM 
and 1.2 mM peroxynitrite was injected into rabbits for antibody induction. Direct 
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binding and inhibition ELISA results suggest that IgG modified by 0.4 mM 
peroxynitrite was most active immunogen and induced highest antibody response. 
IgG modified by more than 0.4 mM of peroxynitrite was found to be less 
immunogenic. It seems that peroxynitrite is toxic to proteins even at low doses and 
at higher concentrations this can damage protein beyond repair. Experimentally 
produced antibodies against peroxynitrite (0.4 mM)-modified IgG were polyspecific 
with respect to antigen binding. The binding of peroxynitrite (0.4 mM)-modified-
IgG by autoantibodies in RA and DM sera points out the role of oxidatively 
modified and nitrated protein antigens in the initiation/progression/secondary 
complications of the diseases. Here it may be relevant to mention that the ROS/RNS 
levels are increased in autoimmune diseases and their over-production may exceed 
the scavenging capacity of antioxidant enzymes or inhibitors, and can modify 
proteins, DNA, lipoprotein structure leading to generation or exposure of neo-
antigenic determinants and antigen driven autoimmune responses. 
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